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Enzymatic Ring Formation in Polyether Tetronate Antibiotic Biosynthesis 
	
Rory Fox Little 
	
The formation of rings in carbon backbones is essential for the biological activity of many 
natural products. The polyether tetronate antibiotics tetronasin, tetronomycin, and 
tetromadurin (SF2487/A80577) are notable for their ring diversity, each possessing a 
tetronate, cyclohexane, tetrahydropyran, and at least one tetrahydrofuran ring. The 
antibiotic activity and complexity of these polyether tetronates has led to research on their 
biosynthesis from actinomycete bacteria. Despite this, the mechanism of stereospecific 
cyclohexane and tetrahydropyran formation has remained mysterious. Although no formal 
[4+2] cycloaddition (Diels-Alder reaction) is predicted in the biosynthesis of these 
compounds, the biosynthetic gene clusters of all three were found to contain a pair of 
genes that encode homologues of two different [4+2] cyclases previously identified in 
complex spirotetronate pathways. Specific gene deletions demonstrated that both classes 
of [4+2] cyclase homologue are essential for polyether tetronate biosynthesis. In the 
tetronasin producer, Streptomyces longisporoflavus, deletion of the [4+2] cyclase enzyme 
homologue gene tsn11 resulted in production of a new metabolite that was characterised 
as an open form of tetronasin lacking both cyclohexane and tetrahydropyran rings. 
Incubating this metabolite with purified Tsn11 resulted in the production of an unknown 
intermediate labelled T-22. The structure of T-22 was determined using NMR to contain an 
unexpected oxadecalin moiety but still lack the tetrahydropyran ring, implicating Tsn11 as 
catalysing an apparent inverse-electron-demand hetero-Diels-Alder reaction. Remarkably, 
incubating T-22 with purified Tsn15, the other [4+2] cyclase homologue, formed the 
tetrahydropyran ring and fragmented the oxadecalin moiety to a cyclohexane ring, 
producing tetronasin. To gain structural insight into the novel activity of Tsn15 it was 
successfully crystallised. The structure of Tsn15 was then solved at 1.8 Å using SAD 
phasing; and Brazilian collaborators solved a Tsn15-ligand structure at 1.7 Å. Tsn15 
shares the same eight-stranded β-barrel fold as its [4+2] cyclase homologues. The two 
main mechanisms considered here for the Tsn15-catalysed conversion of T-22 into 
tetronasin were a general acid/ base or a pericyclic mechanism. Site-directed mutagenesis 
of the Tsn15 active site indicated that none of the acid/base amino acid side chains were 
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Chapter 1: Introduction  
1.1 Bacterial natural products 
 
1.1.1 Nature as a source of medicines 
  
Nature is an essential source for human medicines. Written records dating back to ancient 
Mesopotamia and Egypt both detail the use of plant oils to treat aliments such as coughs, 
inflammation, and infections1. Traditional Chinese medicine is also largely based on 
deriving medicines from natural sources such as plants and animals. A notable example is 
the herb Artemisia annua, which was used for centuries in China to treat malaria. In 1971, 
the compound artemisinin was isolated from A. annua and shown to be the active anti-
malarial component2. Since then, artemisinin and derivatives have been essential drugs for 
controlling malaria, recognised by awarding the key scientist involved in its discovery, Dr. 
Tu Youyou, the 2015 Nobel Prize in Medicine3.  
 
Small molecule compounds such as artemisinin that are isolated from natural sources are 
collectively called natural products (Figure 1.1). Natural products are also typically 
classified as secondary metabolites: metabolites that, in contrast to primary metabolites, 
are not essential for the growth of the organism but may provide a selective advantage 
under certain circumstances4. Aside from plants, medically important natural products are 
also derived from microorganisms, such as fungi and (particularly) bacteria. Natural 
products and their derivatives are significantly represented in the list of drugs approved by 
US Food and Drug Administration (FDA)5. As of 2014, 33% of all FDA approved drugs 
were natural products or their derivatives5. The percentage increases to 54% if synthetic 
compounds that mimic natural product structures are also included5. Natural products 
make good drug candidates because, in addition to possessing desirable characteristics 
such as high levels of structural and stereochemical diversity, they are by definition 
biologically relevant molecules that have evolved to interact with living systems6. Despite 
this, an issue with developing any natural product drug is the problem of supply. From a 
given biological source (such as a plant, bacteria, fungus etc…) a natural product of 
interest may represent only 1% of the total crude extract by mass7. In some cases it is 
possible to increase yields by scaling up cultivation, but many producers (such as a 
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bacterium symbiotically associated with a deep sea sponge) are not amenable to being 





Figure 1.1 Structures of prominent. medically important natural products.  
 
An alternative strategy to produce large amounts of a natural product is via total chemical 
synthesis. However, the complex structures of natural products, often containing multiple 
chiral centres, may render a wholly synthetic approach too difficult or costly for the required 
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product is readily available. Such work has had most impact on the development of anti-
infective molecules, and natural-product based entities represent 73% of all FDA-approved 
antibiotics5. A notable example of an antibiotic natural product is penicillin, isolated in 1928 
from the Penicillium notatum fungus9. Penicillin came to widespread public attention for its 
role in treating infections during World War II10. Despite its initial success, patients 
containing penicillin-resistant strains of Staphylococcus aureus bacteria were detected just 
over a decade later in 194211. Since then, the development of antibiotic resistance in 
bacterial pathogens has only become more prevalent and is a major public health problem 
today.  
 
1.1.2 Antibiotic resistance 
 
Shortly after the discovery of penicillin resistance, what is described as the “golden” era of 
antibiotic discovery began. Between 1940 and 1970 almost all of the major classes of 
antibiotic, including the tetracyclines, macrolides, and aminoglycosides, were 
discovered12,13. During the same period, antibiotic resistance to these new drugs also 
developed, owing to the selection pressure the antibiotics placed on the bacterial 
pathogens. A bacterial pathogen that, by chance, acquires a mutation that confers 
resistance to a given antibiotic is selected for and can generate a resistant population. 
Genes that confer antibiotic resistance (resistance genes) can even be transferred from a 
resistant strain to a non-resistant strain by a process called horizontal gene transfer14. 
Numerous mechanisms of antibiotic resistance in bacteria have been characterised15. 
These include:  
1) Reduced membrane permeability. Hydrophilic antibiotics can only cross a bacterial 
plasma membrane though transmembrane protein channels. Down-regulation of these 
protein channels can therefore decrease entry of the antibiotic into the cell. 
2) Upregulation of antibiotic efflux. Bacteria contain transmembrane efflux proteins that 
often have broad substrate selectivity, enabling the cell to export antibiotics from the 
cytoplasm. The overexpression of these efflux pumps can therefore enhance antibiotic 
resistance.  
3) Mutation/alteration of the antibiotic target. The change in the antibiotic target need 
not be through a mutation, as chemical modification of the target (such as methylation or 
acetylation) can also interfere with antibiotic binding.  
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4) Antibiotic inactivation. Enzymes within the bacterial pathogen may hydrolyse the 
antibiotic or catalyse a chemical modification of its structure that renders it inactive.  
Taken together, these resistance mechanisms have led to the development of 
multidrug-resistant and even totally drug-resistant bacterial pathogens15,16. Combating 
antibiotic resistance is a multi-faceted problem requiring political will, such as implementing 
policies that will prevent antibiotic over/misuse, as much as developing replacement 
antibiotics. From 1990 onwards, advances in DNA sequencing and genetic engineering 
technology have provided an unprecedented opportunity to study how natural products are 
produced by nature i.e., natural product biosynthesis. Understanding the mechanisms of 
natural product biosynthesis has the potential for antibiotic-producing organisms to be 
genetically manipulated to increase product yields or even produce novel analogues. As 
bacteria are some of the most prolific producers of antibiotics and other natural products, 
most of the research on natural product biosynthesis has been conducted on them.  
 
1.1.3 Streptomyces bacteria 
 
Bacteria of the Gram-positive actinobacterial phylum (actinomycetes) produce two-thirds of 
all known antibiotic compounds, with the majority contributed by the Streptomyces genus 
(streptomycetes)17. The streptomycetes likely evolved around 450 million years ago in 
response to the colonisation of land by green plants providing a new nutrient source18. 
They typically live in soil and are saprophytic (consume decaying organic material). The 
breakdown of plant material by streptomycetes is achieved though the extracellular 
secretion of catabolic enzymes, such as cellulases18. In the case of Streptomyces 
coelicolor, upwards of 800 different proteins are predicted to be exported to utilise decaying 
plant and soil nutrients19. Streptomycetes clearly compete with fungi for resources, as 
many secrete chitinases to digest fungal cell walls20 or produce antifungal natural 
products21–23. In addition to a soil environment, streptomycetes are also found in the 
ocean24,25, including the Arctic26, and in symbiotic relationships with eukaryotic organisms. 
Streptomycetes have been found living on wasps27,28, ants21,29,30, beetles31, fungi32, and 
plants33,34, often producing antibiotic or antifungal compounds that protect their host. Other 
interactions with plants are pathogenic, notably potato scab caused by Streptomyces 
scabies35. In rare cases streptomycetes also infect humans to cause actinomycetoma36,37.  
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The phylum name actinomycete is derived from the Greek words “actis”, meaning ray or 
beam, and “mykes” meaning fungus. The actinomycetes were given a name meaning “ray 
fungus” because they were originally misidentified as such18. Such a mistake was 
understandable, as under a microscope actinomycetes often resemble a branching fungal 
mycelium. The fungal comparison is even stronger in the streptomycete genus, as many of 
its species reproduce by sporulation, as fungi do. A typical streptomycete life cycle starts 
with a mononucleate spore germinating and forming a polynucleate, often pigmented, 
substrate mycelium beneath it, releasing extracellular enzymes to solubilise essential 
nutrients for itself from its surroundings17. Antibiotics are often secreted at the same time to 
protect the solubilised nutrients from competitor microorganisms18. In response to depletion 
of nutrients, the substrate mycelium is programmed to lyse, supplying a burst of nutrients 
for aerial hyphae to form and differentiate into white, mononucleate, hydrophobic spores for 
dispersal17,18 (Figure 1.2). This transition typically is accompanied by an increase in the 
number and level of antibiotics released. Most Streptomyces species are present in soil in 
the spore form38, only germinating when conditions are favourable39. In contrast, other 
streptomycetes contain mutations in the bldA “bald” locus and do not form spores39.  
 
 
Figure 1.2 Life Cycle of a Sporulating Streptomycete. Following germination from a single spore, the 
streptomycete life cycle begins with vegetative growth to form a substrate mycelium. Aerial hyphae then 
begin to grow and differentiate into mononucleate spores for reproductive dispersal. Antibiotics are often 
produced during growth of the aerial hyphae to protect the soluble nutrients produced by the catabolic 








Growth of aerial hyphae 
Antibiotic production 
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1.2 Natural product biosynthesis 
 
1.2.1 Biosynthetic gene clusters 
 
Streptomycetes produce a range of natural product classes including polyketides (which 
will be discussed in greater detail later), non-ribosomal peptides, terpenes, and ribosomally 
synthesised and post-translationally modified peptides (RiPPs). The genes responsible for 
the biosynthesis of these natural products are encoded in the bacterial genome or on 
accessory plasmids. Due to the complexity of natural products, multiple genes are often 
required for their biosynthesis. The genes responsible for the biosynthesis of a given 
natural product are also typically grouped together in a biosynthetic gene cluster (BGC). 
BGCs can reach over 200 kbp in size40 and can contain more than 40 genes, all of which 
contribute to the biosynthesis of a single natural product. Genes may directly contribute to 
the construction of the natural product or have a role in resistance or transcriptional 
regulation. A streptomycete genome is comprised of a single linear chromosome41 with 
BGCs mainly concentrated near the chromosome ends19,42,43. The number of BGCs within 
a bacterial species increases with its genome size, with roughly 2.4 BGC per Mbp, 
resulting in an average of 3.7% of the genome being BGCs44. Exceptions exist, notably 
Streptomyces bingchenggensis in which 22%44 of its 12 Mbp43 genome encodes BGCs for 
natural product biosynthesis (2.6 Mbp in total). The genes in a BGC are often organised 
into operons, enabling coregulation and cotranscription of multiple genes. BGCs also 
typically contain genes encoding regulatory elements that control transcription of the entire 
cluster.  
 
The reason why genes involved in natural product biosynthesis evolved to cluster with one 
another has been the subject of much debate. The prevailing theory is called the “selfish 
operon” model, and proposes that biosynthetic genes cluster to increase their chance of it 
being passed on via horizontal gene transfer45–47. As maintaining a large BGC is 
metabolically expensive, unless the natural product they produce provides a survival 
advantage BGCs are typically eliminated from the genome. Dispersal via horizontal gene 
transfer can therefore save a BGC from extinction if does not provide a reproductive 
advantage in its current bacterial host. By having all of the biosynthetic genes clustered 
together, the complete cluster has a better chance of being passed on intact to a different 
host, where the encoded natural product does provide a reproductive advantage45. 
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Phylogenetic analysis of bacterial operons supports this model, indicating that horizontal 
transfer of entire operons is the main process creating co-localised foreign genes in 
bacterial genomes47. A piece of evidence against the selfish operon model is that the 
essential bacterial genes (such as those in primary metabolism) with related functions also 
cluster together and form operons48. However, it is likely that essential genes and 
secondary metabolite genes cluster for different reasons49. Essential genes may cluster 
together in coregulated operons to decrease the chances of a gene deletion disrupting one 
of them49. In contrast, if essential genes are uniformly distributed in the genome and 
independently regulated, the chances that a gene deletion will affect one of them, and 
thereby dismantle the entire metabolic process, is higher49. Regardless of why it occurs, 
the clustering of biosynthetic genes has simplified the identification and study of the BGCs 
responsible for natural product biosynthesis. The polyketide natural products are some of 
most valuable and their biosynthesis has been the most extensively studied. 
 
1.2.2 Polyketide natural products  
 
Polyketides are a structurally diverse and medically important family of natural product. 
Polyketide carbon skeletons are mainly constructed from the successive condensation of 
acetate and propionate units, each derived from an activated form of malonyl-CoA (co-
enzyme A) or (2S)-methylmalonyl-CoA, respectively (Figure 1.3).  
 





Figure 1.3 Acetate and propionate units in polyketide carbon skeletons. The carbon skeletons of 
polyketides typically consist of acetate and propionate units derived from malonyl-CoA and (2S)-
methylmalonyl-CoA, respectively. The structures of four polyketide natural products are shown with the two-
carbon acetate units shown in red, and the three-carbon propionate units shown in blue. 
 
In addition to actinobacteria, polyketides are produced by other bacteria, and also by 
plants50 and fungi51. A recent study even unexpectedly revealed a polyketide produced by 
a nematode52. Polyketides broadly comprise two different classes: the aromatic polyketides 
and the reduced polyketides. Aromatic polyketides contain fused polyphenol rings derived 
from unreduced polyketide chains. In contrast, reduced polyketides contain multiple 
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one of the most clinically successful natural products classes, with roughly 1% of all known 
polyketides possessing a drug-like activity, five times higher than the natural product 
average54. Sales of polyketide drugs annually exceed 20 billion USD55. Clinically used 
polyketide drugs display a wide range of activities, ranging from antibiotic (erythromycin A, 
rifamycin S), immunosuppressant (rapamycin), anticholesterol (lovastatin) or antifungal 
(amphotericin B) to anticancer (epothiolone, doxorubicin, calicheamicin)53,56,57. The potent 
insecticide spinosyn A and its derivatives are also polyketides58. In several notable cases, 
other polyketides are causative agents in disease, such as mycolactone A (produced by 
Mycobacterium ulcerans) in Buruli ulcer formation59, and brevetoxin B (produced by the 





Figure 1.4 Structures of the pathogenic polyketides mycolactone A and brevetoxin B. 
 
1.2.3 Polyketide biosynthesis 
 
Polyketide natural products are produced by polyketide synthase enzymes (PKSs). There 
are three different classes of PKS: type I, type II, and type III. Polyketides produced by 
each type of PKS are accordingly called a type I, II, or III polyketide. While malonyl-CoA 
and (2S)-methylmalonyl-CoA are the most common “building blocks” (also called extension 
units) utilised by PKS enzymes, others, such as (2S)-ethylmalonyl-CoA61, are sometimes 
used. The chemical properties of thioesters of co-enzyme A facilitate the covalent transfer 
of the extension unit to the PKS enzyme, where they can be incorporated into the growing 
polyketide acyl chain. Once attached to the PKS via the acyl carrier protein (ACP) domain, 
each extender unit undergoes a Claisen-like decarboxylative condensation reaction 
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enzyme/domain57. This contributes two carbons to the polyketide carbon skeleton in the 
case of malonyl-CoA, and if the extension unit is (2S)-methylmalonyl-CoA, also an α-
methyl branch57. Successive chain elongation condensation reactions produce the 
polyketide carbon backbone. In this sense, the process of polyketide biosynthesis is highly 
reminiscent of fatty acid biosynthesis62. However, in contrast to fatty acid biosynthesis, 
where each newly-introduced β-ketothioester carbonyl group is fully reduced to form a 
saturated acyl chain, in polyketide biosynthesis the degree of carbonyl reduction is 
variable, introducing chemical variation along the polyketide chain and leading to greater 
structural diversity. Once the final polyketide chain length is reached it is released from the 
PKS, often in a cyclised form. Additional enzymes, called post-PKS enzymes, expressed 
from the BGC may then further tailor the structure of the polyketide, adding chemical 
groups such as sugars and hydroxyls or catalysing additional cyclisation reactions.  
 
Type II PKSs are responsible for the biosynthesis of aromatic polyketide natural products 
such as the medically important tetracycline antibiotics63. Unlike the modular type I PKSs, 
where multiple catalytic domains are required for a single round of chain extension 
(discussed in the next section), type II PKSs consist of iteratively acting standalone 
proteins63. A minimal type II PKS biosynthesis pathway consists of a standalone acyl 
carrier protein and two proteins that resemble ketosynthase domains: a KSα and KSβ. 
These two KS proteins are highly similar to one another, and together catalyse the 
necessary chain initiation and extension events required for polyketide biosynthesis63. Like 
type II PKSs, type III PKSs also produce aromatic products through the iterative 
condensation of malonyl-CoA onto (for example) a cinnamoyl-CoA starter molecule. 
Present in plants, fungi, and bacteria, type III PKSs consist of a single KS-like protein and 
are typically ACP-independent64. The main focus of this thesis, however, is on the function 
of type I polyketide synthases. 
 
1.2.4 Type I polyketide synthases 
 
Modular type I PKSs are large (typically >100 kDa) homodimeric enzymes responsible for 
the biosynthesis of many important polyketide natural products, including macrolides and 
polyethers55. The structure of these massive modular complexes is an on going and difficult 
area of research, covered well in several recent reviews65,66. Several levels of organisation 
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exist within type I PKSs. Each type I PKS enzyme consists of at least one, though usually 
multiple, modules. Each module is responsible for the selection and incorporation of an 
extension unit (typically malonyl-CoA or (2S)-methylmalonyl-CoA) into the growing 
polyketide chain. The number of modules present in a type I PKS therefore dictates (and 
can be used to predict) the length of the polyketide product it produces. There is a separate 
class of single-module type I PKS common in fungi where the module acts iteratively to 
build up the chain, with optional input from additional stand-alone enzymes67.   
Type I PKS modules are, in turn, comprised of discrete regions of catalytic activity called 
domains. There are seven types of catalytic domain typically found in type I PKSs: the 
essential core domains are the acyltransferase (AT), ketosynthase (KS) and an acyl carrier 
protein (ACP) domain bearing a 4'-phosphopantetheine prosthetic group. Additional 
domains that may be present in a module include ketoreductase (KR), dehydratase (DH), 
enoylreductase (ER), and a chain-releasing domain, often a thioesterase (TE) domain. 
Other domains have been identified in several polyketide biosynthesis pathways, such as 
domains that catalyse pyran ring formation (PS domains)68,69, sulphur incorporation70, and 
polyketide chain branching71, but these are less common. To catalyse a specific round of 
polyketide chain extension each module requires the core AT, ACP, and KS domains. The 
role of the AT domain is to select the extension unit and attach it the adjacent ACP domain 
via the 4’-phosphopantethine linker. In some modular type I polyketide pathways, called 
trans-AT pathways, the AT domains are provided as standalone proteins72. An example of 
a polyketide produced by a trans-AT PKS is the polyether antibiotic pederin, produced by 
an unculturable Pseudomonas sp. found on Paederus beetles73. The KS domain then 
catalyses carbon-carbon bond formation to incorporate the extension unit into the growing 
polyketide acyl chain. Any reduction domains present in the module can then modify the 
polyketide acyl chain, reducing the β-keto group to form a secondary alcohol (if only a KR 
domain is present), an E-double bond (if both a KR and DH is present), or saturated acyl 
chain (if a KR, DH, and ER domain is present). The acyl chain is then passed on to the KS 
domain of the neighbouring module, where the process repeats. Final release of the full-
length polyketide from the terminal module is typically accompanied by cyclisation. The 
biochemistry and mechanisms of different domain types will be discussed in more detail in 
Section 1.3. 
The first modular type I PKS genes to be sequenced were those from the BGC of 
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erythromycin A in Saccharopolyspora erythraea74–77. The biosynthesis of erythromycin A is 
a good example to illustrate the key process and mechanisms of type I PKSs. Erythromycin 
A is a 14-membered macrolide antibiotic that inhibits translation by binding to the 50S 
subunit of the prokaryote ribosome78,79. Three genes, eryAI, eryAII, and eryAIII, 
respectively encode the type I PKS enzymes DEBS1 (370 kDa), DEBS2 (374 kDa), and 
DEBS3 (333 kDa). Together the three homodimeric DEBS proteins form a complex close 
to 2 MDa in size, roughly the same size as the prokaryote ribosome erythromycin A 
inhibits65. DEBS1, DEBS2, and DEBS3 work together to produce 6-deoxyerythronolide-B, 
the macrocyclic precursor of erythromycin A, from seven propionate units. Collectively the 
three DEBS proteins contain seven modules that act in a specific order as a molecular 
“assembly line” to correctly synthesise 6-deoxyerythronolide-B. DEBS1 initiates 6-
deoxyerythronolide-B biosynthesis, and consists of three modules: a loading module and 
two extension modules (Figure 1.5). The loading module consists of an AT and ACP 
domain, while extension modules 1 and 2 additionally both contain a KS and KR domain. In 
the case of DEBS1, the AT of the loading module actually selects propionyl-CoA rather 
than (2S)-methylmalonyl-CoA, and attaches it to the ACP domain of the loading module. In 
most type I PKS pathways, the loading module contains a special KS domain called a KSQ 
domain that, while unable to catalyse chain extension, can catalyse the decarboxylation of 
(2S)-methylmalonyl-CoA to propionyl-CoA once it is attached to the ACP of the loading 
module80–82. KSQ domains are labelled as such because their conserved active-site 
cysteine is replaced with glutamine65 (described in more detail in Section 1.3.3). As the 
loading module of DEBS1 lacks a KSQ domain, it is unable to decarboxylate (2S)-
methylmalonyl-CoA so must incorporate propionyl-CoA directly.  
 




Figure 1.5 The first two extension cycles of DEBS1. DEBS1 is the first type I PKS responsible for the 
biosynthesis of 6-deoxyerythronolide-B, the erythromycin precursor. The AT domain of the loading module 
selects a propionyl-CoA unit while the AT domains of modules 1 and 2 select (2S)-methylmalonyl-CoA. The 
KS domains catalyse successive decarboxylative Claisen-like condensation reactions to form a triketide that 
is subsequently translocated to DEBS2.  
The propionate unit bound to the ACP domain of the loading module is translocated to the 
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condensation reaction between the KS-bound propionate unit and a (2S)-methylmalonyl 
unit bound to the ACP domain of module 1 (Figure 1.5). The stereochemistry of the L-α-
methyl of the (2S)-methylmalonyl-ACP undergoes a stereochemical inversion during the 
condensation reaction (changing from the L configuration to the D configuration)83,84 
(Figure 1.6). Modules 1 and 2 contain a KR domain that catalyses the stereospecific 
reduction of β-keto groups (either to the D or L configuration). In addition, KR domains may 
also epimerise the α-substituent. 
 
Figure 1.6 D and L configuration of substituents on polyketide chains. It is common to refer to 
substituents on a polyketide chain as either in the D or L configuration (rather than R or S). Figure adapted 
from65.  
For instance, the KR domain of DEBS module 1 produces a D-configured β-hydroxyl and 
an L-configured α-methyl. The diketide 6-deoxyerythronolide-B intermediate is then 
translocated to the KS domain of module 2, where it is condensed with another (2S)-
methylmalonyl unit bound to the module 2 ACP domain. After processing by module 2, the 
triketide intermediate of 6-deoxyerythronolide-B intermediate is translocated to the KS 
domain of module 3, located on DEBS2. A C-terminal docking domain on DEBS1 and a N-
terminal domain on DEBS2 selectively bring these two PKS enzymes together to facilitate 
this intermolecular translocation85. The triketide intermediate is sequentially translocated 
along extension modules 3-6 of DEBS2 and DEBS3, undergoing an additional chain 
extension reaction at each, until it reaches extension module 6. Module 6 contains a 
terminal TE domain that releases the polyketide acyl chain and catalyses a cyclisation 
reaction to form the 14-membered 6-deoxyerythronolide-B macrolide. Following release 
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deoxyerythronolide-B (Figure 1.7). Post-PKS enzymes catalyse two hydroxylations, two 
glycosylations, and one methyl transfer event to convert 6-deoxyerythronolide-B into 
erythromycin A86. The mechanism of each domain type in type I PKS modules will now be 





Figure 1.7 Type I PKS biosynthesis pathway of the erythromycin precursor 6-deoxyerythronolide-B. 
The DEBS complex consists of three type I PKS multienzymes that collectively consist of a loading module 
and six extension modules. The heptaketide linear 6-deoxyerythronolide-B synthesised by DEBS1-3 is 
cyclised into a 14 membered macrolide by the terminal TE domain of DEBS3. Post-PKS enzymes then 
catalyse two hydroxylations, two glycosylations, and one methyl transfer event to produce erythromycin A. 
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1.3 Domains of type I polyketide synthases 
	
1.3.1 AT domains 
 
AT domains are responsible for selecting the starter unit and each extender unit used for 
type I polyketide biosynthesis65,87. AT domains in cis-PKS pathways (where the AT 
domains are part of the module) are typically ca. 300 amino acids in size65. Most AT 
domains are highly selective for either malonyl-CoA or (2S)-methylmalonyl-CoA, though 
other extender units such as (2S)-ethylmalonyl-CoA or (2R)-methoxymalonyl-ACP are also 
recognised by some AT domains61. Numerous substrate motifs within AT domains have 
been identified that can be used to predict their substrate selectivity (Table 1.1). Distinct 
motifs have also been detected for less common extender units, but they are less well-
defined and less predictable88. While AT domains selective for malonyl-CoA are able to 
exclude the bulkier (2S)-methylmalonyl-CoA, AT domains selective for (2S)-methylmalonyl-
CoA can discriminate against the (2R) -epimer but cannot exclude malonyl-CoA65. Rather, 
it has been shown that (2S)-methylmalonyl-CoA selective AT domains hydrolyse incorrect 
extension units faster than the correct one89. The active site of AT domains contain a Ser-
His catalytic dyad that attacks the thioester carbonyl of the extender unit (Figure 1.8). A 
conserved arginine is then proposed to form a stabilising salt bridge with the α-carboxylate 
group of the extender unit90. The extender unit is then transferred to the adjacent ACP. 
 
AT motif I Selectivity  Source  
ETGYA(7*x)QxAxFGLL Malonyl-CoA (acetate) 91 
RVDVV(7*x)MxSxAxxW (2S)-methylmalonyl-CoA (propionate) 91 
   
AT motif II   
(HTVY)AFH Malonyl-CoA (acetate) 92 
(YVW)ASH (2S)-methylmalonyl-CoA (propionate) 92 
 
Table 1.1 The different selectivity motifs present in AT domains. Selectivity motifs present in the AT 
domains of type I PKSs can be used to predict their substrate selectivity. “x” represents any of the 
proteinogenic amino acids.  




Figure 1.8 The proposed mechanism of AT domains. The active site of an AT domain contains a His-Ser 
catalytic dyad and a conserved arginine residue. The wavy bond to the ACP represents the 4’-
phosphopantetheine group. Figure adapted from65. 
 
1.3.2 ACP domains 
 
 
Acyl carrier protein (ACP) domains are typically ca. 80 amino acids in length and found on 
the C-terminal ends of type I PKS modules. ACPs are non-enzymatic domains bearing a 
covalently attached 4’-phosphopantetheine moiety that tethers the extender unit selected 
by the AT domain of the same module. Each 4’-phosphopantetheine moiety (“arm”) is 
attached to a conserved serine in the ACP ((D/E)xGxDSL), producing holo-ACP. 4’-
phosphopantetheine is a long molecule (18 Å) derived from co-enzyme A that is attached 
to the ACP by a 4’-phosphopantetheinyltransferase (PPTase) enzyme93 (Figure 1.9). Due 
to the necessity of generating holo-ACP for polyketide biosynthesis and analogous primary 
metabolic processes such as fatty acid biosynthesis, PPTases are attractive targets for 
new antibiotics and efforts have been made to find inhibitors94–96. The 4’-
phosphopantetheine arm allows the incoming extender unit and the elongated polyketide 
chain to be tethered as relatively reactive thioesters; and its length and mobility enables it 
to shuttle polyketide intermediates between the catalytic centers of multiple domains within 
the current module; as well as transferring the processed chain to the neighboring module 




























































Figure 1.9 The 4’-phosphopantetheine moiety of ACP domains. The 18 Å long 4’-phosphopantetheine 
moiety is attached to the conserved serine of an ACP domain by a PPTase enzyme. Figure adapted from65. 
 
1.3.3 KS domains 
 
 
The KS domain completes the minimal set of type I PKS domains (AT, ACP, and KS) 
required for polyketide chain extension to occur. KS domains are typically present on the 
N-terminal side of a type I PKS module and are ca. 430 amino acids in size65. The main 
role of the KS is to recruit the polyketide acyl chain from the previous module and catalyse 
a chain extension reaction between this and a carboxylated extender unit65. The active site 
of KS domains contains a conserved Cys-His-His catalytic triad98. The conserved cysteine 
acts as a nucleophile that accepts the nascent polyketide acyl chain from the ACP domain 
of the upstream module, while the two histidine residues promote polyketide chain 
translocation from the ACP to the KS and extender unit decarboxylation65,99 (Figure 1.10). 
KS-catalysed decarboxylation of the ACP-bound extender unit produces an enolate, the α-
substituent of which undergoes inversion of stereochemistry during the subsequent Claisen 
condensation reaction (L to D transition)83,84. KS domains are also known to possess 

























Figure 1.10 The proposed mechanism of KS domains. The active site of KS domains in type I PKSs 
contain a Cys-His-His catalytic triad. a, The polyketide intermediate bound to the upstream ACP domain is 
translocated to the KS catalytic cysteine. R1 = polyketide acyl chain b, Decarboxylation of the extender unit 
bound to the downstream ACP produces an enolate. c, The enolate then undergoes a condensation reaction 
with the KS bound polyketide intermediate, extending the polyketide chain by two carbon units The α-
substituent of the extender unit undergoes inversion of stereochemistry during the condensation reaction. 
Figure adapted from65. 
 
1.3.4 KR domains 
 
 
KR domains reduce the β-keto group of the ACP-bound polyketide acyl chain to a 
secondary hydroxyl using an NADPH hydride donor. Conserved serine, lysine, and tyrosine 
residues are predicted to be essential for catalysis, the conserved tyrosine being the 
source of the hydroxyl proton (Figure 1.11)65. Depending on the nature of the KR domain, 
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also epimerise the α-substituent, making them the domain with the most control over the 
stereochemistry of the final polyketide product. Specific amino acid motifs within the active 
site have been used to classify KRs: those that form L-configured hydroxyl groups are 
denoted A-type, D-configured hydroxyl groups as B-type. KRs lacking epimerase activity 
are placed in subclass 1, while others that epimerise the α-substituent as well as reducing 
the β-keto group are placed in subclass 2101 (Figure 1.12). The final class of KR (C-class) 
is unable to reduce β-keto groups due to mutations in the catalytic tyrosine (C1) or the 
NADPH binding site (C2), but may retain the ability to isomerise at the α-position (type 
C2)101.   
 
Figure 1.11 The proposed mechanism of KR domains. The active site of a KR domain contains a 
conserved serine, tyrosine, and lysine all predicted to assist with the reduction of the β-keto group. NADPH 
acts a hydride donor. In addition, the KR domain may also epimerise the α-substituent to either a D or L 







































Figure 1.12 The stereochemical outcomes of the different classes of KR domains. There are six 
different kinds of KR domains, each type producing a different stereochemical outcome at the α and β 
positions of the polyketide acyl chain. R = polyketide acyl chain. Figure adapted from101. 
 
1.3.5 DH domains 
 
 
Following ketoreduction by a KR domain, the ACP-bound polyketide acyl chain is delivered 
to the active site of a dehydratase (DH) domain if one is present in the module. DH 
domains are ca. 280 amino acids and catalyse dehydration of the β-hydroxyl generated by 
the KR domain, forming an α-β double bond65. The α-β double bond generated is typically 
in trans configuration, but cis double bonds do form in some polyketide biosynthesis 
pathways. Most double bonds in polyketide natural products are the result of DH domains, 
although some are produced by post-PKS acting enzymes102 or, unexpectedly, by some 
thioesterase (TE) domains103. The active site of DH domains contains a His-Asp catalytic 
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chain while the Asp acts as an acid to protonate the β-hydroxyl group, facilitating 
dehydration by creating a better leaving group65 (H2O) (Figure 1.13). Whether a DH will 
form a cis (Z) or a trans (E) double bond is not yet possible to predict from the DH 
sequence alone. However, those that form cis double bonds are typically in the same 
module as an A-type KR, and the evidence suggests that these two modules are 
collectively responsible for cis double bond formation65,104.  
 
Figure 1.13 The proposed mechanism of the DH domain. The active site of DH domains contains a 
conserved His-Asp catalytic dyad. The β-hydroxyl group is protonated by the aspartic acid to make it a better 
leaving group, enabling formation of the (typically trans) α-β double bond. Figure adapted from65. 
 
1.3.6 ER domains  
	
The final reduction domain optionally present in a type I PKS module is the enoylreductase 
(ER) domain. ER domains are ca. 310 amino acids in length and reduce the DH-catalysed 
double bond to a fully saturated carbon-carbon bond65. Like the KR domain, ER domain 
reduction is achieved using NADPH as a cofactor. Hydride donation by NAPDH results in 
the formation of an enolate (Figure 1.14). A proton is then added to either the re face or 

































Figure 1.14 The two different classes of ER domain. ER domains reduce the α-β double bond of a 
polyketide acyl intermediate to a saturated carbon bond. L-ER domains result in the α-substituent being in the 
L-configuration, whereas D-ER domains result in the α-substituent being in the D-configuration. R = polyketide 
acyl chain. Figure adapted from65. 
 
ER domains that produce D-α substituents (D-ER domains) can be distinguished from 
those that produce L-α substituents (L-ER domains) by specific amino acid motifs105. L-ER 
domains contain a key tyrosine residue that donates a proton to the re face of the enolate 
to produce a L-α substituent (Figure 1.15). On the other hand, D-ER domains lack this 
tyrosine residue and the proton is added to the si face, forming a D-α substituent. The 
source of the proton added to the si face is possibly a conserved lysine, but there is also 
evidence that this proton has multiple sources105,106.  
 
Figure 1.15 Proposed mechanism of the ER domain. ER domains reduce the α-β double bond of the 
polyketide acyl chain using NADPH as a hydride donor. The figure displays an L-type ER that uses a 
conserved tyrosine to produce an L-configured α-substituent. R1 = polyketide acyl chain. R2 = α substituent 












































































Chapter 1: Introduction 
	
	 24 
1.3.7 TE domains 
 
The final domain in most type I PKSs is the thioesterase (TE) domain. TE domains are 
240-290 amino acids in size and are typically located at the end of the final extension 
module (module 6 in the case of the DEBS proteins). The role of the TE domain is to 
catalyse chain release from the PKS, either as a macrocycle or as a free acid. The active 
site of a TE domain contains a Ser-His-Asp catalytic triad, with the serine acting as a 
nucleophile to attack the thioester carbonyl of the ACP-bound polyketide acyl chain (Figure 
1.16)65. While thioesterase domains offer the most common mechanism of chain release, 
several other mechanisms exist107,108. For instance, chain release of fumonisin mycotoxin 
polyketides is performed by a standalone pyridoxal 5’-phosphate (PLP) dependent 
enzyme. Another important exception relevant to this thesis are the polyketide tetronate 
natural products, the PKS enzymes of which lack thioesterase domains. Chain release is 
instead concomitant with tetronate ring formation109,110–118. 




Figure 1.16 Proposed mechanism of TE domains. The active site of a TE domain contains a conserved 
Ser-His-Asp catalytic triad responsible for catalysing release of the polyketide acyl chain (the figure shows the 
linear ACP-bound intermediate of 6-deoxyerythronolide-B) either by hydrolysis of intramolecular cyclisation 
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1.4 Tetronate natural products 
	
	
Polyketides or fatty acids containing a tetronic acid (Figure 1.17) moiety (collectively called 
tetronates) are a diverse family of natural products. (Figure 1.18). The first tetronate 
natural product was discovered in 1935119, and since then over 100 have been 
discovered109. Tetronate natural products exhibit a range of activities, including antibiotic, 
anticancer, antiviral, and antifungal109. Most tetronate natural products can be categorised 
into two broad classes: the linear tetronates and the spirotetronates. Linear tetronates 
contain a fatty acid or a polyketide chain attached to a tetronate group (examples including 
sarcotin A, RK-682, and pesthetoxin). The tetronate moiety is a steric and electronic mimic 
of a phosphate group, consistent with many linear tetronates having phosphatase inhibitor 
activity109. The spirotetronates are macrocyclic polyketides where the tetronic acid moiety 
is in a spiro linkage to a cyclohexene ring. The first spirotetronate discovered was 
chlorothricin produced by Streptomyces antibioticus Tü99120. The size of macrocyclic ring 
can vary between spirotetronates, ranging from 11-carbons in the abyssomicins to 13+ in 
the quartromicins and versipelostatin A109.  
 
 













Figure 1.18 Structures of representative polyketide tetronate natural products. Polyketide tetronate 
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The tetronate moiety itself is normally formed by a reaction between the full length ACP-
bound polyketide acyl chain and glyceryl-ACP (derived from 1,3-bisphosphoglycerate)121. 
The mechanism of tetronate formation was elucidated by reconstituting its biosynthesis in 
vitro for the linear tetronate RK-682122. The 3-5 conserved genes typically required for 
tetronate biosynthesis are labelled the “glycerate utilisation operon”. The three essential 
genes in the glycerate utilisation operon are a FkbH-like enzyme, a FabH like enzyme, and 
a standalone acyl carrier protein109. The FkbH enzyme catalyses the formation of glyceryl-
ACP from 1,3-bisphosphoglycerate and the standalone acyl-carrier protein121. The FabH-
like enzyme (homologous to enzymes in fatty acid synthesis that catalyse chain elongation) 
then catalyses both C-C and C-O bond formation between glyceryl-S-ACP and the 
polyketide acyl chain, forming the five-membered tetronate ring and releasing the 
polyketide chain from the PKS122 (Figure 1.19). In polyketide tetronate pathways the full-
length ACP-bound polyketide acyl chain always contains a β-keto group to increase the 
acidity of the α-proton, subsequently increasing the nucleophilicity of the α-carbon to 
promote C-C bond formation.  
 
 
Figure 1.19 The mechanism of tetronate ring biosynthesis. An FkbH-like enzyme catalyses formation of 
glyceryl-ACP from 1,3 bisphosphoglycerate and a standalone ACP. A FabH-like enzyme then catalyses C-C 
and C-O bond formation to create the tetronate ring. R = polyketide acyl chain.  
 
The glycerate utilisation operon may contain two additional genes to introduce an exocyclic 
double bond on the tetronate. In a mechanism elucidated by studying the linear tetronate 
agglomerin A (Agg), an acyltransferase enzyme (Agg4) was found to catalyse acetylation 
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dehydratase-like enzyme (Agg5), forming the exocyclic double bond123 (Figure 1.20). 
Accordingly, homologues of Agg4 and Agg5 are encoded within the BGCs of all tetronate 
products that contain (or contained at one point during their biosynthesis) an exocyclic 
double bond on the tetronate moiety.  
 
 
Figure 1.20 Formation mechanism of the tetronate exocyclic bond. An acyltransferase enzyme catalyses 
acetylation of the C6 primary hydroxyl group. The acetyl group is then eliminated by another enzyme that 
resembles a dehydratase, forming the exocyclic double bond.  
 
These exocyclic double bonds attracted considerable interest as they were hypothesised to 
be involved in spirotetronate formation via an intramolecular Diels-Alder reaction ([4+2] 
cycloaddition) with the terminal 1,3 diene of the polyketide intermediate (Figure 1.21)109.  
 
 
Figure 1.21 Proposed mechanism of spirotetronate formation via an intramolecular Diels-Alder 
reaction. The exocyclic double bond on the tetronate reacts in an intramolecular Diels-Alder with the 1,3 
diene located on the terminal end of the polyketide intermediate.  
 
In its simplest form a Diels-Alder reaction is the reaction between a 1,3 diene and an 
alkene to form a cyclohexene ring. The Diels-Alder reaction is one of the most important 
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might have evolved to catalyse one in a natural product biosynthesis pathway was very 
exciting. Accordingly, whether biosynthetic Diels-Alder reactions occur and whether 
enzymes catalyse them has been the subject of much investigation. 
 
1.5 The Diels-Alder reaction  
	
	
The Diels-Alder reaction was discovered in 1928 by the German chemists Otto Diels and 
Kurt Alder124. The formal description of the Diels-Alder reaction is a [4+2] cycloaddition, 
where a 1,3 diene and an alkene (also called a dienophile) react via a cyclic transition state 
to form a cyclohexene ring (Figure 1.22). If a heteroatom such as oxygen or nitrogen is 
incorporated into the six-membered ring product, the reaction is additionally referred to as 
a hetero-Diels-Alder reaction125. 
 
Figure 1.22 Intermolecular and intramolecular Diels-Alder reaction. a, In an intermolecular Diels-Alder 
reaction two compounds, one a 1,3 diene and the other an alkene, react to form a cyclohexene ring. b, In an 
intramolecular Diels-Alder a single compound that contains both a 1,3 diene and an alkene functionality react 
to form a cyclohexene ring.  
 
The discovery of the [4+2] cycloaddition earned Diels and Alder the 1950 Nobel prize in 
Chemistry126. A cycloaddition reaction is a member of the pericyclic reaction family, the 
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rearrangement reactions. A reaction is classified as pericyclic if it has a cyclic transition 
state and bond formation and bond breakage occur in concert125. The reaction is classified 
as a [4+2] cycloaddition in reference to the number of π-electrons of the 1,3 diene (4π) and 
the alkene (2π). The Diels-Alder reaction, and pericyclic reactions in general, are controlled 
by molecular orbital symmetry of the reagents. In a typical Diels-Alder reaction the highest 
occupied molecular orbital (HOMO) of the diene reacts with the lowest unoccupied 
molecular orbital (LUMO) of the dienophile. The phases of the diene HOMO and dienophile 
LUMO molecular orbitals are symmetrical, such that constructive orbital overlap occurs and 
new bonds can form (Figure 1.23a). By making the relative energy levels of the HOMO 
and LUMO more similar the rate of Diels-Alder reaction can be increased125. Such energy 
level balancing is typically achieved by attaching an electron-withdrawing group (EWG) to 
the dienophile (thereby lowering the LUMO energy) and/or adding an electron-donating 














Figure 1.23 Molecular orbital overlap of the Diels-Alder reaction. a, In a typical Diels-Alder reaction the 
ψ2 molecular orbital (HOMO) of the 1,3 diene reacts with the π* (LUMO) molecular orbital of the alkene. The 
symmetry of these orbitals enables constructive orbital overlap to occur, resulting in two C-C bonds forming in 
a concerted step. b, Energy level diagram of the molecular orbitals used in the reaction between butadiene 
and ethene (the simplest Diels-Alder reaction) to form cyclohexene. c, Adding electron donating groups 
(EDG) substituents to butadiene and EWG substituents to the ethene makes the relative energy level of the 
HOMO and LUMO more similar, enhancing the rate of reaction.  
 
The orientation of the dienophile relative to the diene during the reaction can result in 
multiple products being produced. The major product of a [4+2] cycloaddition reaction is 
typically the endo product: the product that forms when the EWG substituents of the 
dienophile are oriented towards the diene (Figure 1.24). In contrast, the exo product, 
where the EWG substituents of the dienophile are oriented away from the diene, is typically 
the minor product. Why the endo product is favoured is unclear, but may have to do with 
stabilising secondary orbital interactions made between the substituents of the dienophile 
and the diene, though this explanation has been recently challenged127. Regardless of why 
it occurs, the preference for the endo product gives the Diels-Alder reaction its true power: 







































Figure 1.24 endo and exo products of a Diels-Alder reaction. Depending on the orientation of the 
dienophile to the 1,3 diene two different products are possible: called the endo and an exo. Under typical 
conditions the endo product is the major product (an observation known as Alder’s endo rule).  
 
It is also possible for a Diels-Alder reaction to occur between the HOMO of the dienophile 
and the LUMO of the diene. Such a reaction is called an inverse-electron-demand Diels-
Alder reaction and is only possible if there is an EWG on the diene (such as an oxygen 
atom) and/or an EDG on the dienophile (Figure 1.25). While the Diels-Alder reaction is a 
staple in synthetic organic chemistry, whether [4+2] cyclases have evolved has been the 











































Figure 1.25 The molecular orbitals used in an inverse-electron-demand Diels-Alder reaction. a, In an 
inverse-electron-demand Diels-Alder reaction the LUMO of the 1,3 diene (ψ3) reacts with the HOMO of the 
dienophile (π). Adding an electron-withdrawing group (EWG) to the diene and/or an electron-donating group 
(EDG) to the diene can enhance the reaction. b, A normal demand Diels-Alder reaction for comparison.  
 
1.6 The hunt for [4+2] cyclase enzymes 
 
Initial efforts to find a [4+2] cyclase focused on creating one, rather than sourcing one from 
nature. The first synthetic [4+2] cyclases were monoclonal antibodies. To achieve this, 
monoclonal antibodies were raised to bind a small molecule that mimicked the cyclic 
transition state of a specific [4+2] cycloaddition reaction. The rationale was that the 
antibody would bring the diene and dienophile together in a reactive conformation where 
the molecular orbital overlap required for the [4+2] cycloaddition could occur. Furthermore, 
by raising the antibody to a transition state mimic, rather than the product, product 
inhibition could be avoided128. Using this method catalytic antibodies were created that 
could enhance the rate and product selectivity (endo vs exo) of a diverse range of [4+2] 
cycloaddition reactions128–132. In addition to catalytic antibodies, a ribozyme (RNA) [4+2] 
cyclase was also discovered by screening a 2x1014 library of ribose nucleotides133. Despite 
the flexibility of these approaches, they have fallen out of favour due to the rate 
enhancements they provide being poor compared to natural enzymes134. In an attempt to 
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applied to create a synthetic [4+2] cyclase135. Analysis of the active site of the de novo 
[4+2] cyclase revealed it was largely a hydrophobic pocket with containing a glutamine 
(EDG) and a tyrosine (EWG) that were proposed to respectively increase the HOMO 
energy of the diene and decrease the LUMO energy of the dienophile135.  
There are now numerous examples of natural products that apparently require a [4+2] 
cycloaddition reaction in their biosynthesis, and in several cases putative [4+2] cyclase 
enzymes have been identified136,137. Whether these enzymes catalyse true [4+2] 
cycloaddition reactions has been subject to much debate, since it is difficult to prove 
whether the reactions are truly concerted. Reference to one of these enzymes as a [4+2] 
cyclase or as a Diels-Alderase is therefore done largely out of convenience to describe an 
enzyme that catalyses a reaction between a 1,3 diene and an alkene to form a 
cyclohexane ring137. Furthermore, the initial [4+2] cyclase candidates all also possess an 
additional, non-cyclase, activity and/or they catalyse [4+2] cycloadditions that also occurs 
spontaneously138.  
 
1.6.1 Dual function [4+2] cyclases  
 
The first natural product biosynthetic pathway to provide direct evidence of a [4+2] 
cycloaddition reaction occurring was that of the solanopyrones139 (Figure 1.26). 
Solanopyrone A and D are phytotoxic polyketides produced by the Alternaria solani 
fungus140. From the time of their discovery the dialkyldecalin moiety of the solanopyrones 
was predicted to form via an intramolecular [4+2] cycloaddition reaction, solanapyrone A 
being the exo product and solanapyrone D being the endo product. The key experiment 
that demonstrated a Diels-Alder reaction involved feeding Alternaria solani isotopically 
labeled prosolanapyrone II, the proposed precyclisation precursor of the solanopyrones 
(Figure 1.26)	 . The isotopically labelled prosolanopyrone II was incorporated into 
solanopyrone A, strongly suggesting that it had undergone the predicted intramolecular 
Diels-Alder reaction139. A cell free extract from Alternaria solani was found capable of 
oxidising the primary hydroxyl of prosolanapyrone II to an aldehyde, forming 
prosolanapyrone III141. Prosolanapyrone III spontaneously undergoes an apparent [4+2] 
cyclisation to form the exo and endo products at a 3:97 ratio, respectively141. However, the 
cell-free extract, later shown to contain the enzyme Sol5142, accelerated the cyclisation 
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nearly four fold and selectively produced the exo product over the endo at a 7:1 ratio141,142. 
Notably, when purified Sol5 degrades over time, its [4+2] cyclase activity decreases faster 
than the oxidase activity, suggesting specific protein elements are responsible for each143. 
Unfortunately no Sol5 crystal structure is available to investigate this proposal further. 
Whether Sol5 is a true [4+2] cyclase is still subject to debate namely because it has 
monooxygenase activity and the reaction it catalyses also occurs spontaneously.  
 
 
Figure 1.26 Solanopyrone biosynthesis. The enzyme Sol5 oxidises the primary hydroxyl of 
prosolanapyrone I to an aldehyde, forming prosolanapyrone III. Prosolanapyrone III can spontaneously 
undergo an apparent [4+2] cycloaddition to form the exo and endo products at a 3:97 ratio. In the presence of 
Sol5 the exo/endo ratio changes to 7:1 and the rate of the reaction is enhanced four-fold. Figure adapted 
from136  
 
Another notable early example of the difficulties in confidently ascribing [4+2] cyclase 
activity to an enzyme is the LovB/LovC complex from the lovastatin biosynthesis pathway. 
Lovastatin is a fungal polyketide natural product used for the treatment of hyperlipidemia 
and the prevention of cardiovascular disease144. Like solanapyrone A/D, lovastatin also 
contains a dialykyldecalin predicted to form via a [4+2] cycloaddition (Figure 1.26). The 
lovastatin BGC was first sequenced from Aspergillus terreus and found to consist of two 
iteratively acting type I PKS enzymes, LovB and LovF. Together these PKS enzymes are 
responsible for synthesising the nonaketide and diketide portions of lovastatin, 
respectively145 (Figure 1.27). LovB forms a complex with LovC, an enoyl-reductase protein 
required for biosynthesis of the nonaketide146. Intriguingly, the nonaketide offloaded from 
LovB already contains the dialkyldecalin moiety, suggesting that an intramolecular [4+2] 































Spontaneous reaction 3:97 exo/endo
Sol5 catalysed 7:1 exo/endo
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extension cycles146,147. A chemically synthesised N-acetylcysteamine (a short 4’-
phosphopantithine mimic) hexaketide analogue of the predicted pre-cyclisation lovastatin 
intermediate was shown to spontaneously undergo an apparent [4+2] cycloaddition 
reaction to form a mix of endo and exo products. However, none of the products had the 
same ring stereochemistry as lovastatin137,148. On the other hand, when this substrate was 
incubated with purified LovB, the correct dialkyldecalin stereochemistry formed, albeit only 
as a minor product137,148. How LovB functions in vivo to selectively produce the correct 
decalin ring stereochemistry of lovastatin remains unknown, but it is another intriguing 
example of a putative duel function [4+2] cyclase enzyme.  
 
 
Figure 1.27 Lovastatin biosynthesis. The iterative type I PKS LovB synthesises the linear nonaketide 
lovastatin precursor. The nonaketide intermediate undergoes an apparent intramolecular [4+2] cycloaddition 
while still attached to the LovB/LovC complex, suggesting this enzyme complex could have [4+2] cyclase 
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SpnF from the spinosyn biosynthesis pathway was the first documented example of an 
enzyme whose single function appeared to be a [4+2] cycloaddition149. Spinosyn A and D 
(Figure 1.28) are type I polyketide insecticides produced by Saccharopolyspora 
spinosa150,151, an actinomycete isolated from the soil beneath a rum distillery in the British 
Virgin Islands152.  
 
Figure 1.28 Structure of spinosyn A and D. Spinosyn A and D are polyketide natural products produced by 
Saccharopolyspora spinosa. 
 
The spinosyns consist of a 12 membered macrolactone connected to a perhydro-as-
indacene moiety. The latter was predicted to form, in part, via a [4+2] cycloaddition 
reaction153. In contrast to the multifunctional Sol5 or LovB/LovC, a standalone S-
adenosylmethionine-binding enzyme, SpnF, appeared to catalyse this [4+2] cycloaddition 
reaction (although alternative cyclisation mechanisms cannot be entirely ruled out)149,154 
(Figure 1.29). While this apparent [4+2] cyclisation process can also occur spontaneously, 
SpnF enhances its rate 500 fold149, making it the best candidate yet for a bona fide [4+2] 
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mechanism remains largely mysterious (discussed in more detail in Chapter 6)155.  
 
 
Figure 1.29 Apparent [4+2] cycloaddition catalysed by SpnF in spinosyn biosynthesis. The standalone 
protein SpnF was shown to catalyse the apparent [4+2] cycloaddition to form the cyclohexene ring of 
spinosyn149. SpnF PBD: 4PNE155. 
 
1.7.2 VstJ  
 
 
As alluded to earlier, the spirotetronate moiety of spirotetronate natural products are 
predicted to form via an intramolecular [4+2] cycloaddition between the exocyclic double 
bond of the tetronate and 1,3 diene on the terminal end of the polyketide109. Analysis of the 
PKS genes from numerous spirotetronate pathways indicated that all form a 1,3 diene 
moiety at the appropriate position on their terminal end to react via a [4+2] cycloaddition 
with the exocyclic double bond on the tetronate ring110,113,116. The mechanism of 
spirotetronate formation was finally solved by studying versipelostatin biosynthesis. 
Versipelostatin is a spirotetronate produced by a type I modular PKS in Streptomyces 
versipellis 4083-SVS6. This compound downregulates the transcription of grp78, an 
endoplasmic reticulum chaperone protein implicated in Alzheimer’s and Parkinson’s 
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acids) protein, VstJ, of unknown function was identified157. An S. versipellis mutant 
containing a deletion in vstJ no longer produced versipelostatin, demonstrating that vstJ is 
an essential biosynthetic gene157. Instead, the S. versipellis ∆vstJ mutant produced a 
versipelostatin analogue that was characterised as an apparent pre-[4+2] cyclisation 
intermediate (Figure 1.30). When this precyclisation intermediate was incubated with 
purified VstJ the spirotetronate moiety formed, demonstrating that VstJ was indeed an 
apparent [4+2] cyclase responsible for catalysing spirotetronate formation.  
 
Figure 1.30 Spirotetronate formation in versipelostatin biosynthesis. A single enzyme, VstJ, was shown 
to catalyse formation of the spirotetronate moiety of versipelostatin157.  
 
Unlike the previous [4+2] cyclases described, spirotetronate formation did not occur in the 
absence of VstJ157. Consistently, homologues of vstJ were identified in the BGCs of other 
spirotetronates including abyssomicin, chlorothricin, and kijanimicin157, indicating a 
conserved role of these enzymes in spirotetronate formation. The structure of the VstJ 
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its activity verified in vitro158 (Figure 1.31). AbyU is a homodimer, each monomer 
consisting of an eight-strand β-barrel structure with an internal active-site cavity. Molecular 
dynamics simulations were used to dock the linear pre-[4+2] cycloaddition abyssomicin 
substrate into AbyU. The results from these simulations suggest that the primary role of 
AbyU is to promote the substrate forming a reactive conformation, rather than provide key 
catalytic amino acids. The molecular dynamic simulations also indicated that the reaction is 
indeed concerted, as required for a true pericyclic reaction158.  
 
Figure 1.31 The crystal structure of AbyU, PyrI4, and AOC2. The [4+2] cyclases AbyU158 (PBD: 5DYQ) 
and PyrI4159 (PDB: 5BTU) share the same fold as AOC2160 (2DIO). AOC2 catalyses a 4π pericyclic reaction 
during jasmonic acid biosynthesis.  
 
Another VstJ homologue, PyrI4, was found to catalyse an equivalent reaction in 
pyrroindomycin biosynthesis161. Pyrroindomycin is a spirotetramate (nitrogen-containing 
five membered ring) antibiotic produced by Streptomyces rugosporus (Figure 1.30)162. 
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revealed it shares the same eight-strand β-barrel fold159. Intriguingly, the same fold is also 
present in the plant allene oxide cyclase enzymes that catalyse a 4π pericyclic reaction in 
jasmonic acid biosynthesis (Figure 1.31)158–160. Like AbyU, the active site of PyrI4 was 
proposed to function mainly as a hydrophobic binding pocket that imposes conformational 
constraints of the substrate, making it adopt a reactive conformation159. PyrI4 also contains 
an N-terminal domain that, upon substrate binding, adopts an α-helical conformation to act 
as an essential  “lid” domain, holding the substrate in the β-barrel cavity159 (Figure 1.32).  
 
 
Figure 1.32 N-terminal lid domain of the [4+2] cyclase PyrI4. PyrI4 was cocrystallised with its product in 
its active site, revealing an N-terminal lid domain essential for enzyme active159. (PDB: 5BTU, 5BU3). 
 
1.7.3 PyrE3  
 
In addition to containing a spirotetronate or spirotetramate moiety, polyketides such as 
pyrroindomycin, versipelostatin, and chlorothricin also contain a dialkyldecalin ring109. The 
dialkyldecalin was also predicted to form by an intramolecular [4+2] cycloaddition113,116,161. 
Within the 100 kbp BGC of pyrroindomycin a gene, pyrE3, was identified that resembles an 
FAD-dependent monooxygenase. The role of PyrE3 was a mystery, as no monooxygenase 
was predicted to be required for pyrroindomycin biosynthesis161. However, deletion of 
pyrE3 in S. rugosporus abolished pyrroindomycin production, demonstrating that it is an 
essential biosynthetic gene. Furthermore, the S. rugosporus ∆pyrE3 mutant produced an 
apparent pyrroindomycin precyclisation substrate lacking both the dialkyldecalin and 
PyrI4 PyrI4-product complex  
N-terminal-lid 
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spirotetramate moieties. Incubation of this substrate with Tsn11 resulted in formation of the 
dialkyldecalin, indicating that PyrE3 is really a [4+2] cyclase, not a monooxygenase. The 
reaction did not proceed in the absence of PyrE3, and the non-covalently bound FAD 
cofactor was found to play a structural, rather than redox, role in catalysis161,163. Following 
formation of the dialkyldecalin moiety by PyrE3, PyrI4 could then form the spirotetramate 
ring, as discussed above161 (Figure 1.33). Homologues of PyrE3 were found in the BGCs 
of all spirotetronates that contain a dialkyldecalin ring, indicating a conserved mechanism 
of dialkyldecalin formation157,161,163. No essential catalytic amino acids were identified in the 
putative active site of Tsn11, suggesting that, like PyrI4, the role of the active site is to 
facilitate a reactive substrate conformation163.  
 
 
Figure 1.33 Enzymatic [4+2] cyclase cascade in pyrroindomycin biosynthesis. Formation of the 
dialkyldecalin moiety of pyrroindomycin is catalysed by PyrE3, a [4+2] cyclase that resembles an FAD-
dependent monooxygenase. Once the dialkyldecalin moiety has formed PyrI4, a VstJ homologue, catalyses 
another [4+2] cycloaddition to form the spirotetramate moiety161. The same enzymatic cascade is also 
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An interesting recent example of a PyrE3 homologue acting in a non-spirotetronate 
pathway is found in the biosynthesis of the unusual tetronate tetrodecamycin. 
Tetrodecamycin contains a dialkyldecalin moiety like pyrroindomycin but is not a 
spirotetronate164. Accordingly, the BGC of tetrodecamycin only encodes a PyrE3 
homologue, TedJ, and no VstJ homologue (Figure 1.34)118,165.  
 
  
Figure 1.34 The biosynthesis of the dialkyldecalin ring of tetrodecamycin. A PyrE3 homologue TedJ is 
responsible for catalysing formation of the dialkyldecalin core of tetrodecamycin165.  
 
1.7.4 The mystery of Tmn8 
 
Unexpectedly, a vstJ homologue, tmn8, was also identified in the BGC of tetronomycin157. 
Tetronomycin is a polyether tetronate and does not contain a spirotetronate moiety, so the 
role of Tmn8 is a mystery157. Until recently, the polyether tetronate family consisted of three 
closely related members: tetronomycin166, tetronasin167, and SF2487168/A80577169 (referred 
to in this thesis as tetromadurin). All three are characterised by having four different ring 
types: a tetronate, a cyclohexane, a tetrahydropyran, and at least one tetrahydrofuran ring 
(Figure 1.33). Tetronomycin and tetronasin are an interesting pair, as they share near-
identical carbon skeletons but they have opposite configuration at all ten of their equivalent 
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nonthmicin170 and ecteinamycin171 (Figure 1.35), both of which have a tetronate, a 
tetrahydrofuran and two tetrahydropyran rings. All polyether tetronates are ionophore 
antibiotics that bind to metal ions to disrupt ion gradients across cell membranes170–172. 
Polyether ionophores are themselves a diverse class of natural product, some of which 
with notable anticancer activities173. For the purposes of this thesis, the term polyether 
tetronate will only be used to refer to tetronomycin, tetronasin, and tetromadurin (SF2487). 
Due to their impressive array of different rings, there has been much research on their 
biosynthesis. Despite this, the mechanism of cyclohexane and tetrahydropyran formation 
has remained elusive111,174–177. The discovery of tmn8, a previously unannotated cyclase 
gene in the tetronomycin BGC offered the possibility that, despite its resemblance to 
authentic [4+2] cyclases, Tmn8 is actually responsible for creating the cyclohexane and/or 
tetrahydropyran ring of tetronomycin.  
 
 
Figure 1.35 Structures of the polyether tetronate ionophore antibiotics. There are five known polyether 
tetronates, tetronasin, tetronomycin, SF2487/A80577 (tetromadurin), nonthmicin, and ecteinamycin. The 
different types of ring present in polyether tetronate structures are highlighted on the tetronasin structure. 
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1.8 Polyether tetronate biosynthesis  
 
1.8.1 Tetronasin  
 
The biosynthesis of tetronasin (M139603) has been studied more extensively than the 
other polyether tetronates. Tetronasin is a type I polyketide ionophore antibiotic produced 
by Streptomyces longisporoflavus and was the first polyether tetronate to be discovered; 
first described in 1981 by ICI Pharmaceuticals (a precursor company of AstraZeneca)167. 
While tetrahydrofuran and tetrahydropyran rings are common in other ionophores, such as 
monensin178 and salinomycin179, owing to their cation binding ability, tetronasin was the first 
example of a polyether ionophore to contain a cyclohexane ring. Its unusual structure and 
antibiotic activity led to numerous partial and chemical synthesis studies180–184. Tetronasin 
can bind to numerous metal ions but forms the most stable complexes with sodium ions 
(Na+), which it binds at a 1:1 ratio185,186. Bioactivity assays revealed antibiotic activity 
against numerous ruminal microorganisms, particularly Gram-positive bacteria187. When 
added to feedstock, tetronasin has been shown to enhance weight gain in cows188 and 
sheep, also leading to increased wool production in the latter case189. Tetronasin has been 
banned in Europe since 2006, but is still used in animal husbandry in other parts of the 
world109.  
 
The first biosynthetic studies on tetronasin began in the 1980s, before the modular nature 
of type I PKS enzymes was known. The primary areas of interest at the time were in 
identifying its biosynthetic precursors and probing the chemistry of formation of the four 








Figure 1.36 Formation of tetronasin from a linear intermediate. Polyketide synthase enzymes (PKS) were 
predicted to make the displayed linear tetronasin intermediate. From this intermediate four different rings are 
formed: a tetronate, cyclohexane, tetrahydropyran, and tetrahydrofuran177. 
 
 
The biosynthetic precursors of tetronasin were identified by isotope feeding experiments. 
[1-13C] acetate, [1,2-13C] acetate, and [1-13C] propionate were fed to a S. longisporoflavus 
culture and the site of isotope incorporation was determined using 13C-13C NMR. Once 
taken into the cell the isotopically labelled acetate and propionate precursors were 
converted into malonyl-CoA and (2S)-methylmalonyl-CoA forms, respectively, enabling 
them to be used as PKS extension units61. The feeding studies demonstrated that the 
carbon backbone of tetronasin is comprised of six propionate units and seven acetate 
units174 (Figure 1.37). Feeding [Me-C13] methionine additionally demonstrated that the 
methyl of the C25 methoxy group is derived from methionine (in the form of S-adenosyl 
methionine)174. Notably, two of the carbon atoms of the tetronate ring (C33 and C34) were 
not labelled. It was established several decades later that these carbons are derived from 
hydroxypyruvate, converted into a glycolyl-ACP by a dedicated multienzyme complex 
patterned on pyruvate dehydrogenase enzymes (Sun et al, unpublished) (Figure 1.37).  
 










































































Figure 1.37 Summary of the 13C feeding experiments in S. longisporoflavus. [1-C13] acetate, [1,2-C13] 
acetate, [1-C13] propionate, and [Me-C13] methionine were fed to a growing culture of S. longisporoflavus and 
their incorporation detected using NMR174. Several decades later the C33 and C34 carbons of the tetronate 
ring were discovered to be derived from glycolyl-ACP.  
 
The early isotopic precursor experiments also provided insight into the mechanism of 
tetrahydrofuran formation. Feeding S. longisporoflavus with [1-C13, 1-18O2] acetate and [1-
C13, 1-18O2] propionate revealed no incorporation of 18O in the oxygen atoms at C25 or 
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Figure 1.38 Summary of 18O feeding experiments in S. longisporoflavus. [1-C13, 1-18O2] acetate and [1-
C13, 1-18O2] were fed to S. longisporoflavus and the incorporation of 
18O was detected using NMR175. All of 
the oxygen atoms in tetronasin except that of the C25 methoxy group and the C30 acetate group are derived 
from an acetate or propionate extender unit.  
 
The lack of 18O incorporation in C25 suggested that the tetrahydrofuran formed by 
oxidative cyclisation, a common mechanism of tetrahydrofuran formation in natural 
products. Oxidative cyclisation involves the oxidation of an E-alkene to a reactive epoxide 
that is attacked by an adjacent hydroxyl to form a tetrahydrofuran ring190,191 (Figure 1.39a). 
In such cases, epoxide formation is regio- and stereospecifically catalysed by an epoxidase 
enzyme, followed by epoxide hydrolysis by an epoxide hydrolase to form the 
tetrahydrofuran ring191–194. In the case of tetronasin, an E-double bond would have to 
initially be present between C24-C25 before being stereospecifically oxidised to an 
epoxide. A hydroxyl group present at C21 would then need to attack C24 to form the 
tetrahydrofuran ring and the unlabelled C25 hydroxyl (derived from molecular oxygen). 
Feeding S. longisporoflavus isotopically labeled tri- and tetraketide tetronasin intermediates 
containing the C21 hydroxyl and the C24-C25 E-alkene showed that they were 
incorporated intact into tetronasin, providing strong support for this mechanism177,195 









































Figure 1.39 Proposed mechanism of tetrahydrofuran formation in tetronasin biosynthesis. a, The 
tetrahydrofuran ring of tetronasin forms via an oxidative cyclisation mechanism of epoxidation and epoxide 
hydrolysis175. b, The isotopically labelled tetronasin di- and triketide analogues that were incorporated into 
tetronasin when fed to S. longisporoflavus177,195. The numbers is brackets correspond to the atom number in 
the final tetronasin structure.  
 
 
The feeding studies with [1-13C, 1-18O2] acetate/propionate precursors also provided some 
of the first clues as to how the tetrahydropyran and cyclohexane rings might form. The 
oxygen at C17 was labelled by feeding [1-13C, 1-18O2] acetate, indicating that the 
tetrahydropyran ring likely forms by the C17 hydroxyl attacking C13175. Numerous 
mechanisms were proposed by which the electrophilicity of C13 might be enhanced to 
promote nucleophilic attack by the C17 hydroxyl175,176. One of the mechanisms resonated 
more than the others: a scheme in which both the tetrahydropyran and cyclohexane rings 
are closed in a single step, after the tetronate and tetrahydrofuran rings have already 
formed (in a compound labelled pretetronasin) (Figure 1.40). Stereochemical and 
electronic analysis of a pretetronasin model indicated that it could theoretically fold into a 
low-energy conformation where groups that needed to form bonds to make tetronasin were 





































Figure 1.40 Metal-catalysed mechanism of cyclohexane and tetrahydropyran formation in tetronasin 
biosynthesis. One of the proposed mechanisms for formation of the cyclohexane and tetrahydropyran rings 
in tetronasin is a metal-catalysed ring-closing cascade175,177.  
 
It was further speculated that such a reactive conformation could be promoted by 
pretetronasin complexing to a metal ion such as Na+, Mg2+, or Zn2+ 175,177. The proposed 
active metal-bound conformation of pretetronasin even resembles the final conformation of 
tetronasin in solution, providing additional support for this mechanism167,177. While this 
mechanism was never demonstrated in vitro or in vivo, an analogous reaction was 
performed during the second published total synthesis of tetronasin (Figure 1.41)180. Using 
a substrate analogous to pretetronasin, the cyclohexane and tetrahydropyran rings could 
be formed in a single step, with the correct stereochemistry, using a basic catalyst180. It is 
therefore possible that tetrahydropyran and cyclohexane formation in polyether tetronates 





















































Figure 1.41 Method used for cyclohexane and tetrahydropyran in tetronasin total synthesis. The 
reaction used potassium bis(trimethylsilyl)amide (KHMDS) in toluene to produce a single product at 67% 
yield180.  
 
In 2007 the BGC of tetronasin (the tsn cluster) was cloned and sequenced by the Leadlay 
lab (GenBank: FJ462704). The tsn gene cluster is roughly 125 kbp in size and contains ca. 








































Figure 1.42 The biosynthetic gene cluster of tetronasin. The tetronasin gene cluster is 125 kbp in size. 
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Table 1.2 Table 1.2 Tetronasin gene cluster annotation table.  
orf Size Protein homologue and origin  Identity/ 
similarity (%) 
Proposed function 
     
tsn26 218 WP_078074012, Streptomyces niveus 96/97 4'-phosphopantetheinyl 
transferase 
tsn27 293 WP_078074014, Streptomyces niveus 97/97 Metallophosphoesterase 
tsn28 145 WP_078079323, Streptomyces niveus 92/97 Glyoxalase 
tsn1 272 WP_100303314, Streptomyces sp. CNZ306 65/78 Acyltransferase 
tsn2 431 WP_117398905, Actinomadura sp. LHW52907 48/59 E2 dihydrolipoyl 
acyltransferase 
tsn3 334 WP_117398904, Actinomadura sp. LHW52907 70/80 Pyruvate dehydrogenase E1 
beta subunit 
tsn4 345 WP_117398903, Actinomadura sp. LHW52907 73/79 Pyruvate dehydrogenase E1 
alpha subunit 
tsn5 108 WP_117398902, Actinomadura sp. LHW52907 54/69 Acyl-carrier protein 
tsnAII 5136 WP_076682134, Streptomyces alfalfae 50/61 Type I polyketide synthase: 
(KS, AT, DH, KR, ACP, KS, 
AT, DH, KR, ACP, KS, AT, 
KR, ACP) 
tsnAIII 5630 BAE93730 (TmnAIV), Streptomyces sp. NRRL 11266 
 
53/64 Type I polyketide synthase: 
(KR, AT, DH, ER, KR, ACP, 
KS, AT, DH, KR, ACP, KS, 
AT, DH, KR, ACP) 
tsnAIV 6036 WP_047014291, Streptomyces sp. CNQ-509 
 
52/63 Type 1 polyketide synthase: 
(KS, AT, DH, ER, KR, ACP, 
KS, AT, DH, ER, KR, ACP, 
KS, AT, DH, KR, ACP) 
tsnB 139 CAQ64695, Streptomyces lasaliensis 46/57 Epoxide hydrolase 
tsn7 422 WP_076474008, Micromonospora avicenniae 58/73 MFS transporter 
tsn8 290 WP_027756739, Streptomyces sp. CNH099  49/68 Methyltransferase 
tsn9 350 WP_030750290, Streptomyces sp. NRRL S-31  56/70 FabH 3-oxoacyl-ACP 
synthase III 
tsnC 477 B5M9L6 (LasC), Streptomyces lasaliensis 53/67 Epoxidase 
tsn11 495 WP_100249299, Streptomyces tsukubensis  46/60 [4+2] cyclase 
tsnAV 1553 WP_066029228, Streptomyces hygroscopicus 51/63 Type I polyketide synthase 
(KS, AT, KR, ACP) 
tsn12 394 KWX00849, Streptomyces thermoautotrophicus  53/68 Cytochrome P450 
tsn13 350 WP_099855277, Micromonospora sp. CNZ299 56/71 FabH 3-oxoacyl-ACP 
synthase 
 
tsn15 206 BAF73716 (Tmn8), Streptomyces sp. NRRL 11266 29/44 [4+2] cyclase 
tsnAI 5029 CAQ64686, Streptomyces lasaliensis  52/63 Type I polyketide synthase 
(KSQ, AT, ACP, KS, AT, DH, 
KR, ACP, KS, AT, DH, ER, 
KR, ACP) 
tsn14 178 KDN76189, Streptomyces olindensis 59/76 Transcriptional regulator 
tsn15b 540 WP_050066454, Rhodococcus sp. RD6.2 51/69 Tetronasin ABC transporter 
tsn16 301 KDN76193, Streptomyces olindensis 78/87 ABC transporter, ATP 
binding component 
tsn17 256 KDN76194, Streptomyces olindensis 71/82 Pathway specific activator 
tsn18 294 KUJ69111, Streptomyces albus subsp. albus  83/89 Dioxygenase 
tsnDIII 2097 WP_018851410, Streptomyces sp. CNY243 66/75 Type I polyketide synthase 
tsn19 520 KUJ69086, Streptomyces albus subsp. albus 77/85 Acyl-CoA synthase 
tsn20 423 WP_113685098, Streptomyces sp. PT12  61/76 Cytochrome P450 
tsn20a 255 WP_103534038, Streptomyces sp. SM11  67/75 Thioesterase 
tsnDII 1502 BAE93739 (TmnDII), Streptomyces sp. NRRL 11266 58/67 Type I polyketide synthase 
(KS, AT, DH, ACP, TE) 
tsnDI 2476 WP_100303217, Streptomyces sp. CNZ306 
 
62/71 Type I polyketide synthase 
(AT, ACP, KS, ACP, KS, 
ACP, KR) 
tsn21 585 PJJ38674, Streptomyces sp. CNZ306 69/81 Acyltransferase 
tsn22 249 WP_037741229, Streptomyces sp. CNQ-525 62/71 Transcriptional regulator 
tsn23 379 BAE93743 (Tmn22), Streptomyces sp. NRRL 11266  56/74 Putative membrane protein 
tsn24 918 WP_079053178, Streptomyces phaeochromogenes 55/68 LuxR transcriptional 
regulator 
tsn25 249 WP_078074018, Streptomyces niveus 92/95 Methyltransferase 
 
The tsn cluster contains eight type I PKS enzymes, five of which (tsnAI-tsnAV) appear to 
be involved in the biosynthesis of the 26-carbon backbone of tetronasin. Together, these 
five PKS enzymes contribute a loading module and 12 extension modules. The polyketide 
synthase enzymes are responsible for establishing the stereochemistry of the C6, C14, 
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C17, C20, C21, and C22 chiral centers. The configurations of the remaining stereocenters 
are established during ring formation. At one end of the tsn cluster are three additional type 
I PKS enzymes (tsnDI-tsnDIII) that, on the basis of the domains they contain, are very 
unlikely to be involved in tetronasin biosynthesis. In fact, deletion of tsnDIII did not affect 
tetronasin biosynthesis (Demydchuk et al, unpublished). The nine genes adjacent to tsnDI-
tsnDIII (tsn18-tsn25) also have no obvious role in tetronasin biosynthesis, and deletion of 
tsn18 had no affect on tetronasin biosynthesis. At the other end of the cluster are genes 
encoding the E1 (tsn3 and tsn4) and E2 (tsn3 and tsn4) components of the 
hydroxypyruvate dehydrogenase complex and an acyl carrier protein (tsn5). Together 
these proteins have been shown to produce glycolyl-ACP, the origin of the two additional 
carbon atoms (C33 and C34) of the tetronasin tetronate ring (Sun et al, unpublished). 
Unlike other tetronate BGCs, which only contain a single gene for a FabH-like protein, the 
tsn cluster contains two: tsn9 and tsn13. Interestingly, both FabH-like proteins were shown 
to be essential for tetronasin biosynthesis by targeted inactivation (Sun et al, unpublished). 
The role each enzyme plays in tetronate ring formation/PKS chain release is therefore 
unknown. The gene tsn8 encodes a putative methyltransferase enzyme. Selective 
inactivation of tsn8 resulted in production of a new metabolite that corresponded in mass to 
an analogue of tetronasin lacking a methyl group, suggesting it is likely responsible for 
catalysing formation of the C25 methoxy group. Similarly, inactivation of the P450 
monooxygenase tsn12 resulted in production of a tetronasin analogue lacking a hydroxyl 
group, indicating it is likely responsible for catalysing hydroxylation of C30 (Sun et al, 
unpublished). Also within the tsn cluster are the epoxidase (tsnC) and epoxide hydrolase 
(tsnB) genes responsible for catalysing stereoselective tetrahydrofuran formation. Deletion 
of tsnC resulted in production of a novel tetronasin metabolite containing all rings except 
the tetrahydrofuran. In the place of the tetrahydrofuran ring was the predicted C24-C25 E 









Figure 1.43 Tetronasin analogue produced by a S. longisporoflavus ∆tsnC. Deletion of tsnC in S. 
longisporoflavus resulted in the production of a tetronasin analogue where the tetrahydrofuran ring had not 
yet formed (structure solved by NMR). It its place was a C24-C25 E alkene (Hui Hong, unpublished). 
 
 
In addition to verifying the role of tsnC in tetrahydrofuran formation, the accumulation of 
this intermediate demonstrated that formation of the other rings is not dependent on the 
tetrahydrofuran ring having formed. Whether the cyclohexane, tetrahydropyran, and 
tetrahydrofuran rings form while the polyketide is attached to the PKS or after chain release 
is unknown, though evidence from other polyether pathways suggests that the 
tetrahydrofuran and tetrahydropyran rings can form before chain release196,197. Finally, the 
tsn gene cluster also contains several transcriptional regulator genes (tsn14 and tsn17), 
resistance proteins (tsn15b, tsn16, and tsn7)198, and a PPTase (tsn26). Unfortunately, 
analysis of the cluster up until 2015 provided no hints as to how the cyclohexane and 
tetrahydropyran rings formed (the putative cyclases described in this thesis, Tsn11 and 
Tsn15, had not been identified). At the time, none of the enzymes in the BGC appeared to 
be cyclases, nor did the PKS enzymes contain any putative pyran synthase domains68,69, 
that could account for tetrahydropyran or cyclohexane biosynthesis. The proposed 
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Figure 1.44 Proposed biosynthetic pathway of tetronasin. The relative timing of the different reactions are 
unknown and could be different from the order presented. (I) The carbon backbone of tetronasin is 
synthesised by a TsnAI-A12. (II) Hydroxypyruvate is the origin of the two addition carbons of the tetronate 
ring. (III) Pyruvate hydroxydehydrogenase enzymes convert hydroxypyruvate into glycolyl-ACP. (VI) The two 
FabH enzymes in the tetronasin BGC likely both contribute to tetronate ring formation, though the exact role 
of each is unknown. (V) Epoxidation catalysed by TsnC. (VI) Epoxide hydrolysis catalysed by TsnB. (VII) The 
timing and mechanism of cyclohexane and tetrahydropyran formation is unknown. (VIII) Tsn12 catalyses 
hydroxylation of C30. (IX) Tsn8 catalyses methylation of the C25 hydroxyl. 
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1.8.2 Tetronomycin  
 
The BGC of tetronomycin (the tmn cluster) has also been sequenced111 (Figure 1.45). First 
isolated from the terrestrial Streptomyces sp. NRRL 11266, the tetronomycin gene cluster 
has also been identified in sea sponge-associated actinomycetes199 and in polar desert 
soils200. Like tetronasin, tetronomycin also readily binds to sodium ions, and has antibiotic 
activity towards numerous gram-positive bacteria, including Staphylococcus aureus166,201. 
Several partial and total chemical syntheses of tetronomycin have been performed202–205, 




Figure 1.45 Structure and atom numbers of tetronomycin 
 
Given the structural similarities between tetronasin and tetronomycin, it is no surprise that 
the tmn cluster contains similar genes to the tsn cluster; however, it also has some notable 
differences111. The 26-carbon backbone of tetronomycin is synthesised by six type I PKS 
enzymes (TmnAI-TmnAVI), together contributing a loading module and 12 extension 
modules111. The PKS enzymes are responsible establishing the stereochemistry of C6, 
C14, C17, and C21 in the opposite configuration to the equivalent centres in tetronasin 
(Figure 1.46). The other differences in stereochemistry must therefore be introduced 
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Figure 1.46 Theoretical linear intermediate of tetronomycin. The stereochemistry at C6, C14, C17, C21 is 
introduced by the tmn I PKS enzymes. The theoretical linear tetronasin intermediate is included for the sake 
of comparison.   
 
Interestingly, like the tsn cluster the tmn cluster also contains additional type I PKS genes 
at one end with no obvious function (analogous to the tsnD genes identified in the tsn 
cluster). As in the case of the tsn cluster, deletion of one of these PKS genes (tsnDI) 
confirmed its lack of involvement in tetronomycin biosynthesis. The tetronate ring of 
tetronomycin is synthesised in the manner typical for tetronates, using glyceryl-ACP (the 
origin of C31, C32, and C33)109,111 (Figure 1.41). The substrate 1,3-bisphosphoglycerate is 
converted into glyceryl-ACP by the FkbH-like protein Tmn16 and the acyl-carrier protein 
Tmn7a111. A single FabH-like protein, Tmn15 then catalyses C-C and C-O bond formation 
between glyceryl-ACP and the PKS-bound tetronomycin acyl chain, producing the 
tetronate ring and causing chain release111,122. agg4 (tmn20) and agg5 (tmn18) 
homologues are present for the formation of the exocyclic double bond on the tetronate 
(not present in tetronasin)111,123. Like tetronasin, one of the methyl groups of tetronomycin 
is hydroxylated (C28) and it has a methoxy group at C25. Correspondingly, the tsn cluster 
contains a cytochrome P450 (Tmn14) and a methyltransferase (Tmn12), respectively 
responsible for the hydroxylation and methylation111. Like the tsn cluster, the tmn cluster 
also contains the epoxidase (tmnC) and epoxide hydrolase (tmnB) genes required for 
stereoselective tetrahydrofuran formation via oxidative cyclisation. In regards to the 
cyclohexane and tetrahydropyran rings, the authors proposed that they formed 
simultaneously in a reaction very similar to the metal-catalysed ring closure reaction 
originally proposed for tetronasin111. However it was also hypothesised that an enzyme 
Theoretical ACP-bound linear tetronomycin intermediate
Theoretical ACP-bound linear tetronasin intermediate
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could be responsible. The discovery of the [4+2] cyclase homologue, tmn8, in the tmn 
cluster adds fresh impetus to this hypothesis. 
1.9 Aims of this thesis 
 
The central aim of this thesis was to deconvolute the biosynthetic pathway to polyether 
tetronates, a particularly intriguing and unsolved problem in understanding how initial PKS 
products are rearranged into antibiotic products. A particular aim was to examine the role 
of putative [4+2] cyclase homologues recently discovered in the biosynthetic gene clusters 
of polyether tetronates, and to determine whether these enzymes played a role in 
tetrahydropyran and/or cyclohexane biosynthesis. Success in this would potentially reveal 
novel enzymology, as well as providing fresh insight into the evolution of these 
sophisticated assembly-line pathways. 
 
The initial questions to be addressed were whether [4+2] cyclase homologues are also 
present in the biosynthetic gene clusters of tetronasin and tetromadurin, and whether they 
are essential for their biosynthesis, given that no [4+2] cycloaddition is predicted to occur. 
Structural comparison of the polyether tetronate [4+2] cyclase homologues with those from 
spirotetronate pathways might help to shed light on their catalytic roles. It was hoped to use 
the putative cyclases to reconstitute (portions of) the post-PKS pathway in vitro, and hence 
to establish the timing and mechanism of cyclohexane and tetrahydropyran formation in 
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2.1 General methods 
 
2.1.1 Chemical reagents 
 
All chemicals and biomaterials were purchased from Sigma-Aldrich (USA) or Thermo 
Fisher (USA) unless otherwise stated. All chemicals were of analytical grade and all 
organic solvents were of HPLC quality. All water used in this study, unless stated 
otherwise, was distilled and purified though a Milli-Q water purification system (Millipore, 
USA). The purified tetronasin standard was a gift from Dr. Hui Hong.  
2.1.2 Biological reagents. 
 
All restriction endonucleases and DNA ligases were purchased from ThermoFisher 
Scientific (USA). T5 exonuclease and the PhusionTM and Q5TM high-fidelity DNA 
polymerases were purchased from New England Biolabs (USA). For standard PCR 
applications, such as colony PCR, BioMix RedTM was used (Bioline, USA). All enzymes 
were stored at −20 °C and used according to the manufacturer’s instructions. Proteinase K 
and lysozyme were purchased from Sigma-Aldrich (USA). 
2.1.3 Antibiotic solutions 
 
Antibiotic solutions were made up to 1000x concentration stock solutions and filter-
sterilised using a 0.22 µm filter before being stored at −20 °C. The final concentration of 
each antibiotic used is presented in Table 2.1. The antibiotics were then added to liquid 
medium or molten solid medium as required.  
 
 





Antibiotic  Solvent  Final concentration used  
   
Ampicillin H2O 100 µg/mL 
Kanamycin H2O 50 µg/mL 
Chloramphenicol Ethanol 34 µg/mL 
Apramycin H2O 50 µg/mL 
Nalidixic acid  0.15 M NaOH 25 µg/mL 
 
Table 2.1 Antibiotic concentrations used in this work 
 
2.1.4 Oligonucleotides  
 
All oligonucleotide primers were ordered from Sigma Aldrich (USA) in a lyophilised form. A 
master stock was created by dissolving each primer in TE buffer (10 mM TrisCl, 0.5 M 
EDTA, pH 8) to a final concentration of 100 µM. Working primer stocks were made to 10 
µM in H2O. All primers were stored at −20 °C.  
 
Primer Sequence (5’-3’) 
  


















































mad31_NdeI_Fw GGGGCATATGGGCATGACCTCGCTGCGGCCTGG  






























2.1.5 Plasmids used 
 
All plasmids were stored in H2O and kept at −20 °C (Table 2.2).  
Name Description Source 
   
pYH7 tsr, bla, aac(3)IV, cos, oriT, PT7, PT3, 
oripIJ101, oriColEI.  
Used for coding-frame deletions in Streptomyces by 
homologous recombination 
111 
   
pET28a(+) kan, PT7, oripBR322, lacI, N-terminal His6-tag, oriF1. Used 
for the overexpression of genes in E. coli BL21  
Novagen 
   
pIB139 aac(3)IV, oriT, attP (s in N-terminal His6-tag, orIntegrative 
Plasmid used for in trans genetic complementations.  
206 
   
pYH7-tsn11 Gene deletion construct for tsn11  This study 
pYH7-tsn15 Gene deletion construct for tsn15 This study 
pYH7-tmn8 Gene deletion construct for tmn8  This study 
pYH7-mad10 Gene deletion construct for tsn15 This study 
pYH7-mad31 Gene deletion construct for mad31 This study 
pIB139-tsn11 Construct for the heterologous expression of tsn11  This study 
pIB139-tsn15 Construct for the heterologous expression of tsn15 This study 
pIB139-tmn8 Construct for the heterologous expression of tmn8 This study 
pIB139-tmn9 Construct for the heterologous expression of tmn9 This study 
pIB139-mad10 Construct for the heterologous expression of mad10 This study 
pIB139-mad31 Construct for the heterologous expression of mad31 This study 
pET28a(+)-tsn11 E. coli overexpression construct for tsn11  This study 
pET28a(+)-tsn15 E. coli overexpression construct for tsn15  This study  
pET28a(+)-tmn8 E. coli overexpression construct for tmn8  This study 
pET28a(+)-tmn9 E. coli overexpression construct for tmn9  This study 
pET28a(+)-∆N-tsn15 E. coli overexpression construct for ∆N-tsn15. A version of 
tsn15 lacking its first 11 amino acids.  
This study 
pET28a(+)-tsn15-Q84A E. coli overexpression construct for tsn15-Q84A  GenBank 
pET28a(+)-tsn15-R89A E. coli overexpression construct for tsn15-R89A  GenBank 
pET28a(+)-tsn15-Y91F E. coli overexpression construct for tsn15-Y91F  GenBank 
pET28a(+)-tsn15-E109A E. coli overexpression construct for tsn15-E109A  This study 
pET28a(+)-tsn15-D122A E. coli overexpression construct for tsn15-D122A  This study 
pET28a(+)-tsn15-T140A E. coli overexpression construct for tsn15-T140A  GenBank 
pET28a(+)-tsn15-S126A E. coli overexpression construct for tsn15-S126A  GenBank 
pET28a(+)-tsn15-N151A E. coli overexpression construct for tsn15-N151A  GenBank 
pET28a(+)-tsn15-Q164A E. coli overexpression construct for tsn15-Q164A  GenBank 
pET28a(+)-tsn15-W190A E. coli overexpression construct for tsn15-W190A  This study 
pET28a(+)-tsn15-Y202F E. coli overexpression construct for tsn15-Y202F  GenBank 
Table 2.2 Plasmids used in this study. 
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2.1.5 Bacteria strains used 
 
All bacteria were grown on sterilised liquid or solid medium (Table 2.3 and Table 2.4). A 
laminar flow hood and sterile technique was used when working with all strains.  
Name Characteristics Source 
   
E. coli BL21 (erist F– ompT gal dcm lon hsd SB (rB- mB) λ(DE3 [lacI lacUV5-T7 gene 1 
ind1 sam7 nin5]).  
 





E. coli ET12657/pUZ8002 (F- dam -13::Tn9 dcm -6 hsd M hsd R recF143 zjj -202::Tn10 gal K2 
gal T22 ara 14 pac Y1 xyl -5 leu B6 thi -1); pUZ8002: tra, neo, RP4. 
 
Donor strain for conjugation between E. coli and actinomycetes. 
207 
   
E. coli NovaBlue  endA1 hsdR17 (rK12– mK12+) supE44 thi-1 recA1 gyrA96 relA1 
lac F′[proA+B+lacIqZΔM15::Tn10] (TetR). 
 
E. coli strain used for general DNA manipulation and cloning. 
 
Novagen (USA) 
Table 2.3 E. coli strains used in this study. 
 
Name Characteristics Source 
   
Actinomadura verrucosispora  Tetromadurin producer PF168 
Streptomyces sp. NRRL 11266 Tetronomycin producer PF166 
S. longisporoflavus 83E6 Tetronasin producer PFL  
S. longisporoflavus ∆tsn11 S. longisporoflavus 83E6 in which 1356 nt of the tsn11 coding 
frame has been deleted. Producer of T-16.  
This study 
S. longisporoflavus ∆tsn15 S. longisporoflavus 83E6 in which the entire 621 bp tsn15 coding 
frame has been deleted 
This study 
S. longisporoflavus  
∆tsn11 ∆tsn15 
S. longisporoflavus 83E6 in which 1356 nt of the tsn11 coding 
frame and the entire 621 bp tsn15 coding frame were deleted. 
Producer of T-16. 
This study 
S. longisporoflavus  
∆tsn11-tsn11 
S. longisporoflavus ∆tsn11 containing the integrative pIB139-
tsn11 plasmid. Produces tetronasin. 
This study 
S. longisporoflavus  
∆tsn15-tsn15 
S. longisporoflavus ∆tsn11 containing the integrative pIB139-
tsn15 plasmid.  
This study 
S. longisporoflavus  
∆tsn11-tmn9 
S. longisporoflavus ∆tsn11 containing the integrative pIB139-
tmn9 plasmid.  
This study 
S. longisporoflavus  
∆tsn11-mad10 
S. longisporoflavus ∆tsn11 containing the integrative  
pIB139-mad10 plasmid.  
This study 
S. longisporoflavus  
∆tsn15-tmn8 
S. longisporoflavus ∆tsn15 containing the integrative pIB139-
tmn8 plasmid. 
This study 
S. longisporoflavus  
∆tsn15-mad31 
S. longisporoflavus ∆tsn15 containing the integrative  
pIB139-mad31 plasmid. 
This study 
S. sp NRRL 11266 ∆tmn8 S. sp NRRL 11266 83E6 in which the entire 573 bp tmn8 coding 




A.verrucosispora in which 906/1404 bp of the mad10 coding 




A.verrucosispora in which 291/561 bp of the mad10 coding frame 
has been deleted 
This study 
Table 2.4 Actinomycetes used in this study. 
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2.1.7 Bacteria culture media  
 
All bacteria culture media was sterilised by autoclaving at 121°C, 1.5 bar, for 20 min. 
Tryptone, yeast extract, and agar were all purchased from Formedium (UK). Soy flour was 
purchased from Genesee Scientific (USA). D-mannitol was purchased from Alfa Aesar 
(USA). Dextrin was purchased from Acros Organics (USA). Tryptic soy broth was 
purchased from BD (USA). pH was adjusted using HCl and NaOH, measured using a 
Mettler Toledo 340 pH meter (USA). 
 
LB medium 
10 g/L tryptone 
5 g/L yeast extract 
10 g/L NaCl 
H2O to final volume (pH 7.0) 
 
For solid LB medium 15 g/L agar was added before autoclaving. 
 
2TY medium 
16 g/L tryptone  
10 g/L yeast extract 
5 g/L NaCl 
H2O to final volume (pH 7.0) 
 
SOC medium 
20 g/L tryptone 
5 g/L yeast extract 
2.5 mM KCl 
10 mM NaCl 
10 mM MgCl2** 
20 mM D-glucose** 
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M9 minimal medium 
0.2% w/v D-glucose 
2 mM MgSO4 
0.1 mM CaCl2 
100 µg/mL thiamine 
X µg/mL antibiotic solution* 
1x M9 salts** 
20 mM NH4Cl 
0.2x trace metals*** 
20 µM FeCl3**** 
H2O to final volume (pH 7.0) 
 
The M9 salts were autoclaved with 0.78x volume of H2O. The remaining components were added post-
autoclave.  
 
*added according to Table 2.1 
 
**5x M9 salts recipe 
250 mM Na2HPO4    
110 mM KH2PO4    
50 mM NaCl 
H2O to final volume  
Sterilized by autoclaving  
 
***1000x Trace metal solution recipe 
20 mM CaCl2 
10 mM MnCl2  
10 mM ZnSO4 
2 mM CoCl2  
2 mM CuCl2  
2 mM NiSO4  
2 mM Na2MoO4 
2 mM H3BO3 
Dissolved in H2O and filter-sterilised.  
 









20 g/L soy flour* 
20 g/L D-mannitol 
20 g/L agar 
Tap water to final volume 
 
*The soy flour was autoclaved first in 300 mL of tap water, after which it was filtered through a cloth to 
remove large insoluble components. The D-mannitol and agar was added to the filtrate, brought up to 1 L 
using tap water, and autoclaved again.  
 
TSBY 
30 g/L tryptic soy broth  
103 g/L sucrose 
5 g/L yeast extract 
H2O to final volume 
 
Tap water medium (TWM) 
5 g/L D-glucose 
10 g/L sucrose 
5 g/L tryptone 
2.5 g/L yeast extract 
0.036 g/L EDTA  
15 g/L agar 
Tap water to final volume (pH 7.1) 
 
Oatmeal agar 
20 g/L oatmeal* 
H2O to final volume 
 
*The oatmeal was autoclaved first in 300 mL of H2O after which it was filtered through a cloth to remove large 













30 g/L tryptic soy broth 
3 g/L CaCO3 
D4 trace elements (added post autoclave)* 
H2O to final volume  
 
Tsn-medium B 
30 g/L tryptic soy broth 
3 g/L CaCO3 
20 g/L agar 
100 g/L dextrin 
H2O to final volume  
D4 trace elements* 
*D4 trace elements recipe: 
4 mg/L FeSO4 
4 mg/L ZnSO4 
0.6 mg/L CuSO4 
0.4 mg/L MnSO4 
0.4 mg/L KMoO4 
H2O to final volume  
 
2.2 Microbiological methods  
 
2.2.1 Growth and maintenance of E. coli strains  
 
E. coli liquid cultures were grown in LB, 2TY, or M9 medium at 37 °C, 200 rpm in conical 
flasks. E. coli solid cultures were grown at 37 °C on LB agar. Antibiotics were added as 
appropriate. For the long term storage of E. coli cultures, an equal volume of 50% glycerol 
was added to an aliquot and stored at −80 °C. 
2.2.2 Growth and maintenance of actinomycete strains  
 
All actinomycete mycelial liquid cultures were grown at 30 °C 200 rpm in conical flasks. 
The liquid medium was filled to no more than 1/5 of the total flask volume. A steel spring 
was placed at the bottom of each flask that extended around the inside face, preventing the 
culture from clumping. Foam springs were used to seal the flask. Actinomycete solid 
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cultures were grown at 30 °C for 4-7 days. For the long-term storage of actinomycete 
mycelial cultures, an equal volume of 50% glycerol was added and stored at −80 °C. 
Spores of A. verrucosispora were stored in 20% glycerol and stored at −80 °C.  
2.2.3 Preparation of chemically competent E. coli cells 
 
Transforming Buffer I (pH 5.8) 
30 mM potassium acetate 
50 mM MnCl2 
10 mM CaCl2   
15 % glycerol (v/v)  
Transforming Buffer II (pH 7.0) 
10 mM NaMOPS (pH 7.0)  
75 mM CaCl2  
KCl 10 mM  
15 % glycerol (v/v)
E. coli cultures were inoculated in 3 mL of LB + appropriate antibiotics and grown overnight 
at 37 °C 200 rpm. The following day 100 µL of the overnight culture was used to inoculate 
50 mL of LB containing 10 mM MgCl2 and any appropriate antibiotics. The cells were 
grown to an A600 of 0.3-0.4, after which they were placed on ice for 20 min before being 
spun at 2700 x g, 2 °C for 10 min. The supernatant was decanted and the cells were 
resuspended in 0.8x volumes of ice-cold transforming buffer I then placed on ice for 2 h. 
The cells were then spun down again at 2700 x g, for 10 minutes at 2 °C before being 
resuspended in 0.1x volumes of ice-cold transforming buffer II. Aliquots of the cells were 
then snap-frozen and stored at −80 °C.  
2.2.4 Transformation of chemically competent cells 
 
A frozen aliquot of chemically competent cells was defrosted on ice, and 50-100 ng of 
plasmid DNA was added. The cells were kept on ice for 30 min before heat-shocking at 42 
°C for 60 sec, after which 250 µL of SOC medium was added. The cells were incubated at 
37 °C 220 rpm for 1 h before being plated onto LB agar containing any appropriate 
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2.2.5 Conjugation of actinomycete strains 
 
The DNA methylation-deficient ET12567 (pUZ8002) cells were transformed with the 
plasmid to be transferred into the actinomycete host and grown to an A600 of 0.4-0.6 in 2TY 
media containing selective antibiotics at half the usual concentration (see Table 1). The 
ET12567 cells were then spun down and washed twice in 20 mL of 2TY media before 
being resuspended in 300 µL of 2TY. The actinomycete strain to be conjugated (either as 
mycelia or spores) was prepared following the protocol from Practical Streptomyces 
Genetics210. After gentle mixing, the two bacteria types were plated onto 35 mL of SFM 
containing 10 mM MgCl2 and left at 30 °C for 12-20 h. The surface of the plate was then 
flooded with 1 mL of MQ water containing 35 µL of apramycin (50 mg/mL) and 25 µL 
nalidixic acid (25 mg/mL). The plate was then incubated at 30 °C to promote the growth of 
exconjugants. Exconjugants were verified by restreaking onto SFM containing 30-50 µg/mL 
apramycin and 25 µg/mL nalidixic acid.  
 
2.3 Molecular biology methods 
2.3.1 Extraction of genomic DNA from actinomycetes  
 
For the preparation of genomic DNA (gDNA), 250 µL of actinomycete mycelia was 
centrifuged in a 1.5 mL microcentrifuge tube to pellet the cells and the supernatant was 
discarded. The cell pellet was resuspended in 500 µL of SET buffer (20 mM TrisCl, 75 mM 
NaCl, 75 mM EDTA, pH 7.2) containing 10 µL of lysozyme solution (50 mg/mL). After 
incubation at 37 °C for 1 h, 60 µL of 10% SDS (w/v) and 10 µL of proteinase K (20 mg/mL) 
were added and the tube was incubated at 55 °C for an additional 2 h. The sample was 
then mixed with 300 µL of 5 M NaCl and 500 µL of chloroform and centrifuged at 2200 x g 
for 15 min. The aqueous upper layer was transferred to a fresh microcentrifuge tube using 
a T1000 pipette tip with the end cut off to avoid shearing the gDNA. To precipitate the 
gDNA, 0.6x volumes of isopropanol was added followed by gentle mixing. The precipitated 
gDNA was washed twice in 70% ethanol before being air dried for 5-10 min. The gDNA 
pellet was dissolved in 100-200 µL of distilled water.  
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2.3.2 Isolation of plasmid DNA  
 
The extraction of plasmid DNA from E. coli was performed using a Thermo Fisher 
GeneJET Plasmid Miniprep KitTM (Thermo Fisher, USA) following the manufacturer’s 
instructions.  
2.3.3 Quantification of DNA and protein concentration  
 
DNA was quantified by measuring the A260 nm absorbance using a NanoDrop ND-1000 
Spectrophotometer (Thermo Scientific, USA). DNA quality was assessed by measuring the 
260/280 nm and 260/230 nm ratios. Protein concentration was calculated by measuring its 
A280 nm absorbance and its extinction coefficient (calculated using 
web.expasy.org/protparam/). For the quantification of proteins bound to an FAD-cofactor 
the Bradford reagent (Biorad, USA) was used according to the manufacturer’s instructions. 
A bovine serum albumin (BSA) standard curve (presented in Appendix Figure 1) was 
prepared to use with the Bradford reagent.  
 
2.3.4 Restriction enzyme digestion of DNA 
 
DNA (both linear and circular) was digested using ThermoFisher ScientificTM restriction 
enzymes (USA). Restriction digestion mixtures were set up according to the manufacturer's 
instructions and incubated at 37 °C for 1–3 hours. Following digestion restriction enzymes 
were inactivated by heating at 65 °C for 20 min or using a DNA clean and concentrator kit 
(Zymo Research, USA).  
 
2.3.5 Agarose gel-electrophoresis 
 
50x TAE buffer  
242 g/L Tris base 
5.7 % (v/v) acetic acid  
6 g/L EDTA 
 
The size separation of DNA fragments was performed using agarose gel-electrophoresis. A 
1% (w/v) agarose solution (100 mL) was prepared in 1x TAE buffer. Midori GreenTM DNA 
stain (Bulldog Bio) was added to the molten gel according to the manufacturer's 
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instructions. The gel was poured into a gel-caster and a well-comb inserted. Gels were run 
at 120 V, 400 mA, for 30-40 min. GeneRuler 1kb Plus DNA ladder (Thermo Scientific) was 
used as a DNA size standard. 




Resolving gel recipe (single gel) 
1.1 mL ddH2O 
2.5 mL 30% acrylamide mix  
1.3 mL 1.5 M TrisCl pH 8.8 
0.05 mL 10% (w/v) Sodium dodecyl sulfate 
0.05 mL 10% ammonium persulfate (made fresh) 
0.0002 mL Tetramethylethylenediamine  
 
4x SDS Loading Buffer 
200 mM TrisCl pH 6.8 
400 mM DTT 
8% SDS (w/v) 
0.4% bromophenol blue (w/v) 
40% glycerol (v/v) 
Stacking gel recipe (single gel) 
0.68 mL ddH2O 
0.17 mL 30% acrylamide mix  
0.13 mL 1.5 M TrisCl pH 8.8 
0.01 mL 10% (w/v) Sodium dodecyl sulphate 
0.01 mL 10% ammonium persulfate* 
0.0001 mL Tetramethylethylenediamine (TEMED) 
 
10x SDS run buffer 
0.114% glycine (w/v) 
0.03% tris base (w/v) 
0.01 % SDS (w/v) 
 
 
The 15% resolving gel was made first and added into ~3/4 of the gel cast, the remainder of 
which was filled with isopropanol to ensure the surface of the gel set uniformly. The gel 
was then left to set for approximately 20 min at room temperature. Once set, the 
isopropanol was poured off and the 15% stacking gel loaded onto top of the resolving gel. 
A comb was inserted into the stacking gel before it was left to set for 20 min. Protein 
samples were loaded into the gel after being mixed with 1x loading buffer and heated at 98 
°C for 10 min. The gels were immersed 1x SDS run buffer and electrophoresis was carried 
out at 250 V, 20 mA, for 40-50 min. Precision Plus Dual Colour ladder (Bio-Rad) was used 
to provide protein size markers. Protein bands were visualised using InstantBlueTM 
(Expedeon, UK). 
 
2.3.7 Polymerase chain reaction 
 
Polymerase chain reaction (PCR) amplifications of DNA were performed using a 
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GeneAmpTM 9700 PCR machine (PE Applied Biosystems). The two polymerase mixtures 
typically used were 2X PhusionTM High Fidelity Master Mix with GC Buffer (New England 
Biolabs) and 2X BioMix RedTM (Bioline). A typical PCR was carried out in 1X polymerase 
mastermix, 0.5 µM forward primer, 0.5 µM of each primer and 5% (v/v) DMSO, and made 
up to the final volume in H2O. 2-10 ng of DNA was typically used for a PCR template. The 
PCR thermal parameters were taken from the PhusionTM and BioMixTM manufacturer’s 
instructions with consideration for the melting point (Tm) of each primer used in the reaction 
(typically ~3 °C lower than the lowest primer Tm). For colony PCR, a small piece of E. coli 
or actinomycete colony was added directly to the PCR tube. PCR amplification mixtures 
were prepared on ice and added to the PCR thermocycler once it had reached its starting 
temperature. A common two-step PCR protocol for the amplification of high GC DNA 
fragments is presented in Figure 2.1.  
 
 
Figure 2.1 Typical PCR thermal parameters used for the amplification of actinomycete genomes.  
 
2.3.8 Heterologous protein expression from E. coli  
 
Proteins were heterologously expressed from pET-28a(+) within E. coli BL21 (λDE3) cells. 
A pET-28a(+) construct containing a target gene cloned in-frame to the N-terminal His6 tag 
(MGSSHHHHHHSSGLVPRGSH) was transformed into chemically competent E. coli BL21 
(λDE3). A single transformant was selected to inoculate a 3 mL overnight culture of LBK 
(LB + 50 µg/mL kanamycin) media. The following day the overnight culture was added to 
400-1000 mL of LBK media and grown at 37 °C 200 rpm to an A600 of 0.5-0.6 before being 
98 °C  
2 min 
98 °C  
10 s 72 °C  
1 min 
72 °C  
5 min 
x 30 
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placed on ice for 20 min. Isopropyl β-D-1-thiogalactopyranoside (IPTG) was then added to 
a final concentration of 0.5 mM and the cells were incubated at 22 °C 200 rpm overnight. 
The cells were then spun down and frozen at −80 °C until needed.  
 




Protein Binding buffer 
20 mM TrisCl pH 7.9 
0.5 M NaCl 
5 mM imidazole 
 
Protein Wash buffer 
20 mM TrisCl pH 7.9 
0.5 M NaCl 





Protein Elution Buffer 
20 mM TrisCl pH 7.9 
0.5 M NaCl 
200-600 mM imidazole 
 
Protein Strip buffer 
20 mM TrisCl pH 7.9 
0.5 M NaCl 





A frozen aliquot of E. coli BL21 (λDE3) cells in which protein had been induced as 
described (Section 2.3.8) was resuspended in 30-40 mL of protein binding buffer. A 
SigmaFast EDTA-freeTM protease inhibitor tablet was dissolved in the resuspended cells. 
For small-scale protein purifications (<400 mL) cell lysis was performed using sonication. 
For large-scale purifications (>400 mL) lysis was performed using an EmulsiFlex-C5 
(Avestin, Canada) according to the manufacturer’s instructions. The lysed cells were 
centrifuged at 35,000 x g, 4 °C for 20 min. The supernatent was run through a column 
containing 1 mL of charged nickel-NTA resin (Qiagen, DE). After the supernatant had been 
applied to the column, non-specifically bound proteins were washed off the resin using 10 
mL of protein binding buffer followed by 6 mL of protein wash buffer. The fusion-protein 
was eluted from the column using 5 mL of elution buffer. A preparative ÄKTA purifier (GE 
Healthcare Life Sciences) Superdex 200 column was used to purify the protein further, 
exchange the buffer into 20 mM TrisCl pH 7.9, 100 mM NaCl, and remove the imidazole. 
An Amicon Ultra-15 Centrifugal Filter Unit (Merck Millipore, USA) was used to concentrate 
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the protein following preparative gel-filtration. The nickel column was cleaned after each 
use with 5 mL of strip buffer.  
2.3.10 Sanger DNA sequencing  
 
All DNA cloning reactions (such as ligations and isothermal assemblies) were confirmed by 
Sanger DNA sequencing. All sequencing was performed by the DNA Sequencing Facility 
of the Department of Biochemistry, University of Cambridge, UK.  
 
2.3.11 Gibson assembly and method of creation gene-deletion constructs 
 
Gibson assembly211 of two linear DNA fragments into a linearised vector was performed 
using Hot Fusion DNA assembly mix212. The pYH7 vector was linearised using the 
restriction enzyme NdeI. The general method used to create a gene-deletion construct was 
to PCR amplify 2 kb regions upstream and downstream of the gene of interest. The PCR 
primers used to amplify the 2 kb fragments contained regions of overlap with NdeI-
linearised pYH7 and the other 2 kb fragment, enabling all three to be seamless joined 
using Hot Fusion DNA assembly212. Each 2 kb fragment was added in three-fold molar 
excess of the linearised pYH7 vector. Typically the total DNA used in each reaction was 
100 ng. The assembled DNA product was then transformed into chemically competent E 
coli NovaBlue cells. Colony PCR was used to identify E. coli clones containing the correctly 
assembled insert, which were then fully sequenced using Sanger sequencing.  
 
2.3.12 Site-directed mutagenesis 
 
Site-directed mutagenesis was performed using the QuikChange II mutagenesis guidelines 
(Agilent, USA). The gene to be mutated was first cloned into the small vector pUC18. 
Complementary PCR primers each containing the desired mutation were designed and 
used to amplify the entire plasmid. The methylation-specific restriction enzyme DpnI was 
added to the amplified plasmid to digest the methylation template plasmid DNA. The 
remaining reaction was then transformed into chemically competent E. coli NovaBlue. 
Sanger sequencing was then used identify the clones containing the desired mutation. 
Only the Tsn15-E109A, Tsn15-D122A, and Tsn15-W190A were made using this method, 
the rest were ordered directly from GenScript (China). 
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2.3.13 Ligation of DNA  
 
DNA ligase was purchased from New England Biolabs (USA) and used according to the 
manufacturer’s instructions. Typical reactions contained 50 ng of digested vector with 3-6 
fold molar excess of the insert. The ligation reaction was incubated at 16 °C for 1-4 hours 
before being transformed into chemically competent E. coli NovaBlue cells. Colony PCR 
was performed to identify the clones containing the correct ligation product. All ligation 
constructs were confirmed using Sanger sequencing.  
 
2.3.14 Buffer exchange using PD-10 columns  
 
PD-10 columns were used change the buffer of a purified protein/desalt a protein solution. 
PD-10 columns from GE Healthcare Life Sciences (USA) were used according to the 
manufacturer’s instructions.  
 
2.3.15 Analytical ultracentrifugation of proteins 
 
Analytical ultracentrifugation (AUC) sedimentation was used to measure the molecular 
weight of a protein in solution. Purified protein was prepared as described in Sections 
2.3.8 and 2.3.9 and concentrated to 1-2 mg/mL in a final volume of 800 µL. AUC 
experiments were performed using an Optima XL-I (Beckman Coulter) centrifuge fitted with 
an An60 Ti four-hole rotor. Absorbance data was acquired in the continuous mode at time 
intervals of 170 s and at a rotor speed of 40,000 rpm, at 20 °C with systematic noise 
subtracted, but without averaging. The density and viscosity of the buffer (20 mM TrisCl pH 
7.9, 100 mM/150 mM NaCl) and the partial specific volume of the protein were both 
calculated using Sednterp213. The multi-component sedimentation coefficient distributions 
were obtained from 128 scans by direct boundary modelling of the Lamm equation using 
Sedfit v.14.1. All AUC experiments were performed under the guidence of Dr. Katherine 
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2.3.16 HPLC-MS analysis of proteins 
 
For the analysis of small molecules, a HPLC (Hewlett Packard, Agilent Technologies 1200 
series) coupled to a mass spectrometer (Thermo Finnigan MAT LTQ) was used. The HPLC 
was fitted with a 250 mm x 4.6 mm 5µm C4 reverse-phase column (5µ OSD3, 100Å. 
Phenomenex, USA). The mobile phase was aqueous 0.1% trifluoroacetic acid (TFA) and 
acetonitrile (0.1% TFA). The mobile phase flow rate was 0.3 mL/min with the following 
gradient: 0-20 min, 5-95% acetonitrile (0.1% TFA) 20-24 min, 95% acetonitrile (0.1% TFA), 
25-26 min, 95-5% acetonitrile (0.1% TFA).  
 
2.3.17 Protein crystallisation  
 
Proteins to be crystallised were purified using Ni-affinity followed by ÄKTA size-exclusion 
chromatography. Next, a MosquitoTM (TTP Labtech) liquid handling robot was used to mix 
0.2 µL of protein sample into 0.2 µL of the different pre-prepared crystallisation buffers. The 
crystallisation plates, each containing 96 different conditions, screened were: 
 
• The Classics Suite (Qiagen, DE) 
• JCSG plus (Molecular Dimensions, UK) 
• Wizard Classic 1&2 (Emerald Biosystems, USA) 
• Wizard Classic 3&4 (Emerald Biosystems, USA) 
• PACT premier™ HT-96 (Molecular Dimensions, UK) 
• pH Clear I (Qiagen, DE) 
• The PEGs suite (Qiagen, DE) 
• MorpheusTM (Molecular Dimensions, UK) 
 
Droplets were photographed under white and UV light using a Rock Imager 1000 
(Formulatrix, USA) to detect crystallisation events. The Tsn15 crystal selected for analysis 
was grown from 15 mg/mL protein in 0.1 M PCTP (0.1 M each sodium proprionate, sodium 
cacodylate trihydrate, and bis-Tris propane) buffer pH 6, 25% (w/v) PEG 1500. 26% (v/v) 
ethylene glycol was used as cryo-protectant and the crystal was flash frozen in liquid 
nitrogen.  
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To create a selenomethionine labelled version of Tsn15 (SeMet-Tsn15) E. coli BL21 
(λDE3) cells transformed with pET28a(+)-tsn15 were cultured in M9 medium. Once the 
culture had reached A600 = 0.5, 0.1 g/L L-lysine, 0.1 g/L L-threonine, 0.1 g/L L-
phenylalanine, 0.05 g/L L-leucine, 0.05 g/L L-isoleucine, and 0.05 g/L L-valine were added 
to the growing culture, followed by 0.06 g/L of L-selenomethionine. SeMet-Tsn15 was 
purified and exchanged into buffer containing 20 mM Tris-Cl pH 7.9, 100 mM NaCl, 2 mM 
EDTA, and 2 mM tris(2-carboxyethyl)phosphine (TCEP), then crystallised as before. 
Crystals were harvested from the crystallisation drop and transferred into a cryoprotecting 
solution containing the crystallisation solution and 26% ethylene glycol. 
 
The following was performed by Fernanda Paiva (University of São Paulo, Brazil). The 
Tsn15-ligand complex was crystallised using hanging-drop, vapor-diffusion method at 18 
ºC. To obtain the protein complex, a solution composed of Tsn15 protein (15 mg/mL in 20 
mM Tris-Cl pH 7.9 buffer, 0.5 M NaCl) and 10 mM of T-22 was incubated for 10 minutes 
and then crystallised in 0.1 M PCTP pH 6.0 buffer, 27% PEG 1500. 
 
2.3.18 Circular dichroism  
	
Circular dichroism (CD) spectra were collected using an Aviv Biomedical Model 410 (USA) 
circular dichroism spectrometer. The CD spectrometer was operated by the Department of 
Biochemistry (University of Cambridge) Biophysics facility. The buffer of each purified 
protein was exchanged to 10 mM KH2PO4, pH 7.9, as TrisCl-based buffers strongly absorb 
in the far UV. The concentration of each protein used was between 0.1 - 0.2 mg/mL. After 
the CD spectra were collected the data was normalised to the number of peptides present 
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2.4 Analysis of polyether tetronates and related metabolites  
 
2.4.1 HPLC-MS analysis of small molecules  
 
For the analysis of small molecules, an HPLC (Hewlett Packard, Agilent Technologies 
1200 series) coupled to a mass spectrometer (Thermo Finnigan MAT LTQ) was used. The 
HPLC-MS was fitted with a 250 mm x 4.6 mm 5µm C18 reverse-phase column (5µ OSD3, 
100Å. Phenomenex, USA). The mobile phase comprised of 20 mM ammonium acetate and 
methanol. The mobile phase flow rate was 0.7 mL/min with the following gradient: 0-5 min, 
5-75% methanol; 5-30 min, 75-95% methanol, 30-34 min, 95% methanol 35-36 min, 95-5% 
methanol. Normalised collision energy of 35% was used for the molecular fragmentation of 
tetronasin. 
 
2.4.2 Small-scale extraction of polyether tetronates 
 
To check the production of polyether tetronate metabolites from liquid culture, a 500 µL 
aliquot was removed and extracted using 500 µL of ethyl acetate. The ethyl acetate layer 
was then removed and evaporated under reduced pressure to yield a dry organic extract. 
The dried organic extract was dissolved in 1 mL of methanol and centrifuged at 20,000 g 
for 20 min, before HPLC-MS analysis. For the extraction of polyether metabolites produced 
by cultures grown on solid medium, the agar was cut into tiny cubes and extracted by 
submerging in ethyl acetate. The ethyl acetate was evaporated and the organic extract was 
redissolved 1 mL of methanol and centrifuged at 20,000 g for 20 min to remove any 
particulates, before HPLC-MS analysis.  
 
2.4.3 NMR data collection 
 
All NMR data was collected by the Department of Chemistry (University of Cambridge) 
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2.4.4 Isolation of T-16 for NMR analysis 
 
T-16 was isolated from S. longisporoflavus ∆tsn11. Well-grown S. longisporoflavus ∆tsn11 
colonies were inoculated into 5 mL of tsn-medium-A in a 25 mL conical flask and grown for 
two days at 30 °C and 200 rpm. The cultures were then inoculated into flasks containing 50 
mL of tsn-medium-A and grown for an additional two days at 30 °C 200 rpm or until a thick 
mycelial culture had formed. These cells were plated on 100 12 x 12 cm agar plates each 
containing 50 mL of tsn-medium-B in a 250 mL conical flask and grown for seven days at 
30 °C. The agar was then cut into small squares and combined in a large glass flask where 
it was extracted three times by submerging in ethyl acetate (1.5 L each time). The ethyl 
acetate was evaporated under reduced pressure to yield 7 g of a brown crude organic 
extract. The crude extract was dissolved in 8 mL of methanol and loaded onto eight 10g/70 
mL C18 reverse-phase Isolute cartridges (Biotage, Sweden) according to the 
manufacturer’s instructions. Fractions were eluted from the columns using a solution of 20 
mM ammonium acetate, 65% methanol. Fractions containing T-16 were identified by 
HPLC-MS and pooled together (1.15 g in total) before a second round of purification on 
another C18 cartridge. The final purification was performed using an Infinity II 
semipreparative HPLC (Agilent, USA) fitted with a Phenomenex (USA) C18 Prodigy 
column (5 µm ODS-3 100Å, 250 x 10 mm). Gradient elution of T-16 was achieved using a 
mobile phase of 5 mM ammonium acetate and methanol with a flow rate of 3 mL/min: 0-5 
min, 5-75% methanol; 5-15 min, 75-85% methanol; 15-19 min, 85-100% methanol; 19-20 
min, 100-5% methanol. Fractions containing T-16 were identified by detecting its 
characteristic chromophore (λmax=236) nm and pooled together, followed by solvent 
evaporation under reduced pressure. The dried extract was dissolved in ethyl acetate to 
remove the ammonium acetate, followed by freeze-drying to yield purified ca. 12.5 mg T-
16. For structural determination, T-16 was dissolved in deuterated chloroform and analysed 
using a 500 MHz DCH Cryoprobe Spectrometer (Bruker, USA).  
 
2.4.5 Isolation of T-22 for NMR analysis  
 
T-22 was isolated from an in vitro incubation containing T-16 and purified Tsn11. To obtain 
sufficient T-16 for the assay, 300 more 12 x 12 cm tsn-medium-B agar plates containing S. 
longisporoflavus ∆tsn11 were grown. The assay mixture (60 mL in total) contained: 20 mM 
Tris-Cl, 100 mM NaCl, pH 7.9 containing 50 µM Tsn11, 400 µM of T-16, and 5% v/v 
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methanol. After incubation at 30 °C for 1.5 h, the reaction mixture was extracted six times 
using 30 mL of ethyl acetate. The ethyl acetate was evaporated to yield a dried organic 
extract that was redissolved in methanol. The extract was chromatographed on 
semipreparative HPLC described above. Fractions containing intermediate T-22 were 
identified by detecting its characteristic chromophore (λmax = 236 nm) and pooled together 
for solvent evaporation. The dried residue was dissolved in ethyl acetate to remove the 
ammonium acetate, followed by freeze-drying to yield purified T-22 (3.3 mg). For structural 
determination, T-22 was dissolved in deuterated methanol and analysed using a 500 MHz 
DCH NMR Cryoprobe Spectrometer (Bruker, USA).  
 
2.4.6 in vitro enzyme activity assays 
 
In vitro activity assays using Tsn11 and Tsn15 (or their homologues) were performed in 20 
mM TrisCl buffer, 100 mM NaCl, 5% v/v methanol pH 7.9. Typical, reactions were 100 µL 
and contained 200 µM of T-16 or T-22. Tsn11 and/or Tsn15 were added to a final 
concentration of 5 µM. The reactions were carried out at 30 °C for 1 h unless stated 
otherwise. The reactions were terminated by adding 400 µL of methanol (to denature the 
enzymes) before being completely dried under reduced pressure. The dried extract was 
redissolved in 100 µL methanol and analysed by an Infinity II semipreparative HPLC 
(Agilent, USA) fitted with a Phenomenex (USA) C18 Prodigy column (5 µm ODS-3 100 Å, 
250 x 10 mm) using a gradient program of 20 mM ammonium acetate and increasing 
methanol at a flow rate of 3 mL/min: 0-5 min, 5-75% methanol; 5-15 min, 75-85% 
methanol; 15-19 min, 85-100% methanol; 19-20 min, 100-5% methanol. 
 
For analysis of the Tsn11 sodium dithionite assays and the Tsn15 point mutation assays, a 
Poroshell 120, EC-C18, 27 µM, 46 x 100 mm (Agilent, USA) column eluted with 5 mM 
ammonium acetate and methanol at 1 mL/min: 0-5 min, 5-75% methanol; 5-15 min 75-95% 
methanol; 15-19 min, 95% methanol; 19-20 min, 95-5% methanol. When the Tsn11 activity 
assay was conducted in the presence of sodium dithionite, 100 µM of T-16 was used with 1 
µM of Tsn11 and 1 mM of sodium dithionite. Parallel reactions were carried out and 
terminated at 0 min, 2 min, 4 min, and 8 min, respectively. For all in vitro assays, the 
identity of intermediates T-16 and T-22 were confirmed by their unique UV chromophores 
and MS3 fragmentation patterns.  
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2.4.7 High-resolution mass spectrometry (HRMS) 
 
All ESI high-resolution mass (HRMS) spectrometry was performed by the Department of 
Chemistry, University of Cambridge mass spectrometry service.  
 
2.4.8 Hydrogen-deuterium exchange  
 
To exchange the hydroxyl protons of a small molecule with deuteriums, the small molecule 
was dissolved in a 50:50 mix of deuterated methanol and D2O. The mixture was then 
directly injected into the mass spectrometer.  
 
2.4.9 Interception and detection of PKS-bound polyketide intermediates 
	
	
Method written and performed by Dr Manuela Tosin and Robert Jenkins, University of 
Warwick, United Kingdom. All S. longisporoflavus strains were grown in duplicate 10 mL 
tsn-medium A for 2 days at 30 °C at 200 rpm. These were incubated at 30 °C for 5 days. 
After the first day of incubation, the probe (methyl 6-decanamido-2-fluoro-3-oxohexanoate, 
final concentration: 1 mM) was dissolved in 80 µl of MeOH and added portionwise over 4 
days (20 µl each day, days 2-5). Control liquid cultures omitting methyl 6-decanamido-2-
fluoro-3-oxohexanoate were also prepared (in duplicate copy). After 5 days of 
fermentation, the liquid cultures were extracted with ethyl acetate (20 mL). The extracts 
were concentrated and the residues were redissolved in HPLC-grade methanol (1 mL) for 
mass spectrometry analysis. HPLC-HR-ESI-MS analyses of S. longisporoflavus extracts 
were carried out on an LTQ-T Orbitrap Fusion instrument. Reverse phase chromatography 
was used to separate the mixtures prior to MS analysis. Two columns were utilised: an 
Acclaim PepMap µ-precolumn cartridge 300 µm i.d. x 5 mm 5 µm 100 Å and an Acclaim 
PepMap RSLC 75 µm x 15 cm 2 µm 100 Å (Thermo Scientific, USA). The columns were 
installed on an Ultimate 3000 RSLCnano system (Dionex, USA). Mobile phase buffer A 
was 0.1% aqueous formic acid and mobile phase B was composed of 100% acetonitrile 
containing 0.1% formic acid. Samples were loaded onto the µ-precolumn equilibrated in 
50% aqueous acetonitrile containing 0.1% trifluoroacetic acid for 8 min at 10 µL min-1 after 
which compounds were eluted onto the analytical column following a 75 min gradient for 
which the mobile phase B concentration was increased from 50% B to 80% over 15 min, 
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then maintained at 80% B for 50 minutes, then decreased to 50% over 1 min, followed by 
a 9 min wash at 50% B. Species were analysed by electrospray ionisation mass 
spectrometry. Survey scans of precursors from 150 to 1500 m/z were performed at 60K 
resolution (at 200 m/z) with a 4×105 ion count target. Tandem MS was performed by 
isolation at 1.6 Th with the quadrupole, HCD fragmentation with normalised collision 
energy of 32, and rapid scan MS analysis in the ion trap. The MS/MS ion count target was 
set to 2x105 and the maximum injection time was 50 ms. A filter targeted inclusion mass 
list was used to select the precursor ions.  
 
2.5 Bioinformatics and software 
 
2.5.1 Solving protein crystal structures  
 
X-ray diffraction data for SeMet-Tsn15 were collected at the Diamond Light Source (DLS) 
I04 beamline, Oxford, UK. The X-ray data processing was performed using XDS214 and 
scaled using Aimless215 (both from the CCP4 suite216). The phases for SeMet-Tsn15 was 
solved using AutoSol217. The structural model was initially built by AutoBuild218. The models 
were refined using Phenix.refine219 and COOT220. The stereochemical quality of the models 
was assessed using MolProbity221. The final protein structure was visualised using PyMOL 
(The PyMOL Molecular Graphics System, Version 2.0, Schröinger, LLC). 
 
The structure of the Tsn15-ligand complex was solved by collaborators Feranda Paiva and 
Dr. Marcio Dias. X-ray data was collected for the Tsn15-ligand complex was collected at 
PETRAIII, beamline 13, Hamburg, Germany. The phases for the Tsn15-ligand complex 
was determined by molecular replacement using the program Phaser222 from Phenix 
suite223. The SeMet-Tsn15 structure was used as the search model for molecular 
replacement. The protocol for model building and refinement was the Tsn15-ligand 
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2.5.2 Construction of phylogenetic trees 
 
Maximum-likelihood (based on the Le-Cascuel model224) phylogenetic trees were created 
using MEGA7225 by following the protocol described in (226). 1000 bootstrap replicates 
were performed. All positions with less that 95% site-coverage were not included.  
 
2.5.3 Protein software 
 
Protein sequence alignments were performed using ClustalOmega227.  
Protein extinction coefficients and molecular weights were estimated using ProtParam228 
 
BLAST was used for all query-based sequence alignments229. 
 
The PyMOL Molecular Graphics System (Schrödinger, LLC) was used to visualise protein 
crystal structures.  
 
2.5.4 DNA software 
 
All in silico DNA cloning experiments and interpretation of sequence chromatogram data 
was performed using SnapGene (GSL Biotech).  
 
Where appropriate, PCR primers were designed with the assistance of Primer3230. The 
melting properties of primers was assessed using OligoAnalyzer231  
 
2.5.5 Chemistry software 
 
Chemical structures and molecular weights were calculated using ChemDraw Professional 
16.0 (Perkin-Elmer Informatics). Mass spectra were visualised using Xcalibur (Thermo 
Fisher Scientific). Deconvolution of protein mass spectra was performed using ProMass 






Chapter 3: [4+2] cyclase homologues in polyether 
tetronate biosynthetic gene clusters  
 
3.1 The tetromadurin (SF2487/A80577) biosynthetic gene cluster 
 
The unexpected presence of the [4+2] cyclase homologue tmn8 in the tmn cluster157 
prompted the search for tmn8 homologues in the BGCs of tetronasin (tsn) and 
tetromadurin (mad). While the presence of a [4+2] cyclase homologue in only the tmn 
cluster could indicate that it is an unused, vestigial gene, presence in all three polyether 
tetronate BGCs would support a conserved and essential biosynthetic role. Given that the 
arrangement of the cyclohexane and tetrahydropyran rings is identical in tetronomycin, 
tetronasin, and tetromadurin it is reasonable to believe they form by a common 
mechanism. As a first step, it was necessary to identify the biosynthetic gene cluster for 
tetromadurin (the mad cluster) (Figure 3.1).  
 
 
Figure 3.1 Structure of tetromadurin (SF2487/A80577) with atom numbering.  
 
Tetromadurin is a type I polyketide polyether tetronate isolated independently from 
Actinomadura verrucosispora by two industrial research groups, under the designations 
SF2487168 and A80577169. Tetromadurin contains similar elements to both tetronasin and 
tetronomycin. The stereochemistry of the cyclohexane and tetrahydropyran rings is 
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exocyclic double bond. In regards to bioactivity, tetromadurin is active against a range of 
gram-positive organisms168 and inhibits HIV-1 replication in H9 cells232. A 2005 patent 
described the antimalarial activity of tetromadurin, although no further developments have 
occurred since233.  
 
A strain of the tetromadurin producer A. verrucosispora NRRL B-18236 was obtained from 
the Agricultural Research Service Culture Collection (NRRL). Whole-genome sequencing 
of the strain was performed by the Department of Biochemistry DNA sequencing facility 
(University of Cambridge) using combined shotgun and long-range mate pair MiSeq data. 
The genome was assembled into a single scaffold (10.215 Mbp) by Dr. Markiyan 
Samborskyy and analysed by AntiSMASH 4.0234 to identify biosynthetic gene clusters. A 
summary of the results from the AntiSMASH 4.0 analysis is presented in Figure 3.2. 
 
 
Actinomadura verrucosispora NRRL B-18236 
  
Genome size 10.215 Mbp 
No. of scaffolds 1 
No. of annotated BGCs 26 
  






Type III PKS 1 
Non-NRPS siderophore 1 
 
Figure 3.2 Predicted biosynthetic gene clusters in A. verrucosispora. AntiSMASH 4.0234 was used to 
identify the biosynthetic gene clusters in the genome of A. verrucosispora. Dr. Markiyan 
Samborskyy.performed the AntiSMASH 4.0234 analysis.  
 
Three biosynthetic gene clusters containing type I PKSs were identified in the A. 
verrucosispora genome. The carbon backbone of tetromadurin was predicted to be 
composed from six acetate units, eight propionate units, one glyceryl-ACP unit, and an 
unusual (2R)-methoxymalonyl-ACP unit (Figure 3.3). Only one of the type I PKS BGCs in 
A. verrucosispora, 110 kbp in size and containing 32 genes, could feasibly produce 
tetromadurin (Figure 3.4). The exact boundaries of the mad cluster were decided on the 
basis of the presence of genes whose annotation suggested no obvious connection with 
tetromadurin biosynthesis.  






Figure 3.3 Proposed biosynthetic precursors of the tetromadurin carbon backbone. The carbon 
backbone of tetromadurin appears to be derived from six malonyl-CoA derived acetate units (red), eight (2S)-
methylmalonyl-CoA derived propionate units (blue), one glyceryl-ACP (magenta), and one (2R)-
























































Figure 3.4 Biosynthetic gene cluster of the polyether tetronate tetromadurin (SF2487). The total size of 
the mad cluster is 110 kbp (genes not drawn to scale). A total of 32 were predicted to comprise the mad 
cluster. Genes are colour coded according to their predicted function.  
 
Putative functions for the genes in the mad cluster were predicted using BLASTX 
analysis229 and are listed in Table 3.1. Each gene type will be discussed in reference to its 
































Regulatory gene Misc biosynthetic gene 
Type II thioesterase 
Tetronate biosynthesis gene 
(2R)-methoxymalonyl-ACP biosynthesis gene 
PyrE3-like 4+2 cyclase 




VstJ-like [4+2] cyclase 
Type I polyketide synthase 
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Table 3.1 Predicted functions of genes in the tetromadurin (mad) biosynthetic gene cluster. ATa = 





3.1.1 Polyketide synthase genes in the tetromadurin biosynthetic gene cluster 
 
The mad cluster contains seven large genes (madAI-madAVII) encoding type I polyketide 
synthase multienzymes. Together, the seven enzymes collectively consist of one loading 
and 14 extension modules. No thioesterase domain is present in any of the modules, as 
expected for a tetronate pathway. The loading PKS module (MadAI_KS_LM) could be 
differentiated from extension modules by its KSQ domain (Figure 3.5).  
	
orf Size* Homologue and origin  Identity/ 
similarity (%) 
Proposed function 
     
mad1 130 WP_067469187, Actinomadura macra 79/90 SARP activator protein 
mad2 937 KX263301 (MonH) Streptomyces cinnamonensis 
strain ST021 
50/59 LuxR transcriptional activator  
mad3 192 WP_017621714 (EntD), Nocardiopsis gilve 66/73 4'-phosphopantetheinyl transferase 
mad4 285 WP_113699285 (CpdA), Nonomuraea sp. NEAU-
YG30 
74/80 Metallophosphoesterase 
madAI 4869 AJE80656, Streptomyces albus 54/65 Type I PKS: KSQ, ATp, ACP, KS, ATa, DH, 
KR, ACP, KS, ATa, DH, ER, ACP 
mad6 256 WP_110701439 (GrsT) 
Streptosporangium sp. caverna 
59/72 Type II thioesterase 
mad7 642 WP_067456393, Actinomadura macra 66/73 FkbH-like glyceryl-S-ACP synthase 
mad8 75 WP_031047730, Amycolatopsis albispora 63/80 Acyl-carrier protein 
madAVII 1588 WP_093461893, Streptomyces melanosporofaciens 50/60 Type I PKS: KS, ATa, KR, ACP 
mad10 467 ACR50781 (Tsn11), Streptomyces longisporoflavus 48/60 FAD-dependent monooxygenase/ putative 
[4+2] cyclase 
mad11 288 WP_037917628 (FabB), Streptomyces sp. PCS3-
D2 
69/75 Glyceryl-S-ACP dehydrogenase  
mad12 78 PPS67085, Streptomyces sp. 46 55/69 Acyl-carrier protein 
mad13 362 WP_027945620 (CaiA), Amycolatopsis taiwanensis  71/78 2-hydroxy-3-oxopropionyl-S-ACP 
dehydrogenase 
mad14 375 WP_055537123, Streptomyces neyagawaensis 71/80 FkbH-like glyceryl-S-ACP synthase 
mad15 226 WP_086736314, Streptomyces glaucescens 64/78 SAM-dependent methyltransferase 
mad16 342 WP_113696535, Amycolatopsis albispora 64/76 FabH 3-oxoacyl-ACP synthase III family 
protein 
mad17 281 WP_055549000 (AceF), Streptomyces 
kanamyceticus 
58/75 Acyltransferase 
mad18 383 WP_067456402, Actinomadura macra 54/70 Dehydratase 
madC 472 CCD31908, Streptomyces albus  55/70 Epoxidase 
mad20 273 WP_119927171  
Streptosporangiaceae bacterium YIM 75507 
44/61 Hypothetical protein 
madAVI 5623 WP_049717538, Streptomyces caatingaensis 50/62 Type I PKS: KS, ATp, DH, ER, KR, ACP, KS, 
ATp, DH, KR, ACP, KS, ATmethoxy, DH, KR, 
ACP 
madAV 5670 WP_045867303, Streptomyces sp. NBRC 110027 51/63 Type I PKS: KS, ATp, DH, ER, KR, ACP, KS, 
ATp, DH, KR, ACP, KS, ATp, DH, KR, ACP 
madAIV 3343 WP_104651095, Streptomyces cinnamoneus 54/66 Type I PKS: KS, ATp, DH, KR, ACP, KS, 
ATp, KR, ACP 
madAIII 1819 WP_078876216, Streptomyces sp. 769 55/67 Type I PKS: KS, ATa, DH, KR, ACP 
mad25 535 WP_092886900, Actinopolymorpha cephalotaxi 57/72 ABC transporter permease 
mad26 312 WP_026416314, Actinomadura oligospora 69/81 ABC transporter ATP-binding protein 
mad27 180 WP_092886896, Actinopolymorpha cephalotaxi 52/69 MarR family transcriptional regulator 
madB 132 ACR50776 (TsnB), Streptomyces longisporoflavus  53/69 Epoxide hydrolase 
mad29 386 ACR50783 (Tsn12), Streptomyces longisporoflavus 52/65 Cytochrome P450 
mad30 400 WP_055419038, Streptomyces pactum 59/72 Cytochrome P450 
mad31 186 BAF73716 (Tmn8), Streptomyces sp. NRRL 11266 29/45 Putative [4+2] cyclase 
madAII 3978 WP_106436315, Streptomyces bingchenggensis 57/68 Type I PKS: KS, ATp, DH, KR, ACP, KS, 
ATp, DH, ER, ACP 
 
* Amino acid residues 




Figure 3.5 Alignment of the KS domains from the tetromadurin biosynthetic gene cluster. The KS 
domain of the loading module (MadAI_AT_LM) and each of the 14 extension modules (KS1-14) from the 
tetromadurin biosynthetic gene cluster were aligned using ClustalOmega227. The amino acids of the C-H-H 
catalytic triad are highlighted with an asterisk (*). The KS domain of the loading module contains a glutamine 
in place of the catalytic cysteine (highlighted in yellow). 
 
The order in which the remaining six PKS multienzymes act was predicted by a detailed 
examination of their constituent extension modules to determine: (1) the predicted 
substrate selectivity of the AT domain; (2) the tally of reducing domains (KR, DH, and ER) 
present; and (3) whether the KR/ER domains would establish the correct stereochemistry 
of the α-methyl and/or β-hydroxyl groups. Only one arrangement of the PKS enzymes was 
predicted to produce a linear backbone related to tetromadurin, and the PKS multienzymes 
were labelled accordingly MadAI-MadAVII (Figure 3.6). With two exceptions, the predicted 
product of MadAI-MadAVII is identical to the linear intermediate predicted from the 




Extension module Loading module 





Figure 3.6 Hypothetical linear tetromadurin backbone. a, The proposed order of the seven PKS enzymes 
in the mad cluster to produce the linear tetromadurin backbone. ATa domains contain the amino acid motifs 
associated with malonyl-CoA incorporation. ATp domains contain the amino acid motifs associated with (2S)-
methylmalonyl-CoA incorporation. ERD domains are predicted to create a D-configured α-methyl group. B1 
KRs are predicted to create D-configured α-methyl and β-hydroxyl groups. The KS domain in MadAI is a KSQ 
domain. b, Top: the hypothetical linear tetromadurin intermediate predicted to be produced by the MadAI-
MadAVII arrangement. Bottom: the hypothetical linear tetromadurin intermediate predicted from the modules 
of MadAI-MadAVII.  
 
3.1.2 AT domains of the tetromadurin polyketide synthase enzymes 
 
The substrate selectivity of the AT domains was predicted from the presence of specific 
amino acid motifs80,91,92, particularly the presence of a (H/T/V/Y)AFH (acetate-
incorporating), or (Y/V/W)ASH (propionate-incorporating) motif. The AT domain of the 
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loading module contains the hybrid HASH motif, previously found in modules with a relaxed 
selectivity that can incorporate both malonyl-CoA and (2S)-methylmalonyl-CoA235. 
However, no congener of tetromadurin with one fewer methyl group has been reported, 
indicating that (2S)-methylmalonyl-CoA is still specifically recruited by the loading module. 
The predicted AT selectivity of the 14 extension modules is also essentially in accordance 
with the structure of tetromadurin (Figure 3.7). The AT domain of module 13 
(MadAVI_AT_13) contains a YASH motif, indicating selectivity for a (2S)-methylmalonyl-
CoA. However, based on the structure of tetromadurin this module should actually 
incorporate (2R)-methoxymalonyl-ACP to form the C4 methoxy group. The selectivity 
motifs for AT domains that incorporate (2R)-methoxymalonyl-ACP are poorly defined, and 
these AT domains typically resemble either a malonyl-CoA or (2S)-methylmalonyl-CoA 
selective domain236. Despite this, it is likely that MadAVI_AT_13 really does incorporate 
(2R)-methoxymalonyl-ACP, given that the mad cluster contains the genes necessary to 











Figure 3.7 Alignment of the AT domains from the tetromadurin biosynthetic gene cluster. a, The AT 
domain of the loading module (MadAI_AT_LM) and each of the 14 extension modules (AT_1-14) from the 
mad cluster were aligned using ClustalOmega227. The amino acid motif that predicts the selectivity of the AT 
domain is highlighted in either red (acetate-incorporating) or yellow (propionate-incorporating). b, The 
hypothetical linear tetromadurin intermediate predicted by retrobiosynthetic analysis. Propionate units derived 
from (2R)-methoxymalonyl-ACP are coloured in yellow. Acetate units derived from malonyl-CoA are coloured 
in red. The methoxy group predicted to arise from (2R)-methoxymalonyl-ACP is coloured in orange.  
 
3.1.3 KR, DH, and ER domains of the tetromadurin polyketide synthase enzymes 
 
With one exception, the tally of reducing domains (KR, DH, and ER) present in each 
module is also consistent with the structure of tetromadurin. Modules 2, 4, 8, and 11 all 
contain a KR, DH, and ER domain, consistent with complete saturation at C9, C15, C23, 
and C27, respectively (Figure 3.1). Since modules 4 and 11 incorporate propionate units, 
the ER domains in these modules determine the configuration of the α-methyl groups at C8 
and C22, respectively. These ER domains both contain amino acid motifs associated with 
the D-configuration (lacking the key tyrosine)105, consistent with the D-configured α-methyl 
substituents expected at these positions (Figure 3.8).  























Figure 3.8 Alignment of the ER domains from the tetromadurin polyketide synthase enzymes. a, The 
ER domains from the tetromadurin biosynthetic gene cluster were aligned using ClustalOmega227. The 
tyrosine residue associated with the L-configuration at the α-position in the product is marked with an asterisk 
(*). The ER domains are highlighted either yellow (producing L-configuration at the α position) or red 
(producing D-configuration at the α position). Only MadAII_ER_4 and MadAII_ER_11 affect the final 
stereochemistry of tetromadurin, as their respective modules incorporate a propionate unit. b, The linear 
tetromadurin intermediate predicted from its final structure. The fully saturated atoms (C9, C15, C23, and 
C27) produced by an ER domain are highlighted either in yellow (L-configuration-determining ER) or red (D-
configuration-determining ER).  
 
The DH domains of modules 1, 3, 6, 9, 10, and 13 are all appropriately placed to form the 
double bonds at C29, C25, C19, C13, C11, and C5, respectively. Although module 5 
contains a DH domain, C21 contains a hydroxyl group in the final tetromadurin structure, 
suggesting that MadAIII_DH_5 is inactive. Examination of the active sites of MadAIII_DH_5 
confirmed it likely inactivity, as it is missing the tyrosine from the YGP motif. The tyrosine 
side chain of the YGP motif in DH domains is proposed to assist binding to the β-hydroxyl 
group of the substrate65 and has been shown experimentally to be essential237. The 
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Figure 3.9 Alignment of the DH domains from the tetromadurin polyketide synthase enzymes. a, The 
DH domains of the extension modules 1-13 from the mad cluster were aligned using ClustalOmega227. The 
tyrosine of the YGP motif and the catalytic aspartic acid in the HPALLDAAL motif are marked with an asterisk 
(*). DH domains predicted to be active are highlighted in red and those predicted to be inactive are 
highlighted in yellow. b, The linear tetromadurin intermediate predicted from its final structure. The double 
bonds produced by DH domains are highlighted in red.  
 
Ketoredutase domains exert significant stereochemical influence over growing polyketide 
chains, determining the stereochemistry of the β-hydroxyl group and (where appropriate) 
the α-group of each extension unit. In the proposed MadAI-MadAVII module order, the KR 
domains of module 5, 7, and 12 are appropriately placed to form the hydroxyl groups at C7, 
C17, and C21. In the case of tetromadurin, all backbone β-hydroxyl groups and the α-
methyl groups adjacent to these hydroxyls (C33, C34, and C36) are in the D-configuration, 
indicating the activity of B1 type KR domain101. The distinguishing features of a B1 KR 
domain are an (L,V,I)DD motif and the absence of a proline (a feature of A type KRs) two 
residues C-terminal of the catalytic tyrosine in A type KRs101,238. Protein sequence analysis 
confirmed that the KR domains from modules 5 and 7 are indeed B1, but surprisingly 
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Figure 3.10 Alignment of the KR domains from the tetromadurin polyketide synthase enzymes. a, The 
KR domains of the extension modules 1-14 from the mad cluster were aligned using ClustalOmega 227. The 
key features of a B1 type KR domain are highlighted: the (L/V/I)DD motif within the NADPH binding site 
(LDD), the catalytic tyrosine (*), and the locus of the proline found in A type KRs (P). All of the KR domains 
except KR_12 and KR_14 were predicted to be type B1. KR_12 and KR_14 both lacked the catalytic tyrosine 
residue, indicating they are inactive. KR_12 also had a significant deletion in its NADPH binding site. b, The 
linear tetromadurin intermediate predicted from its final structure. The three D-configured hydroxyls (C7, C17, 
and C21) predicted to form from a B1 type KR domain are highlighted in red. The D configuration of the C6 
and C16 methyl groups is also predicted to be governed by B1 type KRs. The KR domain in the position 




 In fact, the KR domains of module 12 and 14 both appear to be inactive, lacking the key 
catalytic tyrosine65,239, with module 12 also containing a large deletion in its NADPH binding 
site. While the inactivity of KR_14 is consistent with the C3 keto group of tetromadurin, the 
inactivity of KR_12 is not. An inactive KR domain at this position would result in a keto 
group at C7 (as shown in Figure 3.6) rather than the C7 D-hydroxyl group observed in the 
tetromadurin. To rule out this apparent inactivity being due to an error in genome 
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again. Resequencing confirmed the original sequence was correct. Furthermore, despite 
possessing this mutated KR domain, the strain was still a competent producer of 
tetromadurin (see Chapter 4). How the C7 hydroxyl group forms in tetromadurin is 
therefore a mystery. Additionally confounding is that module 12 also contains a seemingly 
active DH domain that should replace the C7 D-hydroxyl by a C6-C7 trans double bond. 
Aside from this, the PKS modules present were an excellent fit for producing the carbon 
backbone of tetromadurin.  
 
3.1.4 Genes for tetronate biosynthesis 
 
The mad cluster contains homologues of all five glycerate-utilisation operon genes: mad7, 
mad8, mad16, mad17, and mad18109,122,123. mad7 and mad8 respectively encode a FkbH-
like protein and standalone acyl carrier protein found in the biosynthetic pathways of other 
tetronates111,122. Mad7 likely catalyses formation of glyceryl-ACP from 1,3-
bisphosphoglycerate using Mad8 as the ACP scaffold. Mad16 is the FabH-like protein 
known for catalysing tetronate formation and chain release122. Finally, Mad17 and Mad18 
are homologues of the acyltransferase Agg4 and the dehydratase Agg5, respectively, 
responsible for exocyclic double bond formation in agglomerin biosynthesis123. Mad17 
likely catalyses the acetylation of the C41 hydroxyl, followed by Mad17 catalysing 
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Figure 3.11 Proposed biosynthesis of the tetromadurin tetronate ring. The mad gene cluster contains 
the five genes of the glycerate-utilisation operon responsible for tetronate ring biosynthesis. The FkbH-like 
Mad7 catalyses formation of glyceryl-S-ACP using 1,3-bisphosphoglycerate and the ACP, Mad8. The FabH-
like protein Mad16 then catalyses C-C and C-O bond formation to form the tetronate ring and release the 
polyketide chain from the PKS. Finally, the C40-C41 exocyclic double bond is formed via acetylation of the 
C41 hydroxyl by acetyltransferase Mad17, followed by elimination catalysed by the dehydratase Mad18. R = 
linear tetromadurin intermediate. 
 
 
3.1.5 Genes for (2R)-methoxymalonyl-ACP biosynthesis  
 
Several polyketide natural products are known to incorporate the unusual 
methoxymalonate extender unit derived from (2R)-methoxymalonyl-ACP61. The first 
example of this was the macrocyclic immunosuppressant FK520236. Five genes in the 
FK520 BGC were identified as responsible for the biosynthesis of (2R)-methoxymalonyl-
ACP236 from 1,3-bisphosphoglycerate. Homologues of these five genes have since been 
found in the BGC of other natural products known to incorporate (2R)-methoxymalonyl-
ACP, such as the apoptolidins240, concanamycin A241, and geldanamycin242,243. The mad 
cluster also contains homologues of the same five genes: mad11, mad12, mad13, mad14, 
and mad15 (Figure 3.12), which appear to be part of a single operon. Mad14 encodes a 
second FkbH-like protein, distinct from Mad8, that likely catalyses formation of a second 
pool of glyceryl-ACP using 1,3 bisphosphoglycerate and Mad12, another standalone acyl 
carrier protein. It is unknown if the two pools of glyceryl-ACP can interchangeably be used 
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group of glyceryl-ACP undergoes two oxidation events to form (2R)-hydroxymalonyl-ACP. 
Based on their similarity to the dehydrogenase enzymes in the FK520 pathway, Mad11 is 
proposed to catalyse the first oxidation, forming 2-hydroxy-3-oxopropionyl-ACP. Mad13 
then catalyses the second oxidation to form (2R)-hydroxymalonyl-ACP. The O-
methyltransferase Mad15 likely converts (2R)-hydroxymalonyl-ACP into (2R)-
methoxymalonyl-ACP. The exact timing of O-methylation is uncertain, and it may precede 





Figure 3.12 Proposed biosynthesis of (2R)-methoxymalonyl-ACP. The FkbH-like Mad14 likely catalyses 
formation of glyceryl-ACP from 1,3 bisphosphoglycerate and the acyl-carrier protein Mad12. Glyceryl-ACP 
then undergoes two oxidation steps, catalysed by the dehydrogenases Mad11 and Mad13 to form (2R)-
hydroxymalonyl-ACP, which is methylated by Mad15.  
 
3.1.6 Tetrahydrofuran ring formation  
 
The mad cluster encodes an epoxidase (MadC) and an epoxide hydrolase (MadB), 
homologues of which are present in the BGCs of many other tetrahydrofuran-containing 
polyethers including monensin193, nanchangmycin245, nigericin246, lasalocid194, and 
tetronomycin111. In a mechanism first proposed for monensin247, the epoxidase and 
epoxide hydrolase catalyse a regio- and stereospecific oxidation cyclisation to form one or 
multiple rings. The energetically favourable product of such a reaction is a tetrahydrofuran 
ring, formed though an exo cyclisation, although tetrahydropyran rings may also be formed 
by the less favourable endo cyclisation route194. It is likely that MadC catalyses epoxidation 
of the C24-C25 and C28-C29 E double bonds. MadB then catalyses opening of the two 
epoxide rings to form two tetrahydrofuran rings (Figure 3.13). The timing of tetrahydrofuran 
formation in polyether is not certain, though evidence from other polyether pathways 





































Mad14 - FkbH-like protein
Mad12 - Acyl-carrier protein
Mad11 - Glyceryl-ACP dehydrogenase










Figure 3.13 Proposed biosynthesis of the tetrahydrofuran rings in tetromadurin. MadC catalyses the 
regio- and stereospecific epoxidation of the C24-C25 and C28-C29 E double bonds. Next, the MadB epoxide 
hydrolase catalyses two sequential exo ring-closures to form the two tetrahydrofuran rings.  
 
3.1.7 Hydroxylation of C36 and C38  
 
Two cytochrome P450 enzymes are encoded in the mad cluster. One of these, Mad29, 
strongly resembles Tsn12 and Tmn14—the cytochrome P450s from the tetronasin and 
tetronomycin BGCs, respectively111. Deletion of tsn12 in S. longisporoflavus led to the 
production of a tetronasin intermediate lacking the C30 hydroxyl group (Yuhui Sun, 
unpublished). Likewise, Tmn14 catalyses hydroxylation of the equivalent carbon (C28) in 
tetronomycin111. By analogy, Mad29 is therefore proposed to catalyse hydroxylation of C36 
in tetromadurin (Figure 3.14), leaving the second cytochrome P450, Mad30, to catalyse 
hydroxylation of C38. No ferredoxin gene is present in the mad cluster, so presumably one 










































Figure 3.14 Proposed cytochrome P450-catalysed hydroxylations in tetromadurin biosynthesis. 
Mad29 is a homologue of the cytochrome P450 enzymes Tsn12 and Tmn14 present in the tetronasin and 
tetronomycin BGCs, respectively. It is therefore likely that Mad29 catalyses hydroxylation of C36, leaving 
Mad30 to hydroxylate C38.  
 
3.1.8 Other genes in the mad cluster 
 
The mad cluster contains other genes likely involved in transcriptional regulation of the 
mad cluster and export of tetromadurin itself. On one end of the mad cluster the genes 
mad1 and mad2 encode predicted SARP248,249 and LuxR250 transcriptional regulators, 
respectively. Also within the mad cluster is the gene mad27 encoding a putative MarR 
(multiple antibiotic resistance regulator)-like transcriptional regulator. First described in E. 
coli, marR is a transcriptional regulator of several genes that confer antibiotic resistance251. 
Adjacent to mad27 are the genes mad25 and mad26 which encode an ABC transporter 
and an ABC transporter ATP-binding protein, respectively, both of which are likely involved 
in exporting tetromadurin from the cytoplasm252. Mad27 may induce expression of mad25 
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A gene for a 4'-phosphopantetheinyl transferase (mad3) is also present, required for 
activating ACP domains by attaching a 4'-phosphopantetheine prosthetic group. Adjacent 
to mad3 is a phosphoesterase mad4, homologues of which are found in other polyketide 
BGCs111,112 and which may hydrolyse ACP-bound 4'-phosphopantetheine groups112,254,255. 
A stand-alone gene for a type II thioesterase is also present, likely having an “editing” role 
in hydrolysing PKS active sites containing mis-acylated intermediates256,257. Of the 
remaining genes in the mad cluster, mad20 encodes a hypothetical protein with no 
characterised homologues. The putative functions of the final two genes, mad10 and 
mad31 were initially unclear prior to the analysis performed in the next section157,161.  
 
The bioinformatic analysis of the mad cluster strongly supported that it was responsible for 
tetromadurin biosynthesis. Experimental evidence confirming this conclusion will be 
presented in Chapter 4. Meanwhile, the proposed biosynthetic pathway to tetromadurin is 
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Figure 3.15 Proposed biosynthetic pathway to tetromadurin. The order of post-PKS modifications could 
be different than presented here (I) The seven PKS enzymes (MadAI-MadAVIII) and predicted linear 
tetromadurin intermediates of the mad cluster. ATa domains contain the amino acid motifs associated with 
malonyl-CoA incorporation. ATp domains contain the amino acid motifs associated with (2S)-methylmalonyl-
CoA incorporation. ERD domains are predicted to create a D-configured α-methyl group. B1 KRs are predicted 
to create D-configured α-methyl and β-hydroxyl groups. The KS domain in MadAI is a KSQ domain. (II) The 
key biosynthetic precursor 1,3-bisphosphoglycerate, involved in both tetronate formation and (2R)-
methoxymalonyl-ACP biosynthesis. (III) Formation of glyceryl-ACP by the FkbH-like enzyme Mad14 and the 
ACP Mad12. (IV) Oxidation of glyceryl-ACP by the dehydrogenase Mad11 to form 2-hydroxy-3-oxopropionyl-
ACP. (V) Oxidation of 2-hydroxy-3-oxopropionyl-ACP by the dehydrogenase Mad13 to form hydroxymalonyl-
ACP. (VI) Methylation of hydroxymalonyl-ACP by the O-methyltransferase Mad15 to form (2R)-
methoxymalonyl-ACP. (VII) The (2R)-methoxylmalonyl-ACP is incorporated by the MadAVI_AT_13. (VIII) 
Synthesis of a second pool of glyceryl-ACP by FkbH-like Mad7 and ACP Mad8. (IX) Glyceryl-ACP is a 
substrate of the FabH-like protein Mad16 which catalyses tetronate formation and concomitant chain release 
from the PKS. (X) In the first step of tetrahydrofuran formation, MadC catalyses epoxidation of the C24-C25 
and C28-C29 E double bonds. (XI-XII) Epoxide hydrolase MadB catalyses formation of the two 
tetrahydrofuran rings through cascade epoxide ring-opening; (XIII) Acetylation of the C41 hydroxyl group 
catalysed by Mad17. (XIV) Elimination by Mad18 forms the C40-C41 exocyclic double bond. (XV) The 
formation mechanism of the cyclohexane and tetrahydropyran is unknown, but metal-catalysis is a possibility 
(as proposed for tetronasin174,195). (XVI) Hydroxylation of C36 catalysed by Mad29. (XVII) Hydroxylation of 
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3.2 [4+2] cyclase homologues in the BGCs of tetronasin, tetronomycin, and 
tetromadurin 
 
3.2.1 VstJ-homologues  
 
Now that the sequence tsn, tmn, and mad clusters were all available, BLAST229 could be 
used to search them for putative cyclase enzymes. Homologues of tmn8/vstJ were 
identified in both the tsn cluster (tsn15) and the mad cluster (mad31) (Figure 3.16) 
(Appendix Note 1). However, alignment of the protein sequences of the polyether 
tetronate and spirotetronate/tetramate VstJ-homologues indicated that there is only modest 




Figure 3.16 vstJ-type [4+2] cyclases in the biosynthetic gene clusters of tetronasin and tetromadurin. 
The BGCs of the spirotetronates versipelostatin (vst), abyssomicin (aby), chlorothricin (chl), the 
spirotetramate pyrroindomycin (pyr), and the polyether tetronates tetronomycin (tmn), tetronasin (tsn), and 
tetromadurin (mad) all encode a VstJ-like [4+2] cyclase (highlighted in red). Only partial BGCs are shown and 
genes are not drawn to scale.  
 
 
vstJ-like [4+2] cyclase Type I polyketide synthase 
Other biosynthetic gene 
Spirotetronates and spirotetramates 
aby 
H I U K A1 A2 A3 A4 A5 B1 B2 B3 
vst 
J A3 A4 A4 K B5 B4 B3 I A2 
pyr 
A6 A7 A8 E3 E4 F2 D2 I4 F4 K3 K2 K1 I3 
E3 L A6 A5 A4 A3 E2 A2 A1 M 
chl 
tmn 
AI 10 8 9 AVI B 12 AII AIII AIV 
tsn 
11 15 AI AV 12 13 AIII AIV B 14 7 8 9 C 
Polyether tetronates 
11 13 15 17 
mad 
10 12 14 16 18 C 20 AVI AV 31 AII 
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Figure 3.17 Alignment of VstJ-type [4+2] cyclases. Protein sequence alignment of [4+2] cyclases encoded 
in the biosynthetic gene clusters of the polyether tetronates tetronasin (Tsn15), tetronomycin111 (Tmn8), and 
tetromadurin (Mad31); the spirotetronates abyssomicin (AbyU), versipelostatin (VstJ), chlorothricin (ChlL) and 
the spirotetramate pyrroindomycin (PyrI4). Similar residues in an alignment are coloured accordingly: Blue, 
hydrophobic; Green, polar; Purple, negative; Red, positive; Yellow, proline; Orange, glycine. Alignment was 
made using ClustalOmega227.  
 
Additional support that Tmn8, Tsn15, and Mad31 are genuine homologues of the VstJ-like 
[4+2] cyclases, despite the low sequence similarity, was obtained using the Phyre2 server. 
Phyre2 is an online tool that predicts protein structure by matching its primary sequence 
and predicted secondary structure to previously solved protein structures258. Phyre2 
analysis of Tsn15, Tmn8, Mad34, and VstJ predicted that all shared an allene oxide 
cyclase barrel fold (Figure 3.18). The solved protein structures of PyrI4159 and AbyU158 
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Figure 3.18 Phyre2 structural prediction for VstJ, Tmn8, Tsn15, and Mad34. The primary sequences of 
VstJ, Tmn8, Tsn15, and Mad34 were analysed using the Phyre2 software258. (I) Predicted 3D model of the 
protein, (II) % confidence in the 3D model, (III) % identity between the query sequence and the allene oxide 
cyclase fold library (IV) Information on the 3D template used. 
 
 
Taken together, BLAST and Phyre2 results confirmed that VstJ-like [4+2] cyclase 
homologues are encoded in all three polyether tetronate BGCs. The function of these 
enzymes was unknown, but their conservation suggested an essential biosynthetic role.  
 
3.2.2 PyrE3 homologues 
 
In addition to VstJ-like [4+2] cyclases, a second class of [4+2] cyclases was also identified 
for the first time in polyether tetronate BGCs. This second class are homologues of PyrE3, 
the [4+2] cyclase that catalyses dialkyldecalin formation in pyrroindomycin biosynthesis161 
(Figure 1.33). Using PyrE3 as a BLAST query identified homologues encoded in all three 
polyether tetronate BGCs: Tmn9 from the tmn cluster, Tsn11 from the tsn cluster, and 
Mad10 from the mad cluster (Figure 3.19) (Appendix Note 2 and 3). In contrast to the 
VstJ homologues, the PyrE3 homologues shared a higher degree of sequence identity, ca. 
40-45%. Like PyrE3, BLAST analysis of Tmn9, Tsn11, and Mad10 initially annotated them 

















# Template Alignment Coverage 3D Model Confidence % i.d. Template Information
1 c5dyqA_ Alignment 100.0 27
PDB header:ligase
Chain: A: PDB Molecule:yd repeat-containing protein;
PDBTitle: abyu l73m l139m
2 c5bu3A_ Alignment 100.0 26
PDB header:lyase
Chain: A: PDB Molecule:pyri4;
PDBTitle: crystal structure of diels-alderase pyri4 in complex with its
product








5 c4h69A_ Alignment 96.3 20
PDB header:isomerase
Chain: A: PDB Molecule:allene oxide cyclase;
PDBTitle: crystal structure of the allene oxide cyclase 2 from
physcomitrella2 patens complexed with substrate analog
6 c4revB_ Alignment 93.2 14
PDB header:plant protein
Chain: B: PDB Molecule:disease resistance response protein 206;
PDBTitle: structure of the dirigent protein drr206
7 d1jmma_ Alignment 77.6 13
Fold:Supersandwich
Superfamily:V-region of surface antigen I/II (SA I/II, PAC)
Family:V-region of surface antigen I/II (SA I/II, PAC)
8 c3zf7a_ Alignment 56.9 32
PDB header:ribosome
Chain: A: PDB Molecule:
PDBTitle: high-resolution cryo-electron microscopy structure of the
trypanosoma2 brucei ribosome
9 c3u5eZ_ Alignment 54.6 24
PDB header:ribosome
Chain: Z: PDB Molecule:60s ribosomal protein l27-a;
PDBTitle: the structure of the eukaryotic ribosome at 3.0 a
resolution. this2 entry contains proteins of the 60s subunit, ribosome
a
10 c3j39Z_ Alignment 52.6 21
PDB header:ribosome
Chain: Z: PDB Molecule:60s ribosomal protein l27;
PDBTitle: structure of the d. melanogaster 60s ribosomal proteins
11 c3j3bZ_ Alignment 51.6 18
PDB header:ribosome
Chain: Z: PDB Molecule:60s ribosomal protein l27;












# Template Alignment Coverage 3D Model Confidence % i.d. Template Information




2 d1jmma_ Alignment 83.0 20
Fold:Supersandwich
Superfamily:V-region of surface antigen I/II (SA I/II, PAC)
Family:V-region of s rfac an ig n I/II (SA I/II, PAC)
3 c2wd6B_ Alignment 75.6 18
PDB header:cell adhesion
Chain: B: PDB Molecule:agglutinin receptor;
PDBTitle: crystal structure of th var able domain of the2
streptococcus gordonii surface protein sspb








6 c4h69A_ Alignment 55.1 23
isomerase
A allene xide cyclas ;
crystal str cture of the llene oxide cyclase 2 from
physcomitrella pa ens complexed with substrate analog
7 c4gopB_ Alignment 37.1 17
PDB header:dna binding protein/dna
Chain: B: PDB Molecule:putative uncharacterized protein;
PDBTitle: structure and confo mation change of a replication
protein a2 heterot imer bound to ssdn
8 c4revB_ Alignment 34.1 15
PDB header:plant protein
Chain: B: PDB Molecule:disease resistance response protein 206;
PDBTitle: structure of the dirigent protein drr206




10 c3s4kA_ Alignment 21.2 6
PDB header:hydrolase
Chain: A: PDB Molecule:putative esterase rv1847/mt1895;
PDBTitle: structure of a putative esterase rv1847/mt1895 from
mycobacterium2 tuberculosis
11 d2pi2a1 Alignment 18.5 23
Fold:OB-fold
Superfamily:Nucleic acid-binding proteins












# Template Alignment Coverage 3D Model Confidence % i.d. Template Information








3 c4h69A_ Alignment 78.3 31
PDB header:isomerase
Chain: A: PDB Molecule:allene oxide cyclase;
PDBTitle: crystal structure of the allene oxide cyclase 2 from
physcomitrella2 patens complexed with substrate analog
4 d1jmma_ Alignment 71.7 17
Fold:Supersandwich
Superfamily:V-region of surface antigen I/II (SA I/II, PAC)
Family:V-region of surface antigen I/II (SA I/II, PAC)
5 c2wd6B_ Alignment 42.5 16
PDB header:cell adhesion
Chain: B: PDB Molecule:agglutinin receptor;
PDBTitle: crystal structure of the variable domain of the2
streptococcus gordonii surface protein sspb
6 c3s4kA_ Alignment 39.7 16
PDB header:hydrolase
Chain: A: PDB Molecule:putative esterase rv1847/mt1895;
PDBTitle: structure of a putative esterase rv1847/mt1895 from
mycobacterium2 tuberculosis
7 c2vy2A_ Alignment 35.3 58
PDB header:transcription
Chain: A: PDB Molecule:protein leafy;
PDBTitle: structure of leafy transcription factor from arabidopsis2
thaliana in complex with dna from ag-i promoter








10 c4ql5A_ Alignment 30.7 41
PDB header:translation
Chain: A: PDB Molecule:translation initiation factor if-1;
PDBTitle: crystal structure of translation initiation factor if-1 from2
streptococcus pneumoniae tigr4
11 d1hr0w_ Alignment 30.6 39
Fold:OB-fold
Superfamily:Nucleic acid-binding proteins
Family:Cold shock DNA-binding domain-like
Email rl530@cam.ac.uk
Description Tetromaduran_VstJ_homologue







# Template Alignment Coverage 3D Model Confidence % i.d. Template Information




2 d1zvca1 Alignment 89.9 20
Fold:AOC barrel-like
Superfamily:Allene oxide cyclase-lik
Family:Allene oxide cycla e-like
3 d1jmma_ Alignment 89.0 18
Fold:Supersandwich
Superfamily:V-region of surface antigen I/II (SA I/II, PAC)
Family:V-region of surface antigen I/II (SA I/II, PAC)




5 c4revB_ Alignment 86.9 15
 :plant protein
i : :  l l :disease r sist nce response protein 206;
i l : tr t r  f the dirigent protein drr206
6 c3g4hB_ Alignment 82.2 18
PDB header:hydrolase
Chain: B: PDB Molecule:regucalcin;
PDBTitle: crystal structure of human enescence marker protein-30
(zinc bound)
7 c2wd6B_ Alignment 81.2 18
PDB header:cell adhesion
Chain: B: PDB Molecul :agglutinin receptor;
PDBTitle: crystal structur  of th  va iable omain f the2
streptococcus gordonii surface protein sspb
8 c4h69A_ Alignment 80.8 20
PDB header:isomerase
Chain: A: PDB Molecule:allene oxide cyclase;
PDBTitle: crystal structure of the allene oxide cyclase 2 from
physcomitrella2 patens complex d with substrate analog
9 c3s4kA_ Alignment 67.0 16
PDB header:hydrolase
Chain: A: PDB Molecule:putative esterase rv1847/mt1895;
PDBTitle: structur  of a putative esterase rv1847/mt1895 from
mycobacterium2 tuberculosis
10 c2g3dB_ Alignment 63.5 14
PDB header:luminescent protein
Chain: B: PDB Molecule:green fluorescent protein;
PDBTitle: structure of s65g y66a gfp variant after spontaneous2
peptide hydrolysis
11 c3nwzD_ Alignment 58.6 14
PDB header:structural genomics, unknown function
Chain: D: PDB Molecule:bh2602 protein;
PDBTitle: crystal structure of bh2602 protein from bacillus













# Template Alignment Coverage 3D Model Confidence % i.d. Template Information
1 j li 3. 0
 l li
ll  i  l li
ll  i  l li
2 d1jmma_ li 83.0 0
Supersandwich
V-region of surface antigen I/II (SA I/II, PAC)
V-region of surface antigen I/II (SA I/II, PAC)
3 2wd6B li 75.6 18
cell adhesion
B  gglutinin r eptor;
 l    variable domain of the2
strept coccus gordonii surface protein s p
4 d1zvca1 li 7 .0 20
Fold:AOC barrel-lik
Superfamily:Allen oxide cycl s -like
Family:Allene oxi  cyclase-like




6 c4h69A li 5 1 23
isomerase
allene oxide cyclase;
crystal tr cture of the allene oxide yclase 2 from
physcomitrella2 pat ns c mpl xed with substrate analog
7 4gopB li 37 1 17
PDB header:dna binding protein/d a
Chain: B: PDB Molecule:puta ive uncharacterized prot in;
PDBTitle: structure and conforma io al change of a replication
protein a2 heterotrimer bound to ssdna
8 4revB li 34 1 15
plant protein
B disease resistance response protein 206;
irig nt protein drr206
9 d2cwza1 li 3 4 9
Fold:Thioeste ase/thiol ester dehydrase-isomerase
Superfamily:Thioesterase/thiol ester dehydrase-isomerase
Family:TTHA0967-like
10 c3s4kA_ Alignment 21.2 6
PDB header:hydrolase
Chain: A: PDB M lecule:putative esterase rv1847/ t1895;
PDBTitle: structure of a putative esterase rv1847/mt1895 from
mycobacterium2 tuberculosis
11 d2pi2a1 Alignment 18.5 23
Fold:OB-fold
Superfamily:Nucleic acid-binding proteins
Family:Single strand DNA-b nding domain, SSB
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Figure 3.19 pyrE3-like [4+2] cyclases in the biosynthetic gene clusters of polyether tetronates. The 
BGCs of the spirotetronates versipelostatin (vst), chlorothricin (chl), the spirotetramate pyrroindomycin (pyr), 
and the polyether tetronates tetronomycin, tetronasin, and tetromadurin all encode a PyrE3-like [4+2] cyclase 
(highlighted in yellow) and a VstJ-like [4+2] cyclase. Only partial BGC are shown and genes are not to scale. 
 
 
Tmn9 had even been previously deleted in S. sp NRRL 11266, demonstrating that it was 
essential for tetronomycin biosynthesis111. Further, inspection of a maximum-likelihood 
phylogenetic tree revealed that Tmn9, Mad10, and Tsn11 form a clade together but are 
more related to the PyrE3-like [4+2] cyclases than to their bona fide FAD-dependent 
monooxygenases homologues (Figure 3.20).  
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Figure 3.20 Maximum likelihood phylogenetic tree of PyrE3 homologues. A maximum likelihood 
phylogenetic tree was created for the diverse family of PyrE3 homologues, including: [4+2] cyclases from 
spirotetronate/tetramate pathways; FAD-dependent monooxygenases; and homologues from polyether 
tetronate pathways. 1000 bootstrap replicates were performed.  
 
Despite this, Tmn9, Mad10, and Tsn11 all likely bind to FAD as they contain the negatively 
charged residues that are required in their OxyS/MtmOIV-like monooxygenase 
homologues required for FAD binding163,259 (Figure 3.21). Although PyrE3 also binds an 
FAD cofactor, it was shown to be unable to oxidise NADPH, indicating that the FAD does 
not play a redox role (as it would in a true FAD-dependent monooxygenase)163,259,260. Work 
on MtmOIV identified four positively charged residues crucial for the proper binding of 
NADPH (R169, R173, R174, R277). Although mutating these residues to alanine did not 
significantly affect the NADPH Km binding constant, it did decrease the NADPH kcat value, 
likely by distorting NADPH binding and preventing effective FAD reduction260. PyrE3 
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is likely due to distorted NADPH binding163. Mutations in these residues are also found in 
other PyrE3 homologues with [4+2] cyclase activity such as ChlE3, TedJ, and VstK, 
consistent with these enzymes being [4+2] cyclases rather than monooxygenases163. 
Tmn9, Mad10, Tsn11 are also highly variable in these residues, suggesting they also 
cannot effectively bind to NADPH (Figure 3.21). Exceptions exist however, as the PyrE3 
homologue from the spirotetronate kijanimicin, KijA, contains arginine at each of the four 
loci, indicating it may retain the ability to oxidise NADPH. Nevertheless, that the majority of 
known PyrE3-type [4+2] cyclases lack arginine at these sites provides evidence against 
Tmn9, Mad10, and Tsn11 having FAD-dependent monooxygenase activity and points in 
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Figure 3.21 Alignment of PyrE3-type [4+2] cyclases. Protein sequence alignment of the PyrE3-type [4+2] 
cyclases encoded in the biosynthetic gene clusters of the polyether tetronates tetronomycin (Tmn9), 
tetronomadurin (Mad10), and tetronasin (Tsn11); The [4+2] cyclase TedJ from the tetrodecamycin BGC118, 
The [4+2] cyclase KijA from the kijanimicin BGC115; The [4+2] cyclase PyrE3 from the pyrroindomycin 
BGC161; The [4+2] cyclase VstK from the versipelostatin BGC157, The [4+2] cyclase ChlE3 from the 
chlorothricin BGC116,161; The monooxygenase PgaE from gaudimycin C biosynthesis261; The monooxygenase 
OxyS from oxytetracycline biosynthesis259; the monooxygenase MtmOIV from mithramycin biosynthesis260. 
Red stars (★) indicate amino acids involved in binding FAD259. Black asterisks (*) indicate the locations of the 
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3.3 Chapter 3 Discussion 
	
 
The initial automated analysis of the assembled genome of A. verrucosispora revealed the 
mad cluster as the obvious candidate for tetromadurin biosynthesis. The genes present in 
the mad cluster were a near-perfect fit for both synthesising the tetromadurin carbon 
backbone and performing the necessary post-PKS tailoring modifications. The single 
unexplained feature of the PKS is the origin of the C7 hydroxyl group, which is formed 
despite the KR of module 12 lacking its essential active site tyrosine and several NADPH 
binding site residues. It may be that the KS, AT, and ACP domains of module 12 catalyse 
an extension cycle using (2S)-methylmalonyl-CoA, which is reduced only by the KR 
domain of an adjacent module. Domains acting externally to the PKS module they are 
located in have been proposed for other polyketide biosynthesis pathways64–67. Likewise, 
some domains within iteratively acting modules only function during one of the iterative 
cycles, as was demonstrated for the ER domain of azalomycin F68. The KR domain of 
either module 11 or 13 could therefore be responsible for forming the C7 hydroxyl. Like the 
ER domain in azalomycin F biosynthesis, the other reductive domains in these modules 
may be switchable between active and inactive states, preventing reduction beyond the 
hydroxyl266. The final possibility is that, despite appearing inactive, the KS of module 12 
really is a functional domain. To investigate this in the future, the domain could be 
independently purified to test its activity in vitro, as has been done for other KR domains267.  
 
Having the sequence of the mad cluster provided several useful insights into polyether 
tetronate biosynthesis. First, both the tmn and tsn clusters contain additional flanking PKS 
genes (tmn/tsnD genes) not necessary for the biosynthesis of tetronomycin and tetronasin, 
respectively111. The mad cluster, however, does not have these flanking PKS genes (nor 
are they found anywhere on the genome), confirming that they are not a required feature of 
polyether tetronate BGCs. The glycerate utilisation operon in the mad cluster also further 
highlights the uniqueness of the hydroxypyruvate dehydrogenase genes in the tsn cluster 
(Yuhui Sun, unpublished results).  
 
The second key finding of this chapter was that the gene clusters of all three polyether 
tetronates each contain two different genes for [4+2] cyclase homologues. The 
conservation of these genes across all three clusters, paired with the functional evidence 
that Tmn9 is essential for tetronomycin production111, strongly suggested that these 
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enzymes are essential for polyether tetronate biosynthesis. Tmn8, Tsn15, and Mad31 are 
homologues of the VstJ-like [4+2] cyclases that catalyse biosynthesis of the 
spirotetronate/spirotetramate moiety157,158,161. Meanwhile Tmn9, Mad10, and Tsn11 
meanwhile are all homologues of the PyrE3-like [4+2] cyclases that catalyse dialkyldecalin 
formation in spirotetronate/spirotetramate natural products118,161. Considering that polyether 
tetronate biosynthesis is not predicted to require even one [4+2] cyclisation, let alone two, 
the role of these [4+2] cyclase homologues was a mystery. Phylogenetic analysis of Tmn9, 
Mad10, and Tsn11 indicated they are more related to [4+2] cyclases than to 
monooxygenases and lack the residues associated with NADPH binding260, suggesting 
that they have a non-redox function.  
 
In summary, the BGC of tetronasin, tetromadurin, and tetronomycin were each revealed to 
contain two overlooked cyclase homologues. A reasonable hypothesis at this stage was 
that these cyclase homologues might be involved in cyclohexane and tetrahydropyran 
formation. Experiments to test this hypothesis directly are described in the next chapter.  
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Chapter 4: in vivo studies on polyether tetronate 
[4+2] cyclase homologues 
 
Formal proof that the polyether tetronate homologues of VstJ and PyrE3 are essential for 
biosynthesis required specific deletion of each gene and the demonstration that production 
was lost. Another strong motivation to attempt these deletion experiments was to assess if 
whether by blocking production of the tetronate antibiotic any intermediates or shunt 
products might instead be produced, which might shed light on the role of the deleted 
gene. In previous work on the tmn8 mutant111 no such metabolite was reported, but this is 
a low-yielding strain and compounds may therefore have been overlooked. Further 
encouragement for such experiments was provided by the precedent that deletion of vstJ 
and pyrE3 homologues resulted in the mutant strain producing a late-stage precyclisation 
intermediate157,161. The timing of ring formation may also influence the likelihood of an 
intermediate being detected. For instance, if ring formation occurs before chain release, as 
predicted in other polyethers196,197, disrupting it may prevent the release of any polyketide 
intermediates from the PKS. To increase the chances of detecting metabolites in blocked 
mutants, it was decided to undertake deletions in all three polyether tetronate-producing 
strains. 
 
4.1 Production of tetronomycin, tetromadurin, and tetronasin  
 
Before undertaking gene deletions, it was confirmed that the available stocks of S. 
longisporoflavus, S. sp. NRRL 11266 and A. verrucosispora in the Leadlay lab were 
competent producers of their respective polyether tetronates.  
 
4.1.1 Production of tetronomycin from S. sp. NRRL 11266 
 
S. sp. NRRL 11266 was known to produce tetronomycin on a soy flour/D-mannitol medium 
(SFM)111. In the present study, S. sp. NRRL 11266 grew on SFM medium as dry, pale 
colonies that darkened into a brown colour before forming white spores. Production of 
tetronomycin was also detected from S. sp. NRRL 11266 in these conditions (Figure 4.1). 
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4.1.2 Production of tetromadurin from A. verrucosispora 
 
For the tetromadurin producer Actinomadura verrucosispora, a range of different mediums 
was tested to find one suitable for tetromadurin production. A. verrucosispora was found to 
sporulate and produce tetromadurin on both oatmeal and ISP4 media (Figure 4.2). The 
mass and UV chromophore of tetromadurin were the same as previously reported168. 
 
4.1.3 Production of tetronasin from S. longisporoflavus 
 
Streptomyces longisporoflavus 83E6 is a tetronasin overproducer developed by ICI 
Pharmaceuticals in the 1980s, shown in this laboratory to produce well on a dextrin-
containing medium208,209. Here, Streptomyces longisporoflavus 83E6 grew on TWM 
medium as a pale, non-sporulating mycelia. Sporulation of S. longisporoflavus 83E6 was 
not observed on any growth medium tested. Tetronasin production was also readily 
detected when S. longisporoflavus was grown in tryptic soy broth supplemented with 
dextrin (tsn-medium-B) (Figure 4.3). Confirmation of its identity was obtained by 
comparison of its MS3 fragmentation pattern with an authentic tetronasin sample268 
(Appendix Figure 1).  
  
 




Figure 4.1 Production of tetronomycin by Streptomyces sp. NRRL 11266. a, Growth of S. sp. NRRL 
11266 on SFM. b, Structure of tetronomycin (C34H50O8) m/z [C34H50O8+Na]+ = 609.80. c, Top: total ion current 
(TIC) chromatogram of Streptomyces sp. NRRL 11266 organic extract. A clear peak corresponding to 
tetronomycin was present at 17.5 min. Bottom: Extracted m/z = 609 chromatogram of S. sp. NRRL 11266. d, 
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Figure 4.2 Production of tetromadurin by Actinomadura verrucosispora. a, A. verrucosispora grew on 
oatmeal agar as pale colonies that formed white hydrophobic spores after several days. b, Structure of 
tetromadurin (C42H64O12), m/z [C42H64O12+NH4]+ = 778; m/z [C42H64O12+Na]+ = 783. c, Top: total ion current 
(TIC) chromatogram of A. verrucosispora organic extract. A peak corresponding to tetromadurin 
[C42H64O12+NH4]+ (m/z = 778.82) was visible on the TIC at 19.8 min. Bottom: extracted m/z = 783 
chromatogram of the tetromadurin sodium ion adduct [C42H64O12+Na]+ c, Mass spectrum of the tetromadurin 
peak from the TIC spectrum. *[C42H64O12+Na]+; **[C42H64O12+NH4]+; ***[C42H64O12+H]+. e, UV absorption 
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Figure 4.3 Production of tetronasin by Streptomyces longisporoflavus. a, Streptomyces 
longisporoflavus 83E6 grew on TWN medium as a pale, non-sporulating, mycelia. b, Structure of 
tetromadurin (C35H54O8), m/z [C35H54O8+NH4]+ = 620; m/z [C35H54O8Na]+ = 625. c, Top: total ion current (TIC) 
chromatogram of S. longisporoflavus organic extract. A peak corresponding to tetronasin [C35H54O8+Na]+ 
(m/z = 625) was visible on the TIC at 24.0 min. Bottom: Extracted chromatogram of the tetronasin m/z = 625 
peak from the TIC. c, Mass spectrum of the tetronasin peak from the TIC. *[C35H54O8+Na]+; 
**[C35H54O8+NH4]+; ***[C35H54O8+H]+; ****[C35H54O8+H−H2O]+; *****[C35H54O8+K]+. d, UV absorption spectrum 
of the tetronasin peak: λMAX = 234 nm, 266 nm.  
  
 
These preliminary fermentation experiments confirmed that all three polyether tetronates 
could be produced in detectable quantities from their respective producer strains. Any 
changes resulting from deletion of a vstJ- or pyrE3-like [4+2] cyclase should therefore be 
detectable by HPLC-MS.  
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4.2 Creation of polyether tetronate [4+2] cyclase deletion mutants 
 
All gene deletions were performed by a homologous recombination-based protocol using 
the pYH7 plasmid. pYH7 was previously used to successfully delete genes in both S. 
longisporoflavus (Sun et al., unpublished results) and S. sp. NRRL 11266111. In each case, 
all or a significant portion of the target gene was deleted. To decrease the chances of the 
gene deletion having polar effects on the expression of adjacent genes, deletions were 
made in the coding frame so no frame shift was introduced210. As the S. sp NRRL 11266 
∆tmn9111 mutant had previously been analysed, it was not created again in this study. 
Regions of 2 kb directly flanking the target gene both upstream and downstream were 
amplified by PCR and assembled into pYH7 (an example of this, for the plasmid used to 
delete tsn11, is shown in Figure 4.4). The complete workflow for creating in-frame 
deletions in actinomycetes is presented in Figure 4.6. 
 
A pYH7 deletion construct for each gene was delivered by intergeneric conjugation from E. 
coli into the appropriate actinomycete strain, where it integrated into the genome via a 
single crossover. The pYH7 plasmid contains the acc(3)IV gene, conferring resistance to 
apramycin. The pYH7-containing actinomycete “exconjugants” were grown for several 
generations in the absence of apramycin to cure the pYH7 plasmid by inducing a second 
crossing over event, which either reverted the strain to wild type or introduced the desired 
coding-frame deletion. Exconjugants that had undergone this second crossover were 
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Figure 4.4 Plasmid map of the pYH7 construct used for the in-frame deletion of tsn11 in S. 
longisporoflavus. The 2 kb upstream (red) and 2 kb downstream (blue) fragments were the sites of 
homologous recombination with the S. longisporoflavus chromosome, resulting in the coding-frame deletion 
of tsn11. acc(3)IV: apramycin resistance gene. ampR: ampicillin resistance gene (β-lactamase). oriT: origin of 




      
Figure 4.5 Replica plating of S. longisporoflavus exconjugants containing pYH7-∆tsn15. The 
apramycin-sensitive exconjugants had either undergone a second crossing over event with the pYH7-∆tsn15 
plasmid, in which case tsn15 had been deleted from the chromosome, or had reverted to wild type. The red 
boxes highlight an exconjugant that had lost the pYH7 plasmid and therefore regained apramycin sensitivity. 
The yellow boxes highlight an exconjugant that still contains the pYH7-∆tsn15 plasmid and is therefore 
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Figure 4.6 Workflow for the deletion of [4+2] cyclase homologues in polyether-tetronate producers. 
(I) 2 kb regions upstream and downstream of the target gene were amplified using PCR. (II) The two flanking 
regions were joined and ligated into the pYH7 plasmid using Gibson assembly. (III) The assembled pYH7 
deletion plasmid was conjugated into the tetronate-producing actinomycete using an E. coli donor. (IV) Once 
conjugated, the flanking regions in the pYH7 plasmid could crossover with the homologous regions in the 
chromosome. (V) Either of the two flanking regions could crossover first, creating two alternative single 
crossover genotypes (1) left flank, or (2) right flank. Single crossover events were selected using apramycin, 
as integration of the pYH7 plasmid conferred apramycin-resistance. (VI) To perform the coding-frame 
deletion, a second crossing over event was necessary. A coding-frame gene deletion occurred if the second 
crossing over event used the flanking region not used in the first crossover. If the same flanking region of the 
pYH7 plasmid used for the first was also used for the second, the strain reverted to wild type. Apramycin 
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Using this method S. sp NRRL 11266 ∆tmn8 (Figure 4.7), A. verrucosispora ∆mad10 
(Figure 4.8a), A. verrucosispora ∆mad31 (Figure 4.8b), S. longisporoflavus ∆tsn11 
(Figure 4.9a), and S. longisporoflavus ∆tsn15 (Figure 4.9b) were all successfully created. 





Figure 4.7 Creation of the S. sp NRRL 11266 ∆tmn8 deletion mutant. Left: Diagram showing the double 
crossing-over event between pYH7-tmn8 and the S. sp NRRL 11266 chromosome. In total 573/573 bp of 
tmn8 were deleted in the ∆tmn8 mutant. The primers tmn8_KO_Fw and tmn8_KO_Rv were used to screen 
the genomic DNA of exconjugants to identify those in which the coding-frame deletion had taken place. PCR 
product size wild type: 971 bp. PCR product size ∆tmn8 mutant: 398 bp. Left: Agarose gel demonstrating the 
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Figure 4.8 Creation of the A. verrucosispora ∆mad10 and A. verrucosispora ∆mad31 deletion mutants. 
a, Creation of the A. verrucosispora ∆mad10. Left: Diagram showing the double crossing-over event between 
pYH7-mad10 and the A. verrucosispora chromosome. In total 906/1404 bp of mad10 were deleted in the 
∆mad10 mutant. The primers mad10_KO_Fw and mad10_KO_Rv were used to screen the genomic DNA of 
double crossover exconjugants to identify those containing the mad10 coding-frame deletion. PCR product 
size wild type: 1913 bp. PCR product size ∆mad10 mutant: 1007 bp. Right: Agarose gel demonstrating the 
successful creation of the A. verrucosispora ∆mad10 mutant. b, Creation of the A. verrucosispora ∆mad31 
mutant. Left: Diagram showing the double crossing-over event between pYH7-mad31 and the A. 
verrucosispora chromosome. In total 291/561 bp of mad31 were deleted in the ∆mad31 mutant. The primers 
mad31_KO_Fw and mad31_KO_Rv were used to screen the genomic DNA of double crossover 
exconjugants to identify those containing the ∆mad31 coding-frame deletion. PCR product size wild type: 980 
bp. PCR product size ∆tsn15 mutant: 689 bp. Right: Agarose gel demonstrating the successful creation of a 
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Figure 4.9 Creation of the S. longisporoflavus ∆tsn11 and S. longisporoflavus ∆tsn15 deletion 
mutants. a, Creation of S. longisporoflavus ∆tsn11. Left: Diagram showing the double crossing-over event 
between pYH7-tsn11 and the S. longisporoflavus chromosome. In total 1356/1488 bp of tsn11 were deleted 
in the ∆tsn11 mutant. The primers tsn11_KO_Fw and tsn11_KO_Rv were used to screen the genomic DNA 
of double crossover exconjugants to identify those containing the ∆tsn11 coding-frame deletion. PCR product 
size wild type: 1928 bp. PCR product size ∆tsn11 mutant: 572 bp. Right: Agarose gel demonstrating the 
successful creation of the S. longisporoflavus ∆tsn11 mutant. b, Creation of S. longisporoflavus ∆tsn15. Left: 
Diagram showing the double crossing-over event between pYH7-tsn15 and the S. longisporoflavus 
chromosome. In total 621/621 bp of tsn15 were deleted in the ∆tsn15 mutant. The primers tsn15_KO_Fw and 
tsn15_KO_Rv were used to screen the genomic DNA of double crossover exconjugants to identity those 
containing the ∆tsn15 coding-frame deletion. PCR product size wild type: 1334 bp. PCR product size ∆tsn15 
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4.3 HPLC-MS analysis of polyether tetronate [4+2] cyclase deletion mutants  
 
4.3.1 Analysis of the S. sp NRRL 11266 ∆tmn8 deletion mutant 
 
HPLC-MS analysis revealed that tetronomycin production was abolished in S. sp. NRRL 
11266 ∆tmn8 (Figure 4.10), indicating that Tmn8 is essential for tetronomycin 
biosynthesis. This experiment provided the first evidence that VstJ-like cyclase 
homologues are essential for polyether tetronate biosynthesis.  
 
 
Figure 4.10 HPLC-MS analysis of the Streptomyces sp. NRRL 11266 ∆tmn8 mutant. a, The structure 
and molecular weight of tetronomycin (2) produced by S. sp. NRRL 11266. b, Extracted m/z = 609 
chromatograms of S. sp. NRRL 11266 wild type (WT) and S. sp. NRRL 11266 ∆tmn8. Tetronomycin 2 was 
detected in S. sp. NRRL 11266 WT as ammonium (m/z = 604.42) and sodium (m/z = 609.5) adducts. No 
tetronomycin production was detected from the S. sp. NRRL 11266 ∆tmn8 mutant. Data are representative 
of three independent experiments.  
 
To verify that the deletion of tmn8 had not affected the expression of adjacent genes, an 
attempt was made to complement the Δtmn8 mutant in trans. Such genetic 
complementation typically utilises a vector capable of integrating into a genomic phage 
attachment site210,269. Once integrated, the desired gene is expressed from the integrated 
vector. In this study the plasmid pIB139, which integrates into φC31 phage attachment 
sites, was used206. As an example, the pIB139 construct used to deliver tsn11 in the S. 
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longisporoflavus ∆tsn11 mutant is displayed in Figure 4.11. Unfortunately in the case of S. 
sp. NRRL 11266 ∆tmn8, despite numerous attempts, pIB139-tmn8 could not be conjugated 
into S. sp. NRRL 11266 ∆tmn8. Genetic complementation was therefore not achieved in 





Figure 4.11 Plasmid map of the pIB139-tsn11. tsn11 (yellow) was cloned downstream of the ermE* 
promoter (white). Once conjugated into S. longisporoflavus ∆tsn11, the ΦC31 integrase integrates the 
plasmid into a chromosomal ΦC31 attachment site. tsn11 is then expressed from the ermE* promoter. 
acc(3)IV: apramycin resistance gene. oriT: origin of transfer, ori: origin of replication.  
 
 
4.3.2 Analysis of A. verrucosispora ∆mad10 and A. verrucosispora ∆mad31 deletion 
mutants 
 
Tetromadurin production was abolished in the A. verrucosispora ∆mad10 mutant (Figure 
4.12a, Figure 4.12b), indicating that the PyrE3-like Mad10 is an essential biosynthetic 
enzyme. Unlike S. sp. NRRL 11266 ∆tmn8, pIB139-based plasmids could be successfully 
used for conjugation into A. verrucosispora. Introduction of pIB139-mad10 into A. 
verrucosispora ∆mad10 restored tetromadurin production, albeit only to 28% of the wild 
type level (Figure 4.12b). Tetromadurin production in the A. verrucosispora ∆mad31 
mutant was also abolished, producing tetromadurin at just 3% of wild type levels (Figure 
4.12c). However, in trans complementation with mad31 in A. verrucosispora ∆mad31 did 













Although A. verrucosispora ∆mad10 no longer produced tetromadurin, analysis of the total 
ion current (TIC) and photodiode array (PDA) spectrum of this mutant revealed that it 
produced a new metabolite labelled M-17 (Figure 4.13). A. verrucosispora ∆mad10 
produced M-17 at about half the level that A. verrucosispora WT produced tetromadurin. 
M-17 has a different retention time, UV chromophore, and mass spectra from tetromadurin 
(Figure 4.13). The mass spectra of M-17 contains peaks for putative [M+H]+ (m/z = 745), 
[M+NH4]+ (m/z = 762), and [M+Na]+ (m/z = 767) ions, all of which were 16 Daltons less than 
the equivalent ions of tetromadurin (3) (Figure 4.13c). A mass difference of 16 is 
diagnostic of an absent hydroxyl group, suggesting M-17 has the molecular formula of 
C42H64O11. Likely candidates for this missing oxygen are either of the C36 or C38 hydroxyl 
groups. As discussed in Chapter 1, it is likely that the cytochrome P450 enzymes Mad29 












Figure 4.12 HPLC-MS analysis of A. verrucosispora ∆mad10 and A. verrucosispora ∆mad31. a, The 
structure and molecular weight of tetromadurin (3) produced by A. verrucosispora. b, Extracted m/z = 783 
HPLC-MS spectra from A. verrucosispora WT, A. verrucosispora ∆mad10, and A. verrucosispora ∆mad10 
pIB139-mad10. c, Extracted m/z = 783 HPLC-MS spectra from A. verrucosispora WT, A. verrucosispora 
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Figure 4.13 Novel tetromadurin analogue produced by A. verrucosispora ∆mad10. a, Total ion current 
(TIC) spectra of the crude organic extracts from A. verrucosispora WT and A. verrucosispora ∆mad10. The 
other peaks represent unrelated species. Tetromadurin (3) was produced by A. verrucosispora and eluted at 
19.8 min. A novel tetromadurin-related metabolite (M-17) was produced by A. verrucosispora ∆mad10, eluting 
at 17.4 min. b, HPLC-PDA (photodiode array) spectra of the crude organic extracts from A. verrucosispora 
WT and A. verrucosispora ∆mad10. c, Positive ion mode mass spectrum of tetromadurin (3) and M-17: 
*[M+Na]+, **[M+NH4]+, ***[M+H]+, ****[M+H−H2O]+, *****[M+H−2.H2O]+. For tetromadurin (3): m/z 
[C42H64O12+Na]+ = 783.81; m/z [C42H64O12+NH4]+ = 778.82; m/z [C42H64O12+H]+ = 761.84; m/z 
[C42H64O12+H−H2O]+ = 739.84. For M-17: m/z [C42H64O11+Na]+ = 767.69; m/z [C42H64O11+NH4]+ = 762.58; m/z 
[C42H64O11+H]+ = 745.63; m/z [C42H64O11+H−H2O]+ = 727.70; m/z [C42H64O11+H−H2O]+ = 727.70; m/z 
[C42H64O11+H−2.H2O]+ = 709.79. d, UV absorption spectra of tetromadurin (3) (λMAX = 252 nm, 300 nm, 
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Figure 4.14 Predicted sites of cytochrome P450 hydroxylation on tetromadurin. The OH groups on C36 
and C38 (highlighted in red) are likely added by the two cytochrome P450 enzymes, Mad29 and Mad30, 
respectively, present in the mad cluster.  
 
One explanation for these results is that Mad10, rather than Mad29 or Mad30, is 
responsible for catalysing the hydroxylation at either C36 or C38. However, Mad10 is 
homologous to FAD-dependent monooxygenases, enzymes that typically catalyse 
hydroxylations of aromatic compounds270, exemplified by OxyS in oxytetracycline 
biosynthesis. In contrast, hydroxylation of C-H bonds is a typical reaction catalysed by 
cytochrome P450 enzymes271. Given the presence of two cytochrome P450 enzymes in 
the mad cluster, it is unlikely that Mad10 is directly responsible for either of these 
hydroxylations.  
 
An alternative explanation is that Mad10 catalyses a reaction that must precede one of the 
cytochrome P450-catalysed hydroxylations. Comparison of the M-17 mass spectrum with 
that of tetromadurin revealed telling differences in the relative abundance of several ions. 
While the major ions detected for tetromadurin were the [M+NH4]+ and [M+Na]+ adducts, 
the base peak for M-17 was the [M+H−H2O]+ ion (m/z = 727) (Figure 4.13c). The [M+H-
H2O]+ ion likely arises through the M-17 [M+H]+ ion losing a hydroxyl group in the mass 
spectrometer source. An equivalent [M+H−H2O]+ peak was detectable for tetromadurin (m/z 
= 739) although only at 12% the abundance of the [M+NH4]+ base peak. Taken together 
these data indicate that, in addition to lacking one of the hydroxyl groups added by a 
cytochrome P450, M-17 also contains a labile hydroxyl group that is readily lost in the 
mass spectrometer. A possible candidate for the labile hydroxyl group was the C17 
hydroxyl, which would only be present if the tetrahydropyran ring had not yet formed. 
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cyclohexane ring had also not formed. It seems reasonable that without the cyclohexane 
and tetrahydropyran rings one of the cytochrome P450-catalysed hydroxylations, either at 
C36 or C38, would be unable to occur. From this, two possible structures of M-17 were 
proposed (Figure 4.15a). Both of the proposed intermediate structures could still 
theoretically form the cyclohexane and tetrahydropyran rings in the ring-closing cascade 





Figure 4.15 Proposed structures of M-17 produced by A. verrucosispora ∆mad10. a, Potential structures 
for M-17 that lack the cyclohexane and tetrahydropyran rings and either the C36 (structure 1) or C38 hydroxyl 
groups (structure 2). b, Possible mechanism by which Mad10 could catalyse closure of the tetrahydropyran 
and cyclohexane, followed by hydroxylation of C38 by Mad30.  
 
If true, this proposal would implicate Mad10 as a cyclase enzyme responsible for closing 
both the cyclohexane and tetrahydropyran rings of tetromadurin. However, it would not 
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4.3.4 Analysis of the S. longisporoflavus ∆tsn11 and S. longisporoflavus ∆tsn15 
mutants 
 
Consistent with the results from the S. sp NRRL 11266 ∆tmn8, S. sp NRRL 11266 
∆tmn9111, A. verrucosispora ∆mad10 and A. verrucosispora ∆mad31 deletion mutants, 
tetronasin production was abolished in both the S. longisporoflavus ∆tsn11 and S. 
longisporoflavus ∆tsn15 mutants (Figure 4.16). In trans complementation of tsn11 or tsn15 
deletion mutants with the wild type gene restored tetronasin production to wild type levels, 
confirming the specificity of each gene deletion (Figure 4.16). Tsn11 and Tsn15 are 
therefore essential for tetronasin biosynthesis.  
 
Analogous to the A. verrucosispora ∆mad10 mutant, S. longisporoflavus ∆tsn11 produced 
a new tetronasin analogue. This new metabolite, labelled T-16, had a different retention 
time, UV chromophore, and MS3 fragmentation pattern to tetronasin, but the same 
molecular weight (Figure 4.17, Appendix Figure 3). Notably, the UV absorbance spectra 
of T-16 and M-17 are very similar, each with λMAX = 236 nm. Also as observed with M-17, 
the major T-16 ion detected was the [M+H−H2O]+ ion, whereas for tetronasin the [M+Na]+ 
was the major ion. T-16 therefore also appears to contain a labile hydroxyl group that is 
readily lost in the mass spectrometer. The [M+Na−H2O]+ peak (m/z = 607) did not increase 
in abundance, indicating that when T-16 was a sodium or ammonium ion adduct, 
fragmentation of the labile hydroxyl was unfavourable. As suggested for M-17, a possible 
structure of T-16 that would account for this labile hydroxyl, while retaining the same 
molecular weight as tetronasin, would be an open form of tetronasin lacking the 
tetrahydropyran and cyclohexane rings (Figure 4.18). To investigate this comprehensive 
structural studies were planned for the next chapter.  
 




Figure 4.16 HPLC-MS analysis of S. longisporoflavus ∆tsn11 and S. longisporoflavus ∆tsn15. a, The 
structure and molecular weight of tetronasin (1) produced by S. longisporoflavus. b, Extracted m/z = 625 
HPLC-MS spectra from S. longisporoflavus WT, S. longisporoflavus ∆tsn11, and S. longisporoflavus ∆tsn11 
pIB139-tsn11. c, Extracted m/z = 625 HPLC-MS spectra from S. longisporoflavus WT, S. longisporoflavus 
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Figure 4.17 Production of a novel tetronasin analogue from S. longisporoflavus ∆tsn11. a, Total ion 
current (TIC) spectra of the crude organic extracts from S. longisporoflavus WT and S. longisporoflavus 
∆tsn11. Tetronasin (1) (C35H54O8) was produced by S. longisporoflavus WT, eluting at 24 min. A novel 
tetronasin analogue (T-16) was produced by S. longisporoflavus and eluted at 16.8 min. b, HPLC-PDA 
(photodiode array) spectra of the crude organic extracts from S. longisporoflavus ∆tsn11 and S. 
longisporoflavus ∆tsn15. c, Positive ion mode mass spectrum of tetronasin (1) and T-16: *[M+Na]+;** 
[M+NH4]+; ***[M+H]+; ****[M+H−H2O]+; *****[M+H−2.H2O]+. d, UV absorption spectra of tetronasin (1) (λmax = 
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Figure 4.18 Possible structure and in-source fragmentation of T-16. T-16 produced by S. 
longisporoflavus readily fragmented a hydroxyl group in the mass spectrometer, forming [M+H−H2O]+ as the 
major ion. One explanation for this could be that the tetrahydropyran and cyclohexane rings of T-16 have not 
formed, leaving the C17 hydroxyl exposed for in-source fragmentation.  
 
 
While the S. longisporoflavus ∆tsn15 mutant no longer produced tetronasin, examination of 
the TIC spectrum revealed that, in contrast to the A. verrucosispora ∆mad31 and the S. sp 
NRRL 11266 ∆tmn8 mutants, it also produced a new metabolite related to tetronasin. The 
new metabolite, which was labelled T-21, was produced at a similar level to tetronasin in S. 
longisporoflavus WT strain, and had a different retention time and molecular weight from 
both T-16 and tetronasin (Figure 4.19). Despite being a prominent peak in the TIC 
spectrum, no corresponding absorbance peak was present in the PxwDA spectrum (Figure 
4.19b). Intriguingly, the putative [M+H]+, [M+Na]+, [M+NH4]+, and [M+H−H2O]+ ions for T-21 
were all two mass units greater than the equivalent tetronasin ions (Figure 4.19c, Figure 
4.19d). Such a mass shift could be caused by the reduction of a double bond or of a keto 
group, resulting in the addition of two protons. The major ions of T-21, however, were m/z = 
538 and m/z = 543, the structures of which could not be confidently predicted. These ions 
were unique to the S. longisporoflavus ∆tsn15 mutant and were not detectable in either the 
WT or in S. longisporoflavus ∆tsn11. The mass unit difference of 5 between the two major 
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Figure 4.19 Production of T-21 by S. longisporoflavus ∆tsn15. a, TIC spectra of S. longisporoflavus wild 
type (WT) and S. longisporoflavus ∆tsn15 showing the production of tetronasin (1) and T-21, respectively. b, 
PDA spectra of S. longisporoflavus WT and S. longisporoflavus ∆tsn15. The absorbance peak for tetronasin 
(1) was present in S. longisporoflavus WT, but no new peak corresponding to T-21 was present in the S. 
longisporoflavus ∆tsn15 spectrum. c, Mass spectrum of T-21. d, Mass spectra comparison of tetronasin and 
T-21. *[C35H54O8+Na]+; **m/z [C35H54O8+NH4]+; ***[C35H54O8+H]+; ****[C35H54O8+H−H2O]+.  
 
However, no corresponding [M+H]+ peak at m/z = 520 was detected. It was speculated that 
the m/z = 538 and m/z = 543 ions were in-source fragmentation products of the [M+Na]+ 
and [M+NH4] ions, respectively. However, because the structure of the parent compound 
was unknown it was difficult to draw a plausible fragmentation mechanism to account for 
these ions. Further investigation of the identity of T-21 and its relevance to tetronasin 
biosynthesis is described in Chapter 5 of this thesis.  
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4.3.5 Creation and analysis of an S. longisporoflavus ∆tsn11 ∆tsn15 double mutant 
 
Given that S. longisporoflavus ∆tsn11 and the S. longisporoflavus ∆tsn15 each produced a 
unique metabolite,  reasoned that by creating a S. longisporoflavus ∆tsn11 ∆tsn15 double 
mutant it would provide insight into the order in which Tsn11 and Tsn15 act. The double 
mutant was created by deleting tsn15 from the genome of S. longisporoflavus ∆tsn11 using 
the same pYH7 plasmid used for creating S. longisporoflavus ∆tsn15. The genotype of the 




Figure 4.20 Creation of a S. longisporoflavus ∆tsn11 ∆tsn15 double mutant. tsn15 was deleted from the 
S. longisporoflavus ∆tsn11 mutant to create a S. longisporoflavus ∆tsn11 tsn15 double mutant. The double 
deletion phenotype was confirmed using PCR and DNA sequencing. Left: the expected ∆tsn11 and ∆tsn15 
PCR product sizes in the S. longisporoflavus ∆tsn11 ∆tsn15 mutant were 713 bp and 572 bp, respectively. 
Right: agarose gel showing the products of the PCR reactions from the genomic DNA of S. longisporoflavus 
∆tsn11 ∆tsn15 and S. longisporoflavus WT, confirming the double deletion genotype.  
 
HPLC-MS analysis of S. longisporoflavus ∆tsn11 ∆tsn15 revealed that, like S. 
longisporoflavus ∆tsn11, it also produced T-16 (but not T-21) (Figure 4.21). These data 
indicated epistatic silencing of the ∆tsn15 phenotype in the ∆tsn11 ∆tsn15 double mutant, 
suggesting that Tsn11 acts before Tsn15.  
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Figure 4.21 Production of T-16 by S. longisporoflavus ∆tsn11 ∆tsn15. a, Extracted m/z = 625 HPLC-MS 
of S. longisporoflavus WT, S. longisporoflavus ∆tsn11, and S. longisporoflavus ∆tsn11 ∆tsn15. S. 
longisporoflavus WT produced tetronasin while S. longisporoflavus ∆tsn11 and S. longisporoflavus ∆tsn11 
∆tsn15 both produced T-16. b, The production of T-16 by both S. longisporoflavus ∆tsn11 and S. 
longisporoflavus ∆tsn11 ∆tsn15 was confirmed by comparing the m/z = 603 [M+H]+ MS3 of the T-16 produced 
by (I) S. longisporoflavus ∆tsn11 ∆tsn15, with (II) S. longisporoflavus ∆tsn11, and the m/z = 625 [M+Na]+ MS3 
of T-16 produced by (III) S. longisporoflavus ∆tsn11 ∆tsn15 and (IV) S. longisporoflavus ∆tsn11. Data are 
representative of three independent experiments.  




























0.5 x 105 
1 x 105 
0.5 x 105 
















0.5 x 105 
1 x 105 
m/z = 783 
3 
Tetromadurin (3) (C42H64O12) 
A. verrucosispora 
 
m/z [C42H64O12 + NH4]+ = 778    




























0 4 8 12 16 20 24 28 
Time (min) 
0 
1 x 105 
2 x 105 
0 
1 x 105 
2 x 105 
0 
1 x 105 



































1 x 105 
2 x 105 
∆tsn11 
0 
1 x 105 
2 x 105 
∆tsn11 ∆tsn15 
0 5 10 15 20 25 30 35 
Time (min) 
0 
1 x 105 
2 x 105 
0 












































































Chapter 4: in vivo studies on polyether tetronate [4+2] cyclase homologues 
 
	 144 
4.3 Chapter 4 Discussion 
 
The results from this chapter provided direct experimental evidence that the pyrE3 and vstJ 
[4+2] cyclase homologues in the tmn, tsn, and mad clusters are essential for polyether 
tetronate biosynthesis. When the pyrE3 homologues were investigated, the S. sp NRRL 
11266 ∆tmn9 mutant produced no polyether-related metabolite as previously reported111 
but the S. longisporoflavus ∆tsn11 and A. verrucosispora ∆mad10 mutants did each 
produce a new metabolite: T-16 and M-17, respectively. The mass and UV/Vis spectra of 
T-16 and M-17 suggested that they are analogous compounds, potentially lacking both the 
tetrahydropyran and the cyclohexane ring. M-17 also appeared to lack one of the hydroxyl 
groups added by a cytochrome P450 enzyme, but otherwise the MS evidence indicated 
that it contained the tetronate ring, tetrahydrofuran rings, and that one hydroxylation had 
taken place. T-16 had the same molecular weight as tetronasin, indicating that tetronate 
formation, tetrahydrofuran formation, C25 O-methylation, and C30 hydroxylation had all 
occurred and are not dependent on Tsn11. A notable difference between tetronasin and 
tetromadurin is that tetronasin only has one cytochrome P450-catalysed hydroxylation (at 
C30) while tetromadurin has two (at C36 and C38). Assuming that the equivalent carbon to 
tetronasin C30 is hydroxylated in M-17, C36, it would suggest that the missing hydroxyl 
group in M-17 is that on C38 (as shown in Figure 4.15b).  
 
Deletion of the vstJ-like genes tmn8, tsn15, and mad31 in their respective BGCs provided 
the first functional evidence that these [4+2] cyclase homologues are also essential for 
polyether tetronate biosynthesis. A new metabolite was produced by the S. 
longisporoflavus ∆tsn15 mutant (T-21), but not by the S. sp NRRL 11266 ∆tmn8 or A. 
verrucosispora ∆mad31 mutant. Why some deletion mutants produce novel metabolites 
and others do not is unknown. However, S. longisporoflavus 8E36, is an industrial producer 
of tetronasin reported to produce up to 500 mg/L209. The high tetronasin titre of this strain 
could be a factor in why the S. longisporoflavus ∆tsn11 and S. longisporoflavus ∆tsn15 
mutants produced detectable polyether tetronate analogues, while the other strains did not.  
 
Production of M-17 and T-16 compared to that of tetromadurin and tetronasin, respectively, 
was diminished. A. verrucosispora ∆mad10 produced M-17 at about half the level at which 
A. verrucosispora WT produced tetromadurin. Likewise, S. longisporoflavus ∆tsn11 
produced T-16 at ca. 30% the level S. longisporoflavus WT produced tetronasin. Several 
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factors could explain the decrease in production level of these metabolites. The first is that 
M-17 and T-16 may be unstable in cellular conditions. The second is that Tsn11/Mad10 
normally act while the polyketide intermediate is still attached to the PKS, and that without 
these enzymes subsequent chain extensions are less efficient. The timing of Tsn11 and 
Tsn15 action is investigated further in Chapter 5.  
 
The genetic complementation experiments described in this chapter had mixed success. 
Using pIB139 to introduce tsn11 into S. longisporoflavus ∆tsn11 and tsn15 into S. 
longisporoflavus ∆tsn15 both restored tetronasin production to wild type levels (Figure 
4.16). The A. verrucosispora complementation experiments, on the other hand, were less 
successful. Genetic complementation of mad10 into A. verrucosispora ∆mad10 restored 
production of tetromadurin to 30% of wild type levels, whereas genetic complementation of 
A. verrucosispora ∆mad31 with mad31 into did not rescue production at all (Figure 4.12). It 
cannot be ruled out that the failure to rescue the A. verrucosispora ∆mad31 phenotype was 
due to polar effects of the ∆mad31 deletion on adjacent genes. However, given that mad31 
was deleted in its coding frame, such polar effects are unlikely210. It is more likely that the 
pIB139 constructs are not expressed well in the rare actinomycete A. verrucosispora. 
Expression from constitutive promoters such as ermE* (as found in pIB139) are known to 
be variable in different conditions/hosts272 and the position of the integrated gene in the 
chromosome can also profoundly affect its expression273. Poor expression could explain 
why only partial rescue of tetromadurin production was obtained in the A. verrucosispora 
∆mad10 pIB139-mad10 mutant. Many alternative promoter systems are available for such 
complementation experiments272. Future experiments could therefore try to find alternative 
promoters optimised for the heterologous expression of genes in A. verrucosispora.  
 
The final experiment performed in this chapter involved creating an S. longisporoflavus 
∆tsn11 ∆tsn15 double mutant. Analysis of this double mutant revealed that it produced T-
16, like the S. longisporoflavus ∆tsn11 mutant. This result strongly suggested that Tsn11 
and Tsn15 act sequentially in that order. It is notable that the predicted order of Tsn11 
(PyrE3 homologue) and Tsn15 (PyrI4 homologue) is the same order as the homologous 
proteins act in spirotetronate/tetramate pathways161. However, it is highly unlikely that 
Tsn11 and Tsn15 catalyse [4+2] cycloadditions patterned on PyrE3 and PyrI4. 
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The mass spectra of T-16 and M-17 gave encouraging evidence that Tsn11 and Mad10 
might indeed be cyclases responsible for the biosynthesis of the cyclohexane and 
tetrahydropyran rings. However, to support this hypothesis it was necessary to purify T-16 
and M-17 and characterise their structure. As S. longisporoflavus was easier to manipulate 
genetically and ferment than A. verrucosispora, the next chapter focuses on the structural 











Chapter 5: in vitro reconstitution of tetronasin 
cyclohexane and tetrahydropyran biosynthesis 
 
The findings of the previous chapter established that specific deletion mutants of S. 
longisporoflavus and A. verrucosispora lacking putative [4+2] cyclase genes accumulate 
novel tetronate-related metabolites apparently lacking the central rings of the mature 
antibiotics. This opened the exciting possibility of being able not only to isolate and 
determine the structure of these metabolites, but also to test their competence as 
substrates for each of the candidate cyclases expressed as recombinant proteins from E. 
coli, aiming essentially to reconstitute formation of the central rings in vitro. Success in this 
would not only define the role of each enzyme in this novel transformation, but also open 
the way to a detailed structural and mechanistic exploration of these catalysts.  
 
Some sections of this chapter were done in collaboration with Dr. Finian Leeper (University 
of Cambridge, UK) and Robert Jenkins and Dr. Manuela Tosin (University of Warwick, UK). 
All contributions will be explicitly stated.  
 
5.1 The structure of T-16 
 
5.1.1 Fermentation of S. longisporoflavus ∆tsn11 
 
In the previous chapter, small-scale cultures of S. longisporoflavus ∆tsn11 were grown to 
produce analytical amounts of T-16 for HPLC-MS analysis. To determine its structure by 
NMR, however, it was necessary to significantly increase the amount and purity of T-16. 
Collecting good NMR data typically requires at least 1 mg of highly purified compound, but 
the more the better, especially in case of large and complex natural products.  
 
S. longisporoflavus ∆tsn11 was found to produce T-16 at ca. 30% of the level at which S. 
longisporoflavus WT produced tetronasin. Under optimal conditions, S. longisporoflavus 
8E36 has been reported to produce tetronasin at levels as high as 500 mg/L209. S. 
longisporoflavus ∆tsn11 might therefore produce up to 150 mg/L of T-16, suggesting a 
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relatively modest scale-up would be sufficient. Unfortunately, although T-16 was reliably 
produced by S. longisporoflavus ∆tsn11 in 50 mL and 100 mL liquid cultures, production 
levels dropped to trace amounts when scaled up to 400 mL cultures in 2 L Erlenmeyer 
flasks. In these larger volumes the growth of S. longisporoflavus ∆tsn11 was also clearly 
suboptimal. In contrast, growth of S. longisporoflavus ∆tsn11 on solid agar reliably 
produced T-16 and the metabolite could be efficiently extracted using minimal amounts of 
ethyl acetate. For the initial scale-up, 100 12 x 12 cm tsn-medium-B agar plates were 
inoculated with S. longisporoflavus ∆tsn11 and grown at 30 °C for seven days (Figure 5.1). 
Each plate was then extracted three times using ethyl acetate to yield, after removal of the 
solvent, a total of 7 g of crude organic extract.  
 
      
 
Figure 5.1 Growth of S. longisporoflavus ∆tsn11 on tsn-medium-B agar plates. On tsn-medium-B S. 










S. longisporoflavus ∆tsn11 
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5.1.2 Purification of T-16  
 
T-16 was isolated from the crude organic extract using reverse-phase chromatography 
followed by semi-preparative HPLC. The S. longisporoflavus ∆tsn11 crude organic extract 
was redissolved in methanol and loaded onto C18 solid-phase extraction cartridges 
(Figure 5.2).  
  
 
Figure 5.2 C18 solid-phase extraction cartridge used for the purification of T-16. a, The S. 
longisporoflavus ∆tsn11 crude organic extract was redissolved in methanol and loaded onto C18 solid phase 
extraction cartridges. Non-polar species (dark brown fraction) remained at the top of the C18 resin bed, while 
more polar species, including T-16, could be eluted using 65% methanol. b, Example of fractions collected 
from the C18 solid-phase extraction cartridge (left to right increasing methanol concentration). 
 
Methanol concentrations ranging from 10-100% were passed through the column and the 
flow-through was collected in fractions. The different fractions were analysed by HPLC or 
HPLC-MS to identify those containing T-16. From these initial optimisation experiments a 
reliable isocratic elution protocol was developed for the initial purification of T-16. Passing 
65% methanol through the column eluted T-16 after the majority of more polar species had 
already eluted, but before less polar species started to elute. Typical HPLC traces showing 
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Figure 5.3 HPLC traces from the purification of T-16 using C18 solid phase extraction cartridges. The 
organic extract from S. longisporoflavus ∆tsn11 was loaded on C18 solid-phase extraction cartridges. 
Isocratic elution of T-16 was performed using 65% methanol. Following addition of the 65% methanol to the 
column, six different election fractions were collected one after the other (I-VI). Each of the fractions was 
analysed by HPLC for the presence of T-16. All of the fractions in which T-16 was the major component (III-V) 
were pooled together for the next stage of purification.  
 
The elution fractions in which T-16 was the major component were pooled for further 
purification. The second round of purification was performed using the fraction collector of 
a semi-preparative HPLC instrument. A representative spectrum from the semi-preparative 
HPLC showing the collection of T-16 is displayed in Figure 5.4.  
 
11 5 6 7 8 9 10 













Figure 5.4 The purification of T-16 using semi-preparative HPLC. The figure shows a representative 
example of the fraction collection program used to purify T-16. The grey lines show the boundaries of the 
different fractions automatically collected by the instrument. T-16 was collected in the third fraction 
(highlighted in yellow). The other peaks represent unrelated species.  
 
In this manner a total of 12.5 mg of T-16 was purified from the 100 tsn-medium-B agar 
plates. The purity of T-16 was assessed by HPLC-MS (Figure 5.5a) and high-resolution 
mass spectrometry confirmed that the molecular formula of T-16 was indeed the same as 
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Figure 5.5 Purification and high-resolution mass spectrometry of T-16. a, Total ion current HPLC 
chromatogram of purified T-16. b, High resolution mass spectrum of T-16 obtained on negative ion mode. 
The T-16 peak is highlighted in red. c, Table displaying the data obtained from the high-resolution mass of 
spectrum of T-16, confirming that the molecular formula was C35H54O8. 
 
5.1.3 NMR of T-16 
 
Prior to analysis by NMR, mass spectrometry was used to confirm that T-16 had an 
additional hydroxyl group compared to tetronasin. To achieve this, purified T-16 was mixed 
in a solution of deuterated methanol and D2O to substitute all exchangeable protons, i.e., 
those of hydroxyl groups, with deuterium before being directly injected into the mass 
spectrometer. As predicted in Chapter 4, T-16 was found to have three exchangeable 
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Figure 5.6 Deuterium labelling of exchangeable protons in T-16 and tetronasin. a, T-16 was directly 
injected into the mass spectrometer after being mixed with (I) methanol and H2O or (II) deuterated methanol 
and D2O. T-16 gained three mass units after being mixed with deuterated methanol and D2O, indicating three 
exchangeable protons (hydroxyl groups). b, Tetronasin control (I) A direct injection of tetronasin after mixing 
with methanol H2O. (I) A direct injection of tetronasin after mixing with deuterated methanol and D2O, 
demonstrating that tetronasin had two exchangeable protons (hydroxyl groups)268. 
 
Purified T-16 was then submitted for extensive NMR characterisation consisting of 1H, 13C, 
COSY, HSQC, HMBC, and NOESY experiments. The NMR spectra were analysed in 
collaboration with Dr. Finian Leeper (University of Cambridge). From the NMR data the 
structure of T-16 could be confidently determined (Figure 5.7, Appendix Figure 10-15, 









































































































Figure 5.7 The structure of T-16 as determined by NMR spectroscopy. a, The structure of T-16 with atom 
labels. b, 1H-1H COSY correlations for T-16. c, 1H-13C HMBC correlations of T-16. Arrows point from proton to 
carbon. d, Selected 1H-1H NOESY correlations and 1H coupling constants of T-16.  
 
As proposed in Chapter 4, T-16 is an open form of tetronasin lacking the cyclohexane and 
tetrahydropyran rings, but containing the tetronate and tetrahydrofuran rings, the C25 
methoxy group, and the C30 hydroxylation. Although the HRMS of T-16 confirmed its 
molecular formula was identical to that of tetronasin (C35H54O8), no signals corresponding 
to C3 or the tetronate ring (C1, C2, C33, C34) were present in the 13C spectrum. The 
absence of these signals has been reported previously for simple 3-acyl tetronates274 and 
is due to rotation about the C2-C3 bond being intermediate in speed on the NMR time-
scale, causing extreme line broadening of the 13C signals. Signals for these carbon atoms 
have been detected for tetronasin174,181, probably because its rotational flexibility is reduced 
by coordination to a sodium atom. T-16 is therefore clearly less effective at binding a 
sodium ion than tetronasin. The rest of the 1H and 13C signals could be readily assigned to 
atoms in T-16. The COSY and HMBC signals from C-17 and C28, including the methoxy 
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spectrum of T-16 revealed six olefinic protons, whereas tetronasin only had three174,181. In 
the case of tetronasin, the olefin peaks correspond to protons at the C11-C12 and C18-
C19 double bonds. In contrast, T-16 has double bonds at C4-C5, C10-C11, C12-C13, and 
C18-C19 (the exact locations predicted by the TsnAI-TsnAV enzymes – see Figure 1.44). 
The 1H coupling constants of H10-H11 and H18-H19 double bonds were 15.8 Hz and 15.0 
Hz, respectively, indicating that the double bonds are trans. The configurations of the 
double bonds with only a single attached proton (C4-C5 and C12-C13) were determined by 
the NOESY spectrum as also being trans. The C4-C5 double bond was determined as 
trans due to the methyl protons of C32 having NOEs to the H6, but not to the H5 proton. 
The C12-C13 double bond was likewise determined as trans due to an NOE between the 
H13 proton and H11 proton, but not between the H13 and H30 protons (as would have 
been expected for a cis configuration). The NOESY also revealed that the relative 
stereochemistry of the tetrahydrofuran ring was the same as in tetronasin. The relative 
stereochemistries of the other chiral centres (C6, C14, C17, C20, and C25) could not be 
assigned from the data, but are unlikely to differ from tetronasin.  
 
That T-16 did not have the cyclohexane and tetrahydropyran rings provided the strongest 
evidence to date that formation of these rings is enzyme catalysed, possibly by Tsn11. The 
structure of T-16 also demonstrated that tetrahydrofuran formation, C25 O-methylation, 
and C30 hydroxylation are not dependent on cyclohexane and tetrahydropyran ring 
formation. However, whether T-16 was a real tetronasin intermediate or a metabolic shunt 
product was unknown. To investigate this, it was essential to test whether or not T-16 could 
be converted into tetronasin in vitro using purified Tsn11. Analysis of the S. 
longisporoflavus ∆tsn11 ∆tsn15 double mutant (Figure 4.21) had suggested that Tsn15 
acts after Tsn11, indicating that both enzymes might be required for cyclohexane and 
tetrahydropyran formation. Protein purification protocols were therefore developed for both 
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5.2 in vitro reconstitution of ring formation 
	
5.2.1 Purification of recombinant Tsn11 and Tsn15 
 
The tsn11 and tsn15 genes were amplified from the genomic DNA of S. longisporoflavus 
and individually cloned into the E. coli expression vector pET28a(+). The pET28a(+) vector 
added an N-terminus polyhistidine tag in-frame with each of the genes, enabling Tsn11 and 
Tsn15 to be purified using nickel-affinity chromatography (Figure 5.8). The identity of each 
purified protein was confirmed using mass spectrometry (Figure 5.9). 
 
 
             
 
 
Figure 5.8 SDS-PAGE gel of the purified Tsn11 and Tsn15. Tsn11 and Tsn15 were individually purified 
using nickel-affinity chromatography and analysed for purity on an SDS-PAGE gel. On the SDS-PAGE gel 
from left to right: Marker (M); Tsn11, 55.5 kDa; Tsn15, 24.6 kDa. Protein bands were visualised using 


































         
Figure 5.9 LC-MS of Tsn11 and Tsn15. (I) Total ion current (TIC) chromatogram of purified Tsn11. (II) Mass 
spectrum of Tsn11. (III) Deconvoluted mass spectrum of Tsn11. The detected z=1 mass of 55.4 kDa is 
identical to its predicted mass of 55.4 kDa. (IV) TIC chromatogram of purified Tsn15. (V) Mass spectrum of 
Tsn15. (VI) Deconvoluted mass spectrum of Tsn15. The detected z=1 mass of 24.5 kDa is consistent with the 
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Tsn11 purified as a bright yellow protein with a UVMAX of 450 nm, indicating it has a bound 
flavin prosthetic group (FAD or FMN) (Figure 5.10). To determine which prosthetic group 
was present, a small sample of Tsn11 was boiled to denature the protein and release the 
prosthetic group. HRMS was then used to identify the bound prosthetic group as FAD (as 
in PyrE3)161 (Figure 5.10d). The stoichiometry in which FAD bound was investigated more 







Figure 5.10 The FAD prosthetic group of Tsn11. a, A sample of purified Tsn11 in a 1.5 mL microcentrifuge 
tube. b, UV/Vis absorbance spectrum of Tsn11. c, structure of chemical formula of FAD. d, Table of the 
predicted and detected HRMS of FAD collected from the supernatant of a boiled Tsn11 sample. 
 
5.2.2 in vitro reconstitution of cyclohexane and tetrahydropyran ring formation in 
tetronasin biosynthesis 
 
Purified Tsn11 and Tsn15 were used with T-16 in in vitro assays. The in vitro enzyme 
assays were performed at 30 °C for 1 h, after which the reactions were terminated and the 
products analysed by HPLC (Figure 5.11). When T-16 was incubated with Tsn11, the T-16 
peak disappeared and a peak corresponding to a new metabolite labelled T-22, appeared. 



















































       
FAD C27H33N9O15P2 785.15713 785.1540 784.1467 −H −4.3 
	
d 
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chromophore and retention time (discussed more in Section 5.34). In contrast, no 
conversion occurred when T-16 was incubated with Tsn15 alone. However, incubation of 
T-16 with both Tsn11 and Tsn15 converted T-16 into tetronasin. The identity of tetronasin 
was confirmed by the produced species having an identical retention time, HRMS, UV/Vis 
absorption spectrum, and MS3 fragmentation pattern to a tetronasin standard (Figure 5.12, 
Figure 5.13, Figure 5.14). Incubating T-22 with Tsn15 also produced tetronasin, 
demonstrating that, as predicted by the analysis of the S. longisporoflavus ∆tsn11 ∆tsn15 
mutant (Figure 5.21), Tsn11 precedes Tsn15. No conversion of T-16 was observed in the 
absence of enzymes. An alternative trace of this assay with better separation between T-
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Figure 5.11 In vitro conversion of T-16 into tetronasin using purified Tsn11 and Tsn15. The in vitro 
conversion of T-16 into tetronasin 1 by Tsn11 and Tsn15 was monitored by HPLC analysis. (I) T-16 incubated 
in the absence of enzymes. (II) Conversion of T-16 into T-22 using Tsn11 (III) No reaction occurred when T-
16 was incubated with Tsn15 alone. (IV) Conversion of T-16 into tetronasin 1 using Tsn11 and Tsn15. (V) 
Conversion of T-22 into tetronasin 1 using Tsn15. (VI) Tetronasin 1 standard. Data are representative of three 
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Figure 5.12 UV/Vis spectra comparison of the T-16 assay product and a tetronasin standard. (I) UV/vis 
spectra of the in vitro assay product of T-16 incubated with Tsn11 and Tsn15. UVmax = 234 nm, 266 nm (II) 






Figure 5.13 HRMS data of the product produced by the T-16 + Tsn11 + Tsn11 assay. High-resolution 
mass spectrometry of the product of the T-16 + Tsn11 + Tsn15 assay confirmed that it has the same 




































Product of T-16 + Tsn11 + Tsn15 
220 240 260 280 300 
Formula Theoretical mass Observed m/z Adduct Error (ppm) 
     
C35H54O8Na 625.3711 625.3691 Na+ −3.10 
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Figure 5.14 MS3 comparison between the T-16 + Tsn11 + Tsn15 assay product and a tetronasin 
standard. a, (I) Mass spectrum of the product of T-16 + Tsn11 + Tsn15 assay; (II) a tetronasin 1 standard. 
*[M+Na]+, **[M+NH4]+, ***[M+H]+, ****[M+H−H2O]+. b, MS3 mass spectra of the m/z = 625 [M+Na]+ peak for (I) 
the product of the T-16 + Tsn11 + Tsn15 assay and (II) a tetronasin 1 standard. Normalised collision energy 
35%. c, MS3 mass spectra of the m/z = 603 [M+H]+ peak for (I) the T-16 + Tsn11 + Tsn15 assay and (II) a 
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Boiling Tsn11 abolished its activity, whereas Tsn15 remained active even after boiling for 
ten minutes (Figure 5.15). Adding EDTA to the assay buffer also did not inhibit the 




Figure 5.15 T-16 conversion assay in the presence of EDTA or boiled enzyme. (I) T-16 standard 
incubated in the absence of enzyme. (II) T-16 was not converted into T-22 when incubated with boiled Tsn11. 
(III) Conversion of T-16 into tetronasin 1 when incubated with Tsn11 and boiled Tsn15 (IV). The addition of 1 
mM EDTA to the assay buffer did not interfere with the conversion of T-16 into tetronasin 1 by Tsn11 and 
Tsn15. (V) Tetronasin 1 standard. Data are representative of three independent experiments.  
 
Taken together these data showed that Tsn11 and Tsn15 act in an enzymatic cascade to 
convert T-16 into tetronasin via the unknown intermediate T-22, closing both the 
cyclohexane and tetrahydropyran rings of tetronasin (Figure 5.16). The precise role of 
each enzyme in this process, i.e., if one enzyme forms both rings, or they each form one, 
was unknown. The structure of T-22 was the key piece of information required to answer 
this question.  
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Figure 5.16 Enzymatic cascade for the conversion of T-16 into tetronasin via T-22. T-16 is converted 
into tetronasin via two sequential enzyme-catalysed steps. Tsn11 converts T-16 into the unknown 
intermediate T-22, which is then converted into tetronasin by Tsn15.  
 
5.2.3 Possible mechanisms of cyclohexane and tetrahydropyran ring closure 
 
Prior to solving the structure of T-22 four main possible mechanisms were considered for 
cyclohexane and tetrahydropyran formation (Figure 5.17). Mechanism 1 was proposed by 
the author, Mechanisms 2 and 4 by Professor Gregory Challis (University of Warwick, UK), 
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5.2.3.1 Mechanism 1  
 
Mechanism 1 (Figure 5.17) resembles the previously proposed metal-catalysed 
cyclohexane and tetrahydropyran ring closure mechanism175,177. In this scheme Tsn11 
catalyses cyclohexane and tetrahydropyran formation, leaving C3-C4 in the enol form. To 
form tetronasin Tsn15 catalyses a stereospecific keto-enol tautomerisation to form the C3 
keto and establish the S configuration of C32. Such keto-enol tautomerisation can occur 
spontaneously, but the specific stereochemical outcome required to produce tetronasin 
may indicate that an enzyme is responsible. Such stereospecific keto-enol tautomerases 
have been previously characterised, such as oxaloacetate keto-enol tautomerase275,276. 
This mechanism gains plausibility when considering the equivalent enol intermediate for 
tetronomycin. Both tetronasin and tetronomycin would have very similar C3-C4 double 
bond enol intermediates, yet their C4 methyl groups end up having the opposite 
stereochemistry. A stereospecific keto-enol tautomerase enzyme could therefore be 
required for establishing this stereochemical difference (Figure 5.18). In the second total 
synthesis of tetronasin the cyclohexane and tetrahydropyran rings could be formed in a 
single step using an intermediate resembling T-16180. Although in that case the 
cyclohexane and tetrahydropyran ring stereochemistry was correct, the C4 stereochemistry 








Figure 5.18 Possible mechanism for forming the R-configured C28 methyl group in tetronomycin. a, 
Under the Mechanism 1 proposal for tetrahydropyran and cyclohexane formation, Tmn8 is responsible for 
catalysing the stereospecific keto-enol tautomerisation to form the R-configured C28 methyl group. b, 
Proposed formation of the S-configured C32 methyl group in tetronasin under Mechanism 1.  
 
5.2.3.2 Mechanism 2 
 
Mechanism 2 (Figure 5.17) proposes that Tsn11 is able to bind NADPH and has FAD-
dependent monooxygenase activity. In this scheme Tsn11 oxidises the C30 hydroxyl to an 
aldehyde. The aldehyde activates the C13 for attack by the C17 hydroxyl, closing the 
tetrahydropyran ring. Next, while still bound to Tsn11, the cyclohexane ring forms. Tsn11 
then reduces the aldehyde back to the C30 hydroxyl. A similar oxidation-reduction cycle is 
found in enzymes such as dehydroquinate synthase277. Tsn15 then catalyses the same 
stereospecific keto-enol tautomerisation proposed in Mechanism 1 to form the S configured 
C32 methyl group. One issue this mechanism faces is that formation of an aldehyde at C30 
was previously ruled out176. In that study, two deuterium atoms were incorporated at C30 
by feeding S. longisporoflavus deuterium-labelled propionate176. Retention of deuterium at 
this site is not expected if the hydroxyl was oxidised to an aldehyde then reduced back to 
an alcohol, at which point hydrogen atoms from the solvent would be incorporated 176. 
However, this mechanism could be occurring if the same proton removed by FAD in the 
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FAD prosthetic group of Tsn11 would be essential for Tsn11 activity if this mechanism 
were correct. 
5.2.3.3 Mechanism 3 
 
In Mechanism 3 (Figure 5.17) Tsn11 catalyses an inverse-electron-demand hetero-Diels-
Alder/[4+2] cycloaddition (INVHDA) reaction (Figure 5.19) to form an oxadecalin 
intermediate, closing the cyclohexane ring. Tsn15 then catalyses tetrahydropyran ring 




Figure 5.19 Inverse-electron-demand hetero-Diels-Alder reaction. a, In an inverse-electron-demand 
hetero-Diels-Alder reaction an electron withdrawing group on the diene results in the LUMO of the diene and 
HOMO of the dieneophile (alkene) being closer in energy than the HOMO of the diene and LUMO of the 
dieneophile. b, Energy level diagram for a normal-electon-demand Diels-Alder reaction.  
 
advantage that both Tsn11 and Tsn15 would be catalysing pericyclic reactions like their 
homologues in spirotetronate/tetramate biosynthesis157,158,161 (and AOC2) in the case of 
Tsn15278). Other examples of enzymes catalysing apparent INVHDA reactions have also 
been reported279,280, so there is some precedent. In this mechanism the keto-enol 























5.2.3.4 Mechanism 4 
 
Mechanism 4 (Figure 5.17) is prima facie the least likely mechanism. In this scheme Tsn11 
catalyses carbocyclic decalin formation, just like its homologue PyrE3 from pyrroindomycin 
biosynthesis161. Tsn11 or Tsn15 then catalyses tetrahydropyran formation, requiring attack 
of the C18 hydroxyl onto a sp3 hybridised carbon, and fragmentation of the decalin ring. 
The resulting molecule resembles tetronasin except the C11-C12 double bond is in the cis 
configuration rather than the trans. To form tetronasin from this structure a cis-trans 
isomerisation is required, possibly catalysed by Tsn15.  
 
5.2.4 Purification and structural characterisation of T-22 
 
To gain insight into the mechanism by which Tsn11 and Tsn15 convert T-16 into 
tetronasin, it was necessary to purify and structurally characterise the intermediate. T-22 
has a distinctive chromophore (λ = 254 nm, 288 nm, MeOH) compared to T-16 and 
tetronasin. The mass spectrum of T-22 resembles tetronasin more than T-16, the major ion 
no longer being [M+H-H2O]+ (m/z = 585) (Figure 5.20). The MS3 fragmentation pattern of 






























Figure 5.20 UV/Vis spectrum and mass spectrum of T-22. (A) The UV/vis absorption specta of T-16 (λMAX 
= 236 nm, 272 nm), T-22 (λMAX = 254 nm, 288 nm), and tetronasin (λMAX = 234 nm, 266 nm). (B) Mass 
spectrum of T-16, T-22, and tetronasin. *[M+Na]+, **[M+NH4]+, ***[M+H]+, ****[M+H−H2O]+. 
 
 
T-22 was clearly related to T-21, the metabolite that accumulated in the S. longisporoflavus 
∆tsn15 mutant (Figure 5.21). Like T-21, the major detected ions of T-22 were m/z = 538 
and m/z = 543. However, the putative [M+H]+, [M+NH4]+, and [M+Na]+ of T-22 were not 



















































































Figure 5.21 Comparison of T-22 and T-21 mass spectra. Top: mass spectrum of T-22, produced from an 
in vitro assay containing T-16 and Tsn11. Bottom: mass spectrum of T-21, produced by the S. 
longisporoflavus ∆tsn15 mutant. *[M+Na]+ , **[M+H]+, ***[M+NH4]+. 
 
Given their apparent relatedness, it was tested if T-21, like T-22, is also a substrate of 
Tsn15. Rather than try to purify T-21 from the crude organic extract of S. longisporoflavus 
∆tsn15, the extract itself was incubated with Tsn15 and analysed by HPLC. However, no 
tetronasin production was detected from this assay (Figure 5.22). To rule out other 
metabolites in the crude extract inhibiting Tsn15, the S. longisporoflavus ∆tsn15 crude 
extract was supplemented with T-16. Adding Tsn11 and Tsn15 to this supplemented 
extract produced tetronasin, demonstrating that no component of the crude extract 
inhibited Tsn11 or Tsn15. T-21 can therefore not be converted into tetronasin by Tsn15. 
The exact identity of T-21 remains unknown, but it is potentially a breakdown product of T-
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Figure 5.22 Tsn15 assay using crude organic extract from the S. longisporoflavus ∆tsn15 mutant as a 
substrate. (I) Chromatogram of the crude organic extract from the S. longisporoflavus ∆tsn15 mutant. (II) No 
tetronasin production was observed when Tsn15 was incubated with the S. longisporoflavus ∆tsn15 crude 
organic extract. (III) Production of tetronasin by supplementing S. longisporoflavus ∆tsn15 crude organic 
extract with T-16, Tsn11, and Tsn15.  
 
 
To produce sufficient T-22 for NMR analysis, the conversion of T-16 by Tsn11 was scaled 
up, after first optimising the pH of the assay to maximise production of T-22. To achieve 
this, T-16 was incubated with Tsn11 in buffers ranging in pH from 6.0-9.0, and T-22 
formation was monitored by HPLC (Figure 5.23). Tsn11 was found to be most active in the 
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Figure 5.23 pH optimisation of the Tsn11 assay. T-16 and Tsn11 were incubated together in a range 
different pH buffers. The assay was terminated at 10 minutes, before complete conversion of T-16 into T-22 
had occurred in any of the conditions. (I) T-16 no enzyme control. (II) T-16 + Tsn11 assay run in MES pH 6.0 
buffer. (III) T-16 + Tsn11 assay run in pH MES pH 6.5 buffer. (IV) T-16 + Tsn11 assay run in TrisCl pH 7.0 
buffer. (V) T-16 + Tsn11 assay run in TrisCl pH 7.5 buffer. (VI) T-16 + Tsn11 assay run in TrisCl pH 8.0 




The initial attempt at scaling up the Tsn11 reaction, using the T-16 purified from the 100 
initial plates, was unsuccessful. The amount of T-22 isolated (roughly 1 mg) was not 
sufficient to obtain clear NMR spectra. It was therefore necessary to increase the amount 
of T-16 used in the assay. S. longisporoflavus ∆tsn11 was grown on 300 more tsn-medium-
B plates. From this new batch, about 25 mg of T-16 was isolated as before, 15 mg of which 
was incubated with Tsn11 for conversion into T-22. The large-scale incubation was 
conducted at 30 °C for 1 h, after which T-22 was extracted using ethyl acetate and purified 
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Figure 5.24 Production and purification of T-22 for NMR. a, Tsn11 was incubated with T-16 for 1 h to 
achieve complete conversion to T-22. T-22 was then extracted from the assay using ethyl acetate. When 
mixed with water ethyl acetate formed an upper organic phase b, Representative example of T-22 purification 
using a semi-preparative HPLC fraction collector. The grey lines show the boundaries of the different 
fractions automatically collected by the instrument. The fourth fraction (highlighted in yellow) collected T-22. 
The other peaks represent unrelated species.  
 
 
The second attempt at the scaled-up Tsn11 assay was more successful than the first, 
producing ca. 3.5 mg of purified T-22. 1D and 2D NMR experiments including 1H, 13C, 
COSY, HSQC, HMBC, TOCSY, and NOESY experiments were then performed (Appendix 
Figure 16-21, Appendix Figure 2). NMR data was again analysed in collaboration with Dr. 
Finian Leeper (University of Cambridge). The NMR data enabled the structure of T-22 to 
be solved, revealing that it still lacked the tetrahydropyran ring, but contained a closed 
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cyclohexane ring (the C5-C10 bond had formed) as part of an unexpected oxadecalin 





Figure 5.25 The structure of T-22 as determined by NMR spectroscopy. a, The structure of T-22 with 
atom labels. b, 1H-1H COSY correlations for T-22. c, 1H-13C HMBC correlations of T-22. Arrows point from 
proton to carbon. d, Selected 1H-1H NOESY correlations of T-22. 
 
 
As in T-16, the signals from C17 to C28, including the methoxy group, were very similar to 
those in tetronasin174,181, so could be readily assigned from the COSY and HMBC 
connections. The configuration of the double bonds could be determined as trans by the 
NOESY, as could the relative stereochemistry of the tetrahydrofuran ring (the same as T-
16 and tetronasin). Unlike T-16, however, which had six protons in the olefinic regions of 
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suggested that the cyclohexane ring had closed. Two of the olefinic peaks correspond to 
the protons attached to C18 and C19 in the tetrahydrofuran portion of the molecule. COSY 
and HMBC correlations could determine that the third olefinic peak is the C13 proton 
(showing an HMBC correlation to the C14 methyl group). The TOCSY NMR spectrum 
further supported this assignment, showing all three olefinic protons (C13, C18, and C19) 
are in the same spin system as each other. The 1H chemical shift of C11 proton (3.81 ppm) 
shows that C11 is sp3 hybridised and has an oxygen atom attached. This oxygen appears 
to be cyclised onto C3 to form a cyclic hemiacetal oxadecalin. The evidence for this is the 
chemical shift of C-3 (104.5 ppm). If the C11 hydroxyl were not cyclised onto C3, then the 
major component would contain a keto group at C3 and its 13C chemical shift would be 




Figure 5.26 Closed and open forms of T-22. a, the proposed major component structure of T-22 where a 
cyclic hemiacetal has formed by the C11 hydroxyl cyclising onto C3. The measured 13C shift for C3 is 104.5 
ppm. b, The alternative structure of T-22 where cyclic hemiacetal formation has not occurred, resulting in a 
C3 keto group. The C3 keto structure is not supported as the 13C chemical shift would be expected at around 
190-200 ppm174,274, which is not observed.  
 
Furthermore, the 13C shift of C33 is 179.99 ppm, whereas if C3 were a ketone it would be 
expected at ca. 190 ppm174,274. The final piece of evidence for the cyclic hemiacetal 
structure came from the NOESY spectrum. The NOESY revealed that T-22 was in 
equilibrium with several minor components, resulting in negative NOE peaks (standard 
NOEs show as positive peaks) due to saturation transfer between equivalent protons in 
these major and minor components (Figure 5.27a). The largest saturation transfer 
difference was for the H4 (δ 3.81 major to δ 4.67 minor) and H11 protons (δ 2.355 major to 
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to form a C3 keto and C11 hydroxyl (Figure 5.27b). Smaller saturation transfer signals 
were also present for protons adjacent to H4 and H11. The saturation transfer peaks of the 
two C34 protons (δ 4.62 in the major hemiacetal component), indicate that there are 
actually two minor C3 keto components, likely corresponding to the two different rotomers 
of the C2-C3 bond (singlets at δ 4.46 and δ 4.42). By integrating these peaks the ratio of 
the different components was estimated as 75% cyclic hemiacetal (H-34 δ 4.62), 15% 
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Figure 5.27 Saturation transfer signals in T-22. a, NOESY spectrum of T-22. Standard positive NOEs are 
presented as teal peaks. Negative peaks representing saturation transfer occurring between equivalent 
protons in the major and minor species are presented in dark blue. b, The major component (75%) of T-22 as 
a cyclic hemiacetal oxadecalin. The chemical shifts of protons in equilibrium with minor component forms are 
listed. c, The minor components of T-22 was determined by saturation transfer signals in the NOESY 
spectrum. The largest differences in 1H chemical shifts are between the protons attached to C4 and C11. T-
22 has two minor components due to rotation around the C2-C3 bond giving two rotomers. The ratio of these 
different components can be estimated as 75% cyclic hemiacetal, 15 % ketone rotamer 1 (H-34 δ 4.46), and 

































































The stereochemistry of H-11 was determined by its coupling constant to H-10 (J 9.7 Hz) 
indicating the two protons are trans axial-axial to each other. As H-10 is part of the 
cyclohexane ring its stereochemistry is highly unlikely to differ from that found in tetronasin. 
H-10 also has an NOE to the C32 methyl group, the stereochemistry of which is also 
almost certainly the same as in tetronasin. Taking these data together H-11 can be 
confidently assigned as being in an axial position on the oxadecalin ring and trans to H-10. 
The axial configuration of H-11 is also sterically favourable, as it places the bulky C12-C30 
part of the compound in an equatorial position.  
 
The stereochemistry of the C3 hydroxyl group could not be determined from the NMR, but 
there are good reasons for concluding that it is in the axial form as depicted. As the cyclic 
hemiacetal is reversibly opening and closing, the two stereoisomers of the ring-closed form 
should be in equilibrium. The isomer where the C3-OH is in the axial position should be 
preferred by the anomeric effect. The bulky tetronate is also sterically preferred in the 
equatorial position. As the second isomer is not observed it must be present at too low a 




Figure 5.28 Stereoisomers of the T-22. The cyclic hemiacetal of T-22 had two possible stereoisomers. Only 
stereoisomer 1 was observed, likely due to the C3-hydroxyl being in the axial position, favourable due to the 
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The additional hydroxyl group should make T-22 18 mass units heavier than T-16 or 
tetronasin. However, HRMS analysis could not detect this additional hydroxyl, its mass 
corresponding to the same molecular formula as the tetronasin sodium adduct 
(C35H54O8Na) (Figure 5.29). However, hemiacetals are known to be unstable in mass 
spectrometers and readily fragment. It is therefore proposed that the detected mass 
corresponds to the [M+Na−H2O]+ ion. Having solved the structure of T-22, the enzymatic 
cascade converting T-16 into tetronasin, forming four stereocenters in the process, was 
fully resolved (Figure 5.30). Tsn11 converts T-16 into the oxadecalin T-22, establishing the 
final stereochemistry of C4, C5, and C10. Three chemical transformations are required to 
convert T-22 into tetronasin: dehydration of the cyclic hemiacetal, tetrahydropyran 
formation, and breakage of the C11-O bond (not necessarily in that order). Tsn15 appears 
to catalyse all three of these transformations and establish the stereochemistry of C13 in 






        
 
        
Figure 5.29 HRMS of T-22. The HRMS of T-22 indicated that its molecular weight was the same as 
tetronasin and T-16 (C35H54O8Na). The additional hydroxyl group of the hemiacetal was not detected by the 
mass spectrometer. As hemiacetals are known to readily fragment in mass spectrometers, it is therefore likely 


























T-22 Major species detected
 C35H54O8C35H56O9
Formula Theoretical mass Observed m/z Adduct Error (ppm) 
     
C35H54O8Na 625.3711 625.3698 Na+ −2.02 
	





Figure 5.30 Formation of the cyclohexane and tetrahydropyran rings of tetronasin. The precyclisation 
substrate T-16 is converted into T-22 by Tsn11. The cyclohexane ring is closed in T-22 as part of a larger 
oxadecalin ring system. T-22 is then converted to tetronasin by Tsn15. Tsn15 catalyses formation of the 
tetrahydropyran ring, dehydration of the hemiacetal hydroxyl, and fragmentation of the oxadecalin. Together, 
Tsn11 and Tsn15 appear to establish the stereochemistry at C4, C5, C10, and C13 in tetronasin.  
 
  
5.2.5 Possible mechanisms of enzyme-catalysed cyclohexane and tetrahydropyran 
formation  
 
Given the structure of T-22, there are at least six alternative mechanisms that could 
account for the conversion of T-16 into tetronasin via T-22 by Tsn11 and Tsn15 (Figure 
5.31). Some mechanisms are more likely than others, as shall be discussed. Tsn11 could 
convert T-16 into T-22 via an INVHDA reaction (Mechanisms 5, 6, 9, and 10), as first 
proposed in Mechanism 3 (Figure 5.17). The resulting dihydropyran product must then 
tautomerise to the keto form, followed by attack by water onto C3 to form T-22. 
Alternatively, Tsn11 could catalyse attack of water onto C11, closing the cyclohexane ring 
in a stepwise reaction (Mechanisms 7 and 8).  
 


































































































































































































































































Figure 5.31 Possible mechanisms for the conversion of T-16 to tetronasin via T-22. At least six different 
mechanisms (Mechanism 5-10) are possible for the conversion of T-16 to tetronasin via T-22 by Tsn11 and 
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Following formation of T-22, Tsn15 then catalyses its conversion into tetronasin. Tsn15 
could catalyse tetrahydropyran formation and oxadecalin fragmentation either via 
nucleophilic attack of C17 onto C13 (Mechanism 5, 6, 7 and 8) or a pericyclic 
rearrangement (Mechanism 9 and 10).  
 
Depending on the mechanisms used by Tsn11 and Tsn15 to convert T-16 into tetronasin 
via T-22, the oxygen of the C3 keto group in tetronasin could be derived from either water 
(mechanisms 7 and 10), or (2S)-methylmalonyl-CoA (mechanisms 5, 6, 8, and 9). Feeding 
experiments using a precursor of 18O-labelled (2S)-methylmalonyl-CoA previously 
demonstrated that the oxygen of C3 keto is derived from (2S)-methylmalonyl-CoA175. To 
confirm this here, the Tsn11 and Tsn15 assays were conducted in excess H218O and 
assessed for the incorporation of 18O. These assays revealed no incorporation of solvent 
18O in either T-22 or tetronasin (Figure 5.32). The lack of incorporation of oxygen from the 
water solvent there makes mechanisms 7 and 10 unlikely, favouring Tsn11 catalysing an 
apparent INVHDA reaction (analogous to the [4+2] cycloaddition catalysed by its homologue 
PyrE3161). While mechanism 8 (the other mechanism where Tsn11 catalyses a stepwise 
reaction), is still theoretically possible, it seems unlikely as it would require the minor 
form(s) of T-22 (with an open hemiacetal ring) (Figure 5.27) to be the true substrate(s) of 
Tsn15. As the oxadecalin moiety of T-22 is not present in tetronasin, the reaction catalysed 
by Tsn11 is latent. Discriminating between the possible mechanisms of Tsn15 (nucleophilic 
attack vs. pericyclic) was more difficult and required the enzyme structural studies 
discussed in Chapter 6. Regardless of the mechanism, it is clear that both Tsn11 and 








Figure 5.32 Mass spectra of the Tsn11 and Tsn15 assay performed in H218O. a, Mass spectra of T-16 
incubated without enzyme in H2O or H218O. b, Mass spectra of T-22 generated by incubating T-16 with Tsn11 
in H2O or H218O. c, Mass spectra of tetronasin generated by incubating T-16 with Tsn11 and Tsn15 in H2O or 




5.3 The role of the FAD prosthetic group of Tsn11 
 
None of the mechanisms presented in Figure 5.31 requires the bound FAD prosthetic 
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obvious role in the apparent INVHDA catalysed by Tsn11. As discovered in Chapter 1, 
Tsn11 also lacks several of the residues predicted to be involved in oxidising NADPH. 
Nonetheless, it was important to determine experimentally whether or not the FAD 
prosthetic group participates in Tsn11 catalysis. A first approach to achieve this was to 
disrupt the interaction between Tsn11 and FAD by mutating a key FAD binding residue. 
The ability of Tsn11 lacking FAD to convert T-16 to T-22 could then be assayed in vitro. 
From the homology between Tsn11 and PyrE3/OxyS Asp282 was identified as likely to be 
an essential FAD binding residue161,259 (Figure 5.33).  
 
 
Figure 5.33 FAD binding residue of Tsn11. Alignment of OxyS and PyrE3 with Tsn11 enabled Asp282 to 
be identified as a likely residue involved in binding FAD. 
 
tsn11 D282A was successfully created using site-directed mutagenesis and cloned into a 
pET28a(+) plasmid for expression. Unfortunately expression of tsn11 D282A E. coli only 
yielded insoluble (albeit no longer yellow) protein. The lack of solubility and colour of Tsn11 
D282A suggested that disrupting FAD binding altered protein folding, decreasing solubility. 
As Tsn11 D282A could not be purified, our next approach was to prevent any redox cycling 
by keeping the FAD prosthetic group reduced for the duration of the assay. The E. coli 
flavin reductase protein Fre had previously been shown to selectively reduce the FAD 
prosthetic group of PyrE3163, so the fre gene was amplified from the genome of E. coli and 
overexpressed from pET-28a(+) for Ni-affinity purification (Appendix Figure 6). Although 
the purified Fre did possess flavin reductase activity (Appendix Figure 6), it was unable to 
reduce the FAD prosthetic group of Tsn11 (Figure 5.34a). Notably, no reduction of FAD 
was detected when Tsn11 was incubated with either NADH or NADPH, indicating that its 
FAD prosthetic group is unable to oxidise these common redox cofactors. The chemical 
reducing agent sodium dithionite (Na2S2O4) was tried next, also previously shown to be 
effective at reducing the FAD prosthetic group of PyrE3163. Incubating Tsn11 with sodium 
dithionite successfully reduced its FAD group, detectable both visually (yellow to 
colourless) and by its UV/Vis absorbance spectrum (Figure 5.34a, Figure 5.34b). 
       





Figure 5.34 Reduction of the Tsn11 FAD prosthetic group in the presence of sodium dithionite. a, 
UV/Vis spectra of 100 µM Tsn11 in the presence of NADH (1 mM), NADPH (1 mM), sodium dithionite (3 
mM), or Fre (50 µM) + NADPH (1 mM). Flavin reduction was only observed in the presence of sodium 
dithionite. b, bleaching of the oxidised FAD prosthetic group of Tsn11 due to reduction by sodium dithionite.  
 
 
However, no inhibition of the ability of Tsn11 to convert T-16 into T-22 was detected in the 
presence of excess sodium dithionite (Figure 5.35). These experiments demonstrated that, 
as proposed for PyrE3161,163, the FAD prosthetic group of Tsn11 does not participate in any 
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Figure 5.35 Tsn11 assay in the presence of sodium dithionite. Conversion of T-16 into T-22 by Tsn11 
was monitored over time in the presence of excess of Na2S2O4 (sodium dithionite). 100 µM of T-16 was 
incubated with 1 µM Tsn11 in the presence of 1 mM sodium dithionite at 30 °C. (I) t = 0 min control. (II) 
reaction terminated at 2 min (III) reaction terminated at 4 min (IV) reaction terminated at 8 min. Control 
reactions were performed in the absence of sodium dithionite (V) t = 0 min control. (VI) reaction terminated at 
2 min (VII) reaction terminated at 4 min (VIII) reaction terminated at 8 min. Data are representative of three 
independent experiments.  
 
 
5.4 Exchanging Tsn11 and Tsn15 with homologues from the tmn and mad 
pathways 
 
Given the structural similarities between tetronomycin and tetromadurin with tetronasin, 
their cyclohexane and tetrahydropyran rings are likely to be formed by the same 
mechanism. The four stereocenters established in the reactions catalysed by Tsn11 and 
Tsn15, C4, C5, C10, and C13, all have the opposite configuration in tetronomycin. It was 
therefore wondered if these stereocenters could be inverted by substituting Tsn11 and/or 
Tsn15 for their respective tmn homologues, Tmn9 and Tmn8. Furthermore, as 
tetromadurin has the same stereochemistry as tetromadurin at these centres, attempting to 
substitute Tsn11 and Tsn15 for the Mad10 and Mad31, respectively, would provide insight 
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were performed as before but Tsn11 and Tsn15 were replaced by their mad and tmn 
homologues. Tmn9, Tmn8, and Mad31 were readily purified as recombinant proteins from 
E. coli, as was done for Tsn11 and Tsn15 (Figure 5.36). Unfortunately Mad10 could not be 
purified as soluble protein.  
 
    
 
Figure 5.36 Purification of Tmn9, Tmn8, and Mad31. a, Purification of Tmn9 expressed from E. coli BL21 
(λDE3). Marker (M); Tmn9, 56.3 kDa; Tsn11, 55.5 kDa. b Purification of Tmn8 and Mad31 expressed from E. 
coli BL21 (λDE3). Marker (M); Tmn8, 21.9 kDa; Mad31, 22.0 kDa; Tsn15, 24.6 kDa. Protein bands were 
visualised using Coomassie Blue.  
 
In vitro assays were then performed containing T-16 and all possible combinations of the 
purified Tsn11 and Tsn15 homologues. The assay results demonstrated that Tmn8, Tmn9, 
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Figure 5.37 in vitro enzyme swapping experiments using Tsn11 and Tsn15 homologues. T-16 was 
incubated with Tsn11 and Tsn15 homologues before the reaction was analysed by HPLC. I) T-16 standard. 
II) T-16 incubated with Tmn9 and Tmn8. III) T-16 incubated with Tmn9 and Tsn15. IV) T-16 incubated with 
Tmn9 and Mad31. V) T-16 incubated with Tsn11 and Tmn8, producing T-22. VI) T-16 incubated with Tsn11 
and Tsn15, producing tetronasin 1. VII) T-16 incubated with Tsn11 and Mad31, producing T-22. VIII) 
Tetronasin 1 standard. Data representative of three independent experiments.  
 
To test the substrate tolerance of tmn and mad enzymes in vivo, genetic cross 
complementation experiments in S. longisporoflavus ∆tsn11 and S. longisporoflavus 
∆tsn15 were performed. Genetic complementation of the S. longisporoflavus ∆tsn11 strain 
using pIB139-mad10 did not rescue tetronasin production (Figure 5.38). Likewise, genetic 
complementation of S. longisporoflavus ∆tsn11 using pIB139-tmn9 and of the S. 
longisporoflavus ∆tsn15 strain using pIB139-tmn8 or pIB139-mad31 failed to restore 
tetronasin production or produce any novel metabolites. Despite the structural similarities 
between tetronasin, tetronomycin, and tetromadurin, the tmn and mad Tsn11 and Tsn15 
homologues have no detectable activity with the tetronasin intermediates T-16 and T-22.  
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Figure 5.38 in vivo cross-complementation using Tsn11 and Tsn15 homologues. a, Genetic 
complementation of the S. longisporoflavus ∆tsn11 mutant. I) Production of tetronasin 1 by S. 
longisporoflavus WT. II) Production of T-16 by S. longisporoflavus ∆tsn11. III) Production of T-16 by S. 
longisporoflavus ∆tsn11 pIB139-tmn9. IV) Production of T-16 by S. longisporoflavus ∆tsn11 pIB139-mad10. 
V) Production of tetronasin 1 by S. longisporoflavus ∆tsn11 pIB139: tsn11. b, Genetic complementation of the 
S. longisporoflavus ∆tsn15 mutant. I) Production of tetronasin 1 by S. longisporoflavus WT. II) Lack of 
tetronasin production by the S. longisporoflavus ∆tsn15 mutant. III) Lack of tetronasin production by the S. 
longisporoflavus ∆tsn15 pIB139: tmn8 mutant. IV) Lack of tetronasin production by the S. longisporoflavus 
∆tsn15 pIB139: mad31 mutant. V) Production of tetronasin 1 by S. longisporoflavus ∆tsn15 pIB139: tsn15. 
Data representative of three independent experiments.  
 
 
5.5 Order and timing of ring formation  
The final experiment performed in this chapter concerned the timing of cyclohexane and 
tetrahydropyran formation. Namely, it was wondered if Tsn11 and Tsn15 act while the 
tetronasin intermediate was still PKS bound, or after chain release has occurred. A 
chemical technique recently developed by collaborator Dr Manuela Tosin (University of 
Warwick) has enabled PKS-bound intermediates to be prematurely offloaded in vivo281–283, 
enabling analysis like never before. The technique uses compounds such as methyl 6-
decanamido-2-fluoro-3-oxohexanoate (M623), which compete with (2S)-methylmalonyl-
ACP to accept the polyketide acyl chain during a PKS extension reaction281,282. M623 is 
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membrane283. Once within the cell, ester hydrolysis occurs (catalysed by intrinsic 
esterases) and the activated M623 can begin offloading polyketide intermediates283 
(Figure 5.39). The identity of these intermediates can often be inferred using high-
resolution mass spectrometry. 
All M623 experiments were performed by Robert Jenkins and Dr. Manuela Tosin 
(University of Warwick (UK)) using cultures of S. longisporoflavus, S. longisporoflavus 
∆tsn11, and S. longisporoflavus ∆tsn15. The growth medium of all three strains was 
supplemented with M623, followed by extraction using organic solvents and analysis by 
HRMS. It was hypothesised that if cyclohexane and/or tetrahydropyran rings form during 
chain extension on the PKS, then disrupting formation of these rings would affect the 
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Figure 5.39 Offloading of tetronasin intermediates by methyl 6-decanamido-2-fluoro-3-oxohexanoate 
(M623). a, M623 crosses the cell membrane in the ester form. Upon entering the cell, intracellular esterase 
enzymes catalyse ester hydrolysis to produce the acid form. b, Mechanism of polyketide intermediate 
offloading by M623. I) Standard extension cycle. II) Alternative M623 extension product released from the 
PKS.  
 
However, the results from these experiments revealed no major differences in the profiles 
of offloaded intermediates between S. longisporoflavus, S. longisporoflavus ∆tsn11, and S. 
longisporoflavus ∆tsn15, indicating cyclohexane and tetrahydropyran formation likely 
occurs post-PKS. When grown with M623 all three strains produced an undecaketide 
tetronasin intermediate containing the tetrahydrofuran ring (Figure 5.40), indicating that 
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undecaketide tetronasin intermediate also contains the C30 hydroxylation and C25 
methoxy group, suggesting these modifications also occur prior to chain release.  
 
Taken together, the results from this chapter suggest that the first ring to form is the 
tetrahydrofuran ring, which occurs during chain extension. The next ring formed is the 
tetronate, which also results in release of T-16 from the PKS. Tsn11 then converts T-16 to 
T-22, in which the cyclohexane ring has formed (albeit as part of a larger oxadecalin). 
Finally, Tsn15 catalyses formation of the tetrahydropyran and fragments the oxadecalin, 
producing tetronasin (Figure 5.41). These results demonstrate that Tsn11 and Tsn15 have 
evolved to catalyse novel reactions from their homologues in spirotetronate/spirotetramate 
biosynthesis, setting the stage for the detailed structural analysis of these proteins, and 
closer examination of their mechanism, as described in the next chapter. 
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Figure 5.40 LC-HRMS analyses of S. longisporoflavus WT, ∆tsn11, and ∆tsn15  grown with M623. 
Figure made by Dr. Manuela Tosin. a, Extracted ion chromatogram (EIC) for a putative intercepted 
undecaketide ([M+H]+ adduct) from the S. longisporoflavus ∆tsn15 mutant that has undergone dehydration, 
oxidation, cyclisation and methylation (highlighted in blue). The same putative undecaketide species was 
found in S. longisporoflavus ∆tsn11 organic extracts and S. longisporoflavus wild type. The key MS2 
fragments are indicated on the structure. Full spectrum HRMS2 analyses of the putative undecaketide. c, 
HRMS2 analyses expansion showing fragments belonging to M623. HRMS2 analysis showing fragments 
belonging to the polyketide portion of the molecule. The species was absent when the three strains were 






Figure 5.41 Proposed order of ring formation in tetronasin biosynthesis. The tetrahydrofuran ring forms 
first likely when the polyketide is still attached to the PKS. Tetronate formation is concomitant with chain 
release, so this is the next ring to form. Tsn11 then catalyses cyclohexane formation within a larger 
oxadecalin moiety. Finally, Tsn15 catalyses tetrahydropyran formation, the last ring to form, and fragments 
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5.6 Chapter 5 Discussion 
 
The work described in this chapter is a significant contribution to our understanding of 
polyether tetronate biosynthesis. Two late-stage biosynthetic intermediates of tetronasin 
were isolated and shown to be competent substrates of the [4+2] cyclase homologues 
Tsn11 and Tsn15, enabling in vitro reconstitution of cyclohexane and tetrahydropyran 
formation. From an open form of tetronasin lacking the cyclohexane and tetrahydropyran 
rings (T-16), Tsn11 closes the cyclohexane by producing an oxadecalin hemiacetal (T-22). 
Tsn15 can then catalyse tetrahydropyran formation and fragmentation of the oxadecalin, 
producing tetronasin.  
 
To produce sufficient T-16 for NMR a 100 12 x 12 cm agar plates containing tsn-medium-B 
were grown for seven days. Though labour intensive, the upscaling of S. longisporoflavus 
∆tsn11 required to purify sufficient T-16 for NMR was relatively minor. For a sobering 
comparison, to isolate the precyclised pyrroindomycin from S. rugosporus ∆pyrE3 (a 
homologue of Tsn11) the authors grew a 120 L of culture to purify only 13.4 mg of the 
compound284.  
 
Solving the structure of T-16 revealed it as an open form of tetronasin in which the 
cyclohexane and tetrahydropyran rings were unformed. The structure of T-16 gave several 
key insights into tetronasin biosynthesis. Foremost, given that T-16 accumulated as a 
result of deleting tsn11, it provided the first evidence that cyclohexane and tetrahydropyran 
formation is enzymatically controlled. Secondly, it demonstrated that tetronate formation, 
tetrahydrofuran formation, C25 O-methylation, and C30 hydroxylation are not dependent 
on the cyclohexane or tetrahydropyran rings. The missing 13C NMR peaks for the tetronate 
portion of T-16 indicate that rotation around the C2-C3 double bond occurs much more 
readily than it does in T-22. The different NMR solvents used for these compounds could 
account for this. The d-chloroform used for T-16 (unlike the d-MeOH used for T-22) may 
have been slightly acidic, increasing rotation around the C2-C3 bond. Changing the T-16 
NMR solvent to deuterated MeOH could therefore resolve this issue in the future. 
 
The structure of T-16 also provided compelling evidence that M-17, the tetromadurin 
metabolite produced by A. verrucosispora ∆mad10 is the equivalent open form of 
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tetromadurin lacking cyclohexane and tetrahydropyran rings. As discussed in Section 
4.32, M-17 is missing one of the cytochrome P450-catalysed hydroxylations. That T-16 is 
hydroxylated at C30 strongly suggests that M-17 is also hydroxylated at the equivalent 
residue (C36). The missing hydroxyl group of M-17 is therefore likely that on C38 and its 
insertion is dependent on cyclohexane formation (Figure 5.42). Cyclohexane and 
tetrahydropyran formation are therefore not necessarily the final two steps in polyether 




Figure 5.42 Proposed structure of M-17 based of the structure of T-16. The hydroxylation of C30 in T-16 
suggests it is not dependent on the cyclohexane and tetrahydropyran rings being present. The equivalent 
carbon in M-17, C36, is therefore also likely to be hydroxylated. Hydroxylation of C38 is proposed to occur 
after cyclohexane and tetrahydropyran ring formation. 
 
Following the purification of structural characterisation of T-16, its competency as a 
substrate for Tsn11 and/or Tsn15 was tested. Tsn11 and Tsn15 were readily purified using 
E. coli as an expression host. Like PyrE3, Tsn11 purified with a bound FAD prosthetic 
group (Figure 5.8, Figure 5.10)161. Incubating T-16 with Tsn11 resulted in conversion into 
a new metabolite, T-22. Tsn15 could then convert T-22 into tetronasin. No conversion 
occurred when T-16 was incubated with Tsn15 alone. Tsn11 and Tsn15 therefore act 
sequentially in an enzymatic cascade to form the cyclohexane and tetrahydropyran rings of 
tetronasin. Like PyrI4, boiling Tsn15 did not abolish its activity, further demonstrating the 
stability of this class of cyclase proteins159. While EDTA did not affect the activity of either 
Tsn15 or Tsn11, it is still unknown whether sodium ions, or another non-chelatable 
metal175, have a role. That T-16 appears to be a less effective ionophore than tetronasin 
provides some evidence against this proposal, but it cannot be ruled out. Intriguingly, 
despite Tsn11 and Tsn15 catalysing different reactions from their homologues PyrE3 and 
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same161. Tetronasin may have therefore evolved from a biosynthetic pathway that initially 
produced a versipelostatin/chlorothricin-like spirotetronate, or visa versa. Either way, it is 
remarkable that, within the tetronate natural product family, PyrE3 and VstJ homologues 
have evolved to catalyse markedly different types of reactions in the polyether tetronates 
compared to the spirotetronates.  
 
To characterise the structure of T-22, the Tsn11 reaction with T-16 was scaled up. The in 
vitro route was selected because the S. longisporoflavus ∆tsn15 mutant did not produce T-
22, but instead a likely breakdown product of it (T-21). Through scaling up the Tsn11 
reaction, 3.3 mg of purified T-22 was isolated and its structure was solved. Unexpectedly, 
T-22 was found to contain a closed cyclohexane ring within a larger oxadecalin moiety. The 
tetrahydropyran ring was still unformed in T-22, indicating that it forms after the 
cyclohexane ring. The formation of the oxadecalin moiety by Tsn11 is strikingly reminiscent 
to dialkyldecalin formation catalysed by its homologue PyrE3 in pyrroindomycin 
biosynthesis161. Notable, as the oxadecalin moiety is absent form tetronasin, the reaction of 
Tsn11 is latent. To convert T-22 into tetronasin, T-22 must undergo tetrahydropyran 
formation, dehydration of the hemiacetal hydroxyl group, and oxadecalin fragmentation. 
Remarkably, all three of these transformations occurred when T-22 was incubated with 
Tsn15 (Figure 5.11, Appendix Figure 4). The latent ring formation catalysed by Tsn11 
and the concomitant ring formation/ring opening reactions catalysed by Tsn15 is an 
unusual and unexpected mechanism of cyclohexane and tetrahydropyran formation. Some 
parallels can be drawn to the epoxidase/epoxide hydrolase enzymes involved in 
tetrahydrofuran ring formation (where the epoxide ring forms and then fragments)193,194. 
Otherwise, such a reaction is unprecedented.  
 
Six mechanisms (mechanisms 5-10) were proposed for the conversion of T-16 to 
tetronasin via T-22, catalysed by Tsn11 and Tsn15 (Figure 5.31). All of these mechanisms 
had parallels to mechanism 3, the reaction scheme proposed prior to knowing the identity 
of T-22 (Figure 5.17). In Mechanisms 5, 6, 9 and 10 Tsn11 converts T-16 into an 
oxadecalin via an apparent INVHDA, whereas in mechanisms 7 and 8 oxadecalin formation 
occurs via a stepwise mechanism. Following oxadecalin formation, Tsn15-catalysed 
tetrahydropyran formation could either occur nucleophilic attack of the C17 hydroxyl onto 
C13 (as included in mechanisms 5, 6,7 and 8) or a pericyclic rearrangement (mechanisms 
9 and 10). Converting T-16 into tetronasin using Tsn11 and Tsn15 in the presence of 
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excess H218O showed no incorporation of the oxygen isotope (Figure 5.32), consistent with 
previous isotopic feeding studies175. Mechanisms where oxygen derived from water is 
incorporated into tetronasin could therefore be ruled out (Mechanisms 7 and 10), favouring 
Tsn11 catalysing an INVHDA. Enzymes catalysing apparent INVHDA reactions have been 
described in other natural product pathways, such as LepI in leporin A biosynthesis280 and 
IccD in ilicicolin biosynthesis285. The reaction catalysed by LepI is the most similar to 
Tsn11, also catalysing an inverse-electron-demand hetero (oxygen) Diels-Alder reaction to 
form an oxadecalin (Figure 5.43)280. Despite this, Tsn11 and LepI are unrelated, with LepI 
resembling a SAM-dependent methyltransferase. The mechanism of Tsn15 is explored 
more in the next chapter.  
 
 
Figure 5.43 INVHDA reaction catalysed by LepI. LepI catalyses an apparent INVHDA reaction to form the 
dihydropyran core of leporin A280. Ph = phenol group.  
 
Like PyrE3, the FAD prosthetic group of Tsn11 was found to not be essential for its 
activity161. Reducing the FAD group of Tsn11 using sodium dithionite did not inhibit its 
activity, indicating that FAD is not used for any redox chemistry. Aligning Tsn11 with PyrE3 
and OxyS enabled a putative FAD binding residue (D282) to be identified. Mutating D282 
to alanine prevented its soluble expression in E. coli. The loss of Tsn11 D282A solubility 
suggests that this residue is critical for the structure of Tsn11, likely though its hydrogen 
bonding interaction with FAD. Loss of this interaction results in decreased solubility, likely 
due to protein misfolding. Changes in the PyrE3 tertiary structure were observed upon 
mutating key FAD binding residues, confirming its important role in proper protein 
folding161. Interestingly, Tsn11 and PyrE3-family proteins are not the only [4+2] cyclase 
enzymes to bind FAD. The FAD-binding solanapyrone synthase, Sol5, oxidises the primary 
alcohol group of prosolanapyrone II to produce prosolanapyrone III. In addition to this, Sol5 
also accelerates an exo intramolecular [4+2] cycloaddition to convert prosolanapyrone III 
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light on the possible evolutionary origin of FAD-binding [4+2] cyclases. Exclusive FAD-
binding [4+2] cyclase enzymes such as PyrE3 and Tsn11 may have initially been 
monooxygenases that developed a promiscuous [4+2] cyclase side activity like Sol5. The 
evolution of such promiscuous activities in enzymes is tolerated as they often do not affect 
the native function of the enzyme286. Over evolutionary time the monooxygenase activity 
could have been selected against until the [4+2] cyclase activity became the dominant 
activity. Whether FAD-binding proteins are more predisposed than others to evolve [4+2] 
cyclase activity requires further investigation.  
 
          
Figure 5.44 cis-decalin formation catalysed by the [4+2] cyclase Sol5. The FAD-binding Sol5 oxidises 
the primary alcohol of prosolanapyrone II, producing prosolanapyrone III. Sol5 also accelerates an exo Diels-
Alder reaction to form a cis decalin. (This chapter 1 figure is repeated here for clarity).  
 
One application of Tsn11 and Tsn15 type enzymes could be the production of novel 
cyclohexane and tetrahydropyran-containing polyether tetronates. Of particular interest 
was whether the tmn pathway homologues, Tmn9 and Tmn8, could produce a tetronasin 
analogue with opposite, tetronomycin-like stereochemistry, at C4, C5, C10, and C13. 
Unfortunately the Tsn11 and Tsn15 homologues from the tetronomycin (Tmn9 and Tmn8) 
and tetromadurin (Mad10 and Mad31) biosynthesis pathways had no activity with T-16 or 
T-22 (Figure 5.37, Figure 5.38). While these experiments were unsuccessful, other [4+2] 
cyclases have been shown to be tolerant of alternative substrates. For example the Tsn11 
and Tsn15 homologues from the chlorothricin pathway, ChlE3 and ChlL, respectively, were 
able to substitute for PyrE3 and PyrI4 both in vitro and in vivo to reconstitute biosynthesis 
of the dialkyldecalin and spirotetramate rings of pyrroindomycin161. The polyketide cores of 
pyrroindomycin and chlorothricin are highly similar to each other in terms of 
stereochemistry and substituents, more so than the three polyether tetronates, likely 
explaining why the enzymes could be swapped. Inversion of product stereochemistry has 
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cyclase responsible for trans decalin formation in equisetin biosynthesis287. When the fsa2 
gene was inserted in place of phm7, a homologous gene from phomasetin biosynthesis, a 
phomasetin homologue was produced with equisetin-like decalin stereochemistry288. In the 
case of tetronasin and tetronomycin, it may be that the stereochemistry of C17 hydroxyl 
(determined by a KR domain) sterically prohibits alternative stereochemistries at C13. 
Other intrinsic steric constraints of T-16 may also restrict the stereochemistry of the 
cyclohexane ring. This idea is supported by the total synthesis of tetronasin in which both 
rings spontaneously formed the correct stereochemistry from an intermediate similar to T-
16180 (Figure 1.41). More work is clearly needed to determine why Tmn8 and Tmn9 have 
no activity with T-16 or T-22 and to delineate the role Tsn11 and Tsn15 have in 
establishing the final stereochemistry of tetronasin.  
 
The Tsn15 [4+2] cyclase homologue AbyU from abyssomicin biosynthesis was shown to 
tolerance substrate analogues, enabling the creation of novel spirotetronates158. There is 
some evidence that Tsn11 and Tsn15 may be able to tolerate substrate analogues to 
produce novel tetronasin compounds. Feeding S. longisporoflavus non-natural SNAC 
triketide precursors resulted in the production of novel tetronasin analogues289 (Figure 
5.45), indicating that Tsn11 and Tsn15 can tolerate changes to the tetrahydrofuran portion 
of the compound. The S. longisporoflavus ∆tsnC mutant (Figure 1.43), produced a form of 
tetronasin completely lacking the tetrahydropyran ring, further indicates that Tsn11 and 
Tsn15 do not interact with this portion of the molecule.  
 





Figure 5.45 Triketide tetronasin analogue feeding experiments in S. longisporoflavus. Feeding 
tetronasin with either of the displayed SNAC-triketide analogues resulted it its incorporation into tetronasin. 
Figure adapted from289 
 
Finally, the premature offloading experiments (Figure 5.39) performed by Robert Jenkins 
and Dr. Manuela Tosin suggested that tetrahydrofuran formation likely occurs whilst the 
tetronasin intermediate is PKS bound, as also predicted for the polyether lasalocid A196. It 
cannot be ruled out, however, that these enzymatic modifications actually occurred after 
M623 offloaded the intermediate from the PKS; in vitro enzymatic oxidative cyclisation 
assays would be required to test this. Cyclohexane and tetrahydropyran ring formation are 
therefore likely to be post-PKS events, making T-16 and T-22 true biosynthetic 
intermediates rather than shunt products. The rapid and complete turnover of T-16 and T-
22 by Tsn11 and Tsn15, respectively, is further evidence they are true substrates. For 
comparison, deletion of the pyran synthase salBIII in Streptomyces albus resulted in a 
production of a precyclisation form of salinomycin lacking its tetrahydropyran ring197. 
Incubation of this precyclisation substrate with purified SalBIII for 20 h resulted in only 1% 
conversion to the tetrahydropyran ring, a strong hint that SalBIII acts on the ACP bound 
polyketide intermediate, rather than the free acid197,290. If the tetrahydrofuran of tetronasin 
does indeed from prior to chain release, then the order of ring formation would be 1) 
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In summary, this chapter demonstrated that the [4+2] cyclase homologues Tsn11 and 
Tsn15 act in an enzymatic cascade to form the cyclohexane and tetrahydropyran rings of 
tetronasin. A similar cascade is likely responsible for forming the cyclohexane and 
tetrahydropyran rings of tetronomycin and tetromadurin (putative intermediates presented 
in Figure 5.46). Despite this, the enzymatic mechanisms underlying this transformation 
were unknown, leading us to perform the detailed structural and mechanistic analysis 






Figure 5.46 Proposed biosynthesis of cyclohexane/tetrahydropyran rings of tetronomycin and 
tetromadurin. Based on the structures of T-16 and T-22, the theoretical biosynthetic pathways for the 
biosynthesis of the cyclohexane and tetrahydropyran rings of a, tetromadurin and b, tetronomycin are 
presented here. The final hydroxylation of tetromadurin is predicted to occur after cyclohexane formation (see 
















































































































Chapter 6: Structural studies on Tsn11 and Tsn15 
 
A crystal structure of either Tsn11 or Tsn15 would potentially provide key insights into its 
active site and catalytic mechanism. However, obtaining the crystal structure of a protein is 
not a trivial task. Whether a protein will crystallise is highly unpredictable and numerous 
factors, such as pH, temperature, and salt concentration influence its success291. The first 
step towards crystallising any protein is to purify it in a single oligomeric state292. For crystal 
nucleation to occur the protein must reach a supersaturated state in an appropriate 
buffer292. Selecting the ideal protein concentration and crystallisation buffer often comes 
down to trial and error, much of which can now be performed by crystallisation robots. 
Some of the experiments described in this chapter were done by or in collaboration with 
Fernanda C.R Paiva and Dr. Marcio V.B Dias. In such cases the contributions are explicitly 
stated.  
 
6.1 Quaternary structure of Tsn11 and Tsn15 
 
Before attempting to crystallise Tsn11 or Tsn15, their oligomeric states in solution were 
determined. Knowing the oligomeric state of a protein prior to crystallisation is valuable, as 
the solved crystal may depict an unnatural oligomeric state. The homologues of Tsn11 and 
Tsn15 are typically homodimeric, though Tsn15 does have several trimeric homologues 
(AOC2 and PodA)158–160,163,293. The oligomeric state of Tsn11 and Tsn15 in solution was 
determined using (sedimentation velocity) analytical ultracentrifugation (AUC). AUC 
involves centrifuging a protein in a specialised chamber and monitoring its sedimentation 
rate to the bottom of the chamber294. The AUC data collected for Tsn11 and Tsn15 
indicated that both are overwhelmingly homodimeric in solution (Figure 6.1), though low 











Figure 6.1 Analytical ultracentrifugation of Tsn11 and Tsn15. a, Analytical ultracentrifugation absorbance 
data of Tsn11 was fitted with an r.m.s deviation of 0.026, showing a mean S20,w (sedimentation coefficient 
corrected for the density and viscosity of water at 20 °C) of 5.8 and a best fit frictional ratio (f/f0) of 1.42. The 
mean molecular weight calculated was 115 kDa, in good accordance with 111.0 kDa, the theoretical 
homodimeric mass of Tsn15 expressed with a pET28a(+) polyhistidine tag. b, Tsn15 analytical 
ultracentrifugation absorbance data was fitted with an r.m.s deviation of 0.014, showing a mean S20,w of 3.4 
and a best fit frictional ratio (f/f0) of 1.35. The mean molecular weight calculated was 47.1 kDa, in good 
accordance with 49.1 kDa, the theoretical homodimeric mass of Tsn15 expressed with a pET28a(+) 
polyhistidine tag. For both a and b: i) Sedimentation fringes of purified Tsn15 collected by absorbance optics. 
ii) Residuals from the Lamm equation solutions. iii) Continuous c(S) distributions of Tsn15 from the range 0-
15 S. A small solvent redistribution peak is present at S = 0.  
 
 
An idea from the outset of this project was that Tsn11 and Tsn15 might interact with one 
another, forming a ring-closing heterocomplex. While the cascade mechanism discovered 
in Chapter 5 made such a heterocomplex unlikely, Tsn11 and Tsn15 were nevertheless co-
sedimented to confirm. As expected, the co-sedimentation data clearly demonstrated that 































































































Figure 6.2 Cosedimentation of Tsn11 and Tsn15. Tsn11 and Tsn15 were mixed together and co-
sedimented together in an analytical ultracentrifuge. The sedimentation of Tsn11 alone (blue), Tsn15 alone 
(purple), and Tsn11 and Tsn15 together (teal) were each monitored by UV absorbance compared to a buffer 
only control. The S20,w (sedimentation cooefficient corrected for the density and viscosity of water at 20 °C) of 
Tsn11 and Tsn15 were the same whether cosedimented alone or together, indicating that no heterocomplex 
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6.2 Purification of Tsn11 and Tsn15 for crystallisation 
 
 
To produce sufficient protein for crystallisation trials, E. coli cultures overexpressing Tsn11 
or Tsn15 were grown in 2-3L batches (typically yielding 10-15 mg/L of the overexpressed 
protein). Tsn11 and Tsn15 were purified using Ni-affinity chromatography as before, then 
further purified using preparative ÄKTA size-exclusion chromatography. As the AUC of 
Tsn11 and Tsn15 indicated, both proteins appeared largely monodisperse when 
independently passed though an ÄKTA column, though some aggregation and/or 
alternative states were clearly present for Tsn11 (Figure 6.3). The major peaks of Tsn11 
and Tsn15, each corresponding to homodimer, were collected using a ÄKTA fraction 
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6.3 Crystallisation of Tsn11 and Tsn15 
 
Over 500 different crystallisation conditions (from commercial premade kits) were 
attempted for the crystallisation of Tsn11 and Tsn15. The Mosquito crystallisation robot 
(TTP Labtech) was used to mix 0.2 µL of purified protein with 0.2 µL of each different 
crystallisation buffer to form a sitting drop. Water slowly diffused out of these drops to 
concentrate the protein, eventually bringing it to a supersaturated state where crystal 
nucleation could potentially occur292. Tsn11 and Tsn15 were both successfully crystallised 
using this technique (Figure 6.4). Crystals of each protein were harvested and 'shot' at the 
Diamond Synchrotron (UK). Due to time constraints, only 14 crystals of Tsn11 were 
analysed, all of which diffracted poorly at ca. 6 Å. Optimising several conditions resulted in 
larger crystals growing, resulting in slightly better diffraction (ca. 4 Å). Despite this, the 





Figure 6.4 Crystals of Tsn11 and Tsn15. Tsn11 and Tsn15 were both successfully crystallised using the 
sitting-drop vapour-diffusion technique. Scale bar for the Tsn11 crystal drop image = 800 µm. Scale bar for 
the Tsn15 crystal drop image = 700 µm. The red arrow indicates the Tsn15 crystal used to generate the x-ray 
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The Tsn15 crystals diffracted much better and from one a 2.0 Å resolution dataset was 






Figure 6.5 X-ray diffraction pattern of Tsn15. The X-ray diffraction pattern of Tsn15 from which a 2.0 Å 
dataset was collected. The Tsn15 crystal used is indicated on Figure 6.4 by an arrow. 
 
When X-rays diffract from a crystal, only wave amplitude information is collected, while the 
phases of the wave remain unknown295. It is therefore also necessary to measure the 
phases (called solving the “phase problem”) before the electron density of the crystal can 
be calculated and structural models be built. A common method of obtaining phases is 
called molecular replacement, where the previously solved phases of a homologous 
protein are used to calculate the unknown phases295. For molecular replacement to be 
successful, typically >30% identity is required between the two proteins. Unfortunately the 
sequence identity of the Tsn15 homologues (AbyU158, PyrI4159, and AOC2160,296) was too 
low (ca. 20%) for any to be used as models for molecular replacement. An alternative 
method is to incorporate a heavy atom (typically selenium) into the protein structure to 
introduce an anomalous signal, from which the phases of the scattered waves can be 
calculated (called single-wavelength anomalous “SAD” phasing)297. Selenium can be 
incorporated into a protein overexpressed from E. coli relatively easily by first inhibiting de 
novo methionine biosynthesis and then feeding the culture D-selenomethionine (SeMet) 
(Figure 6.6).  
 




Figure 6.6 Method used to produce a selenomethionine-labelled protein. The overexpression of Tsn15 
was induced from E. coli BL21 (λDE3) in minimal medium (M9). Prior to inducing protein expression, L-
leucine, L-valine, L-lysine, L-phenylalanine, L-isoleucine, and L-threonine were added to the medium to inhibit 
de novo methionine biosynthesis. L-selenomethionine was then added and incorporated into the 
overexpressed protein.  
 
When expressed from pET28a(+) with an N-His tag, Tsn15 has four methionine residues 
(excluding the N-terminus methionine that is typically cleaved298). Using the method 
presented in Figure 6.6, each of these four methionine residues was efficiently replaced by 
a selenomethionine, producing SeMet-Tsn15 (Figure 6.7). SeMet-Tsn15 was then 
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Figure 6.7 Incorporation of selenomethionine into Tsn15. a, Total ion current (TIC) spectrum of purified 
SeMet-Tsn15. b, Mass spectrum of SeMet-Tsn15. c, Deconvoluted mass spectrum (z=1) of SeMet-Tsn15. 
The unrounded mass of SeMet-Tsn15 detected was 24666.6 Da, corresponding well to 24666.9, the 
theoretical mass of Tsn15 where four methionines have been replaced with L-selenomethionine (and the N-
terminal methionine has been enzymatically cleaved). The theoretical mass of unlabelled Tsn15 is 24.5 kDa.  
 
The SeMet-Tsn15 crystal diffracted even better than the unlabelled crystals, enabling the 
phases to be measured and the structure of Tsn15 to be solved at 1.8 Å (Figure 6.8). 
Refinement data and statistics are presented in Appendix Table 3. The author did the 
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Figure 6.8 The structure of Tsn15. The structure of Tsn15 was solved to 1.8 Å using SAD phasing. a, 
Ribbon diagram of chain A (yellow) and chain B (blue) of Tsn15. b, Surface diagram of Tsn15. c, Ribbon 
diagram of chain A (yellow) and chain B (blue) of Tsn15 from above. d, Surface diagram of chain A (yellow) 
and chain B (blue) of Tsn15 from above.  
 
There was a single homodimer in the asymmetric unit of Tsn15, consistent with the solution 
structure of Tsn15 calculated using AUC (Figure 6.8). The two monomers of Tsn15 are 
oriented in an antiparallel direction to one another. Each monomer chain is comprised of a 
α-helical dimerisation domain (α1-α3) and an eight-strand β-barrel (β1-β8, α4). Fernanda 
Paiva used the PDBsum299 software to identify the residues, primarily through hydrophobic 
interactions, contributing to the dimerisation interface (primarily hydrophobic interactions) 
(Appendix Figure 7). Within each β-barrel is a largely hydrophobic pocket (Figure 6.9) 
that is likely the location of the active site. Within this cavity a polyethylene glycol (PEG) 
fragment (derived from the crystallisation buffer) was bound. The PEG fragment interacted 
with the β-barrel through a direct hydrogen bond to E109, a water-mediated hydrogen bond 
to D122, and hydrophobic interactions with W190 (Figure 6.10). Whether these residues 
are also important for catalysis was investigated later. Like PyrI4159, Tsn15 also contains 
14 amino acids at its N-terminus which could potentially act as a capping/lid-domain (as 
observed in PyrI4159) (Figure 6.11). 
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Figure 6.9 Hydrophobic cavity in Tsn15. a, Ribbon diagram of Tsn15, chain A. b, surface diagram of 
Tsn15, chain A with hydrophobic resides coloured red (darker red = more hydrophobic). c, Surface 
representation and surface electrostatics of Tsn15, chain A. Contouring at ±5 kT/eV. The putative active site 
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Figure 6.10 Bound PEG fragment in the β-barrel cavity of Tsn15. a, Ribbon representation of Tsn15 with 
a PEG fragment in its β-barrel cavity. b, Surface representation of Tsn15 with a PEG fragment in its β-barrel 






Figure 6.11 N-terminal region of Tsn15. The 14 amino acids of the N-terminal domain of Tsn15 are 
highlighted in yellow.  
 
 
Tsn15 shares the same fold as its homologues AbyU and PyrI4, and the allene oxide 
cyclases (such as AOC2) (Figure 6.12). Interestingly, Tsn15 was discovered to share its 


















































Figure 6.12 Structural homologues of Tsn15 and their respective reactions. The Cα chain of Tsn15 was 
aligned with its structural homologues AbyU, PyrI4, AOC2, and PodA to calculate its rmsd value (alignment 
performed by Dr. Marcio Dias). Presented beside each structure is its rmsd value to Tsn15, amino acid 
identity (%) to Tsn15, and the reaction it catalyses.  
rmsd to Tsn15 = 1.8 Å 
Amino acids ID = 20.0% 
AbyU (5DYQ) 
 
rmsd to Tsn15 = 2.3 Å 
Amino acid ID = 18.8% 
PyrI4 (5BTU) 
rmsd to Tsn15 = 1.8 Å 
Amino acid ID = 18.5% 
AOC2 (2DIO) 
rmsd to Tsn15 = 1.6 Å 
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6.4 Tsn15-ligand complex 
 
While the structure of Tsn15 provided insight into its fold and dimerisation interface, it 
unfortunately did not provide any obvious mechanistic insights. The major reason being 
that how T-22 interacted with Tsn15 was unknown. It was therefore attempted to 
cocrystallise Tsn15 with T-22 in its active site. The success of such cocrystallisation 
experiments is unpredictable, as the substrate will often be converted into a product that 
does not bind with a high enough affinity to cocrystallise. T-22 purified by the author was 
sent to Fernanda Paiva, who performed the rest of the work described in this paragraph 
(figures were made by the author). Purified Tsn15 was mixed with T-22 before being added 
to a crystallisation drop (using the same crystallisation buffer as before). The Tsn15 
crystals that grew were harvested and analysed at the PETRAIII synchrotron (Germany). 
From one of the crystals a 1.7 Å resolution dataset was collected. The phase problem was 
solved by molecular replacement using the previously solved Tsn15 structure. The 
structure of Tsn15 generated from the new crystal showed no significant differences from 
the first (Appendix Figure 8). However, there was additional electron density present in 
the β-barrel cavity of chain A, into which most of T-22 could be confidently modelled (mean 
B factor = 34 ± 11 Å2) (collectively called the Tsn15-ligand complex) (Figure 6.13). The 
only part of T-22 missing electron density in the crystal was the C3 hemiacetal hydroxyl, 
indicating that T-22 had undergone a dehydration event either before binding or while 
bound to Tsn15. This dehydrated version of T-22 was labelled dT-22 and was also present 
in chain B, although in this chain the electron density from C17-C28 was too weak to 









Figure 6.13 Structure of the Tsn15-ligand complex. a, The structure of dT-22. b, The structure of Tsn15-
ligand complex was solved to 1.7 Å. Ribbon representation of the Tsn15-ligand structure with dT-22 bound in 
chain A. c, Three-dimensional structure of dT-22 overlaid with the calculated Fo−Fc electron density map 
(contoured at 2.0 σ). d, Ribbon diagram of Tsn15 containing dT-22 in its β-barrel cavity (Fo−Fc map contoured 
at 2.0 σ). e, Surface representation of Tsn15 containing dT-22 in its β-barrel cavity. f, Surface electrostatics of 
Tsn15 contoured at ±5 kT/eV.  
 
The resolution of dT-22 was high enough to confirm that the stereochemistry of the chiral 
centres at C4, C5, C6, C10, C14, C17, C20, C21, C22, C24, and C25 are identical to 
tetronasin as predicted (Section 5.2.4). The tetronate ring of dT-22 is completely inserted 
into the β-barrel cavity of Tsn15, forming hydrogen bonds with S142 and Q164 (Figure 
6.14). In chain B an additional hydrogen bonding interaction between R89 and the C30 
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Figure 6.14 Polar interactions between dT-22 and Tsn15. Ribbon representation of the Tsn15-ligand 
complex (chain A). Hydrogen bonds are represented as dotted grey lines. Water molecules are presented as 
red spheres. The side chains of S142 and Q164 formed hydrogen bonds with the tetronate ring of dT-22.  
 
 
The oxadecalin portion of dT-22 is oriented against the planar face of W190 through 
apparent π-stacking interactions (Figure 6.14). The tetrahydrofuran portion of dT-22 does 
not form any hydrogen bonds with amino acid side chains, likely making this portion of the 
molecule more flexible (consistent with its poor electron density in chain B). The 
conformation adopted by dT-22 does not appear to be the reactive conformation, as the 
atoms that must bond to form the tetrahydropyran ring, O17 and C13, are 4.6 Å apart 
(Figure 6.15). The reason for this is unknown, but numerous factors could be responsible, 
expanded upon in Section 6.6). Regardless, the apparent inert conformation of dT-22 
bound to Tsn15 meant it was difficult to draw conclusions about the mechanism of Tsn15 






















Figure 6.15 π-stacking interactions between W190 and the oxadecalin moiety of dT-22. Ribbon 
representation of Tsn15 chain A. The oxadecalin moiety of dT-22 is oriented parallel with W190 though 




Figure 6.16 Distance between O17 and C13 in dT-22. In the conformation that dT-22 bound in the active 
site of Tsn15 O17 and C13 are 4.6 Å apart.  
  
The proposed mechanisms for Tsn15 fell under two broad categories: first, Tsn15 may 
catalyse the nucleophilic attack of O17 onto C13 (mechanisms 5, 6, 7, and 8); alternatively, 
Tsn15 may catalyse a pericyclic rearrangement (mechanism 9 and 10). The nucleophilic 
attack mechanism was initially predicted as the most likely, as it would be similar to the 
mechanisms of other tetrahydropyran synthases such as Lsd19300, MupZ301, RED1302, and 
SalBIII197 (Figure 6.16). In all of these examples, a basic amino acid side chain extracts a 
proton from a hydroxyl group on the substrate, thereby increasing its nucleophilicity. An 

































Figure 6.17 Enzymatic Mechanisms of tetrahydropyran formation. Proposed mechanism of: a, Lsd19 
from lasalocid A biosynthesis300; b, MupZ from mupirocin biosynthesis301; c, RED1 in actinorhodin and 
dihydrogranaticin biosynthesis302; and d, SalBIII from salinomycin biosynthesis197. All of the enzymes 
presented use acid/base catalysis for tetrahydropyran formation.  
 
As the active site of Tsn15 contains several acid/base residues (R89. E109, D122), it was 
hypothesised that these residues could be responsible for catalysing tetrahydropyran 
formation (Figure 6.17), even though in the Tsn15-ligand complex none of these acidic or 
































































































Figure 6.18 Potential Tsn15 acid/base-catalysed mechanism. A basic side chain that activates the O17 
hydroxyl group could facilitate its attack onto C13. An acidic side chain adjacent to the tetronate ring could 





Figure 6.19 Amino acids present in the active site of Tsn15. Ribbon representation of Tsn15 (Chain A). 
The amino acids present on the internal face of the β-barrel are displayed as sticks. Hydrogen bonds are 
represented as dotted grey lines. Water molecules that form hydrogen bonds with dT-22 are represented as 
red spheres.  
 
6.5 Site-directed mutagenesis of Tsn15 
 
To probe the function of these and other residues site-directed alanine mutagenesis was 
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coli. In addition to acidic and basic amino acids, polar amino acids and other possible 
proton donors (such as tyrosine) were also mutated to alanine (or phenylalanine in the 
case of tyrosine). A truncated form of Tsn15 lacking N-terminal residues 1-11 (Tsn15-∆N) 
was created to assess whether they form an essential substrate-docking lid domain, 




Figure 6.20 Creation of Tsn15 point mutants. a, DNA sequencing chromatograms confirming the 
successful creation of a, tsn15-E109A (GAG glutamic acid codon changed to a GCG alanine codon); b, 
tsn15-D122A (GAC aspartic acid codon changed to a GCC alanine codon); and c, tsn15-E109A (TGG 
tryptophan codon changed to a GCG alanine codon). Blue = cytosine; Red = thymine; Green = adenine; 
Black = guanine.  
 
Each Tsn15 mutation was assayed by mixing it with T-16 and Tsn11 then measuring 
tetronasin production compared to a wild type Tsn15 control (Figure 6.20). These 
experiments demonstrated that none of the acidic/basic residues (R89A, E109A, D122A) 
nor Y91 or Y202 were essential for enzyme activity, suggesting Tsn15 does not use an 
acid/base mechanism. The pericyclic rearrangement (as depicted in mechanisms 9 and 10) 
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is therefore more likely (expanded upon at the end of the chapter). The Tsn15-∆N mutant 
was still able to produce tetronasin. The only Tsn15 mutants displaying decreased activity 
compared to wild type Tsn15 were Q164A and W190. Tsn15 activity was completely 
abolished in the W190A mutant while Q164A mutant only had ca. 30% of the activity of 
Tsn15 wild type. 
 
 
Figure 6.21 in vitro activity assays of Tsn15 mutants. T-16 was incubated with Tsn11 and a Tsn15 
mutant. Production of T-22 and/or tetronasin (1) was monitored by HPLC (λ = 266 nm). (i) T-16 no enzyme 
control. Conversion of T-16 in the presence of Tsn11 and (ii) Tsn15 lacking its 11 N-terminal amino acids; (iii) 
Tsn15-Q84A; (iv) Tsn15-R89A; (v) Tsn15-Y91F; (vi) Tsn15-E109A; (vii) Tsn15-D122A; (viii) Tsn15-T140A; 
(ix) Tsn15-S126A; (x) Tsn15- N151A; (xi) Tsn15-Q164A; (xii) Tsn15- W190A; (xiii) Tsn15- Y202F; (xiv) Tsn15 
wild type control. Data are representative of three independent experiments.  
 
The decreased activity of these Tsn15 mutants is likely due to disrupted substrate binding; 
W190 normally making π-stacking interactions and Q164 normally hydrogen bonding 
(Figure 6.14). A tryptophan residue is present at the equivalent locus in both Tmn8 and 
Mad31 (Figure 6.21), suggesting a conserved role in binding to the oxadecalin 
intermediates of tetronomycin, and tetromadurin, respectively (Figure 6.21). Unfortunately, 
a S142A mutant could not be created in the time frame of this work; however, this residue 
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is likely also important for substrate binding as it hydrogen bonds with the tetronate ring. An 
equivalent serine (or threonine) is conserved in both Tmn8 and Mad31, indicating that 
these residues may also have a conserved role in bonding to the tetronate ring of the 




Figure 6.22 Secondary structure and multiple sequence alignment of Tsn15. Tsn15 was aligned with its 
homologues from polyether tetronate (Tmn8 and Mad31) and spirotetronate (AbyU, PyrI4, VstJ, and ChlL) 
pathways using ClustalOmega227. The secondary structure of Tsn15 is presented above its sequence. The N-
terminal residues removed in the Tsn15-∆N mutant are highlighted with blue stars (★). Amino acid residues 
involved in the dimerisation interface are highlighted with magenta stars (★). Amino acids involved in binding 
the dT-22 complex are highlighted with back diamonds (u). 
 
To check that the decreased activity of the W190 and Q164 mutants was due to the amino 
acid substitution, rather than a major change in Tsn15 conformation, circular dichroism 
(CD) spectra were collected. Circular dichroism is a spectroscopic method for analysing 
protein secondary structure. In CD spectroscopy a beam of light is polarised into clockwise 
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the two circularly polarised light waves to different extents. Crucially, α-helices and β-
sheets each have characteristic CD absorption spectra303, enabling their detection in a 
protein of interest. Comparing the CD spectra of Tsn15-Q164 and Tsn15-W190 revealed 
they had no significant differences in protein secondary structure compared to wild type 
Tsn15 (Figure 6.22). The decreased activity of these mutants is therefore due to the amino 




Figure 6.23 Circular dichroism (CD) spectra of Tsn15 mutants. CD spectra of Tsn15 (black), Tsn15-
Q164A (magenta), Tsn15-W190A (orange), and Tsn15-∆N.  
 
6.6 Chapter 6 Discussion  
 
This work describes the first structural and mechanistic studies on the [4+2] cyclase 
homologues from a polyether tetronate biosynthetic pathway. Like many of their 
homologues, both Tsn11 and Tsn15 were determined to be homodimeric in solution 
(Figure 6.1)158–160,163,259,293. Based on its similarity to PyrE3, each monomer of Tsn11 likely 
binds a single molecule of FAD163. Both proteins were crystallised in commercially 
available, premade, crystallisation screening plates (Figure 6.4). The FAD-binding Tsn11 
crystallised as long, thin, yellow protein crystals that diffracted poorly (>4 Å), meaning its 
structure could not be solved. The only example of an INVHDA-catalysing enzyme with a 
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mechanism is still unclear305. Solving the structure and understanding the mechanism of 
Tsn11 is therefore of great interest. Furthermore, if the mechanism of LepI is eventually 
discovered it could lead to interesting comparisons with Tsn11, providing insights into the 
convergent evolution of these two enzymes. Several strategies could assist in obtaining 
better diffracting Tsn11 crystals in the future. First of all, the ÄKTA trace of Tsn11 indicates 
that it is not entirely monodisperse in solution (Figure 6.3). The low levels of non-
homodimeric Tsn11 could have interfered with protein packing during the crystallisation 
process, resulting in a poorly diffracting crystal. A future experiment could test a range of 
different protein buffers to identify one in which Tsn11 remains in a single oligomeric state 
better. Additionally, truncated forms of Tsn11 could be crystallised and screened for their 
diffraction potential. The crystal structure of PyrE3 revealed that its C-terminal region forms 
a thioredoxin-like domain apparently not involved in catalysis163. From the alignment of 
Tsn11 with PyrE3, it is likely that Tsn11 shares this same domain (Figure 3.21). Removing 
the thioredoxin-domain of Tsn11 could therefore be performed in an attempt to reduce the 
flexibility of the protein and improve crystal packing.  
 
Unlike Tsn11, the structure of Tsn15 could be solved to 1.8 Å using SAD phasing. 
Following this, Fernanda Paiva cocrystallised Tsn15 with T-22 to solve the structure of a 
Tsn15 with dT-22 bound in its active site. The amino acids S142, Q164, and W190 were 
identified as being key substrate binding residues (Figure 6.13, 6.20). That Tsn15 contains 
a specific residue (W190) for interacting with the oxadecalin moiety of T-22 provides 
additional evidence against mechanism 8 (Figure 5.31) (where the minor, open ring, 
component of T-22 is the Tsn15 substrate) being the true mechanism. Fragmentation of 
the oxadecalin to form the cyclohexane ring of tetronasin could decrease the strength of 
the W190 π-stacking interactions, preventing product inhibition. That the tetrahydrofuran 
portion of T-22 was facing out of the β-barrel cavity towards the solvent could explain why 
changes in this part of the molecule do not affect Tsn15 catalysis. As discussed in Chapter 
5, the cyclohexane and tetrahydropyran rings of tetronasin can still form if the 
tetrahydrofuran ring is modified (or in an C24-C25 E alkene open form).  
 
Tsn15 shares its fold with enzymes possessing a diverse range of activities, including the 
[4+2] cyclases PyrI4159 and AbyU158, the allene oxide cyclases160,296, and the demethylase 
PodA293. These different homologues highlight the versatility of this enzyme fold for 
catalysing a diverse range of reactions, including non-pericyclic ones. Research into the 
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evolution of these enzymes/conserved folds would be an interesting future topic, 
particularly if more examples of the fold are characterised. The versatility of this enzyme 
fold could also make it a useful scaffold for developing novel catalysts for synthetic biology 
with a diverse range of possible activities158.  
 
The Tsn15 mutagenesis experiments established unequivocally that certain residues that 
were candidates to supply acid-based catalysis are not essential. In contrast, in the Tsn15 
W190A, mutant activity is completely abolished. The Q164A mutant displayed a 30% 
decrease in activity, but whether this reflects a change in enzyme affinity or rate can only 
be speculated. The tolerance of Tsn15 to mutations would assist in engineering the 
enzyme to accept substrate analogues to produce novel polyether tetronates. 
Unfortunately, due to time constraints and the limited amounts of the T-16 and T-22 
substrates available, Km and kcat values for Tsn15 and Tsn11 were not measured, and this 
ought to be addressed in future work on those mutants where activity is altered. 
 
That dT-22 crystallised in the active site of Tsn15, rather than T-22 or tetronasin, 
complicated the mechanistic analysis. Further confounding was that dT-22 appears to be in 
an inert conformation in the Tsn15 active site. However, if dT-22 is the substrate of Tsn15, 
then its inert conformation in the crystal must explain its persistence there. Another 
possibility is that T-22 is the true substrate of Tsn15 and dT-22 is an inert spontaneous 
dehydration product (Figure 6.23b). While dT-22 not being a substrate of Tsn15 could 
explain its presence in the Tsn15 crystal, the direct conversion of T-22 into tetronasin has 
problems of its own. For T-22 to be converted into tetronasin in a single enzymatic step, 
the hemiacetal hydroxyl must act as a leaving group. As hydroxyl groups are poor leaving 
groups, it would almost certainly need to accept a proton for this mechanism to be possible 
(as water is a much better leaving group) (Figure 6.23a).  
 




Figure 6.24 Possible mechanisms for Tsn15-catalysed formation of the tetronasin tetrahydropyran 
ring. a, In mechanism 6, T-22 is the direct substrate of Tsn15 and tetrahydropyran formation and hemiacetal 
dehydration occur simultaneously. An acidic group would likely be required to protonate the hemiacetal 
hydroxyl to make it a better leaving group. A basic side chain could also help the reaction by activating the 
C17 hydroxyl nucleophile. b, Another possibility is that dT-22 could be an inert spontaneous dehydration 
product of T-22, explaining why it co-crystallised in the active site of Tsn15. c, In mechanism 5, dT-22, rather 
than T-22, is the substrate of Tsn15. It is likely that this mechanism would also require a basic side chain to 
activate the C17 hydroxyl nucleophile d, In mechanism 9, Tsn15 catalyses a pericyclic reaction to form the 
tetrahydropyran ring of tetronasin. Acidic and basic amino acid side chains are not necessarily required for 
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The source of this proton would likely be an acidic amino acid side chain in the active site. 
A basic side chain (such as a histidine) could also accelerate this reaction by extracting a 
proton from the C17 hydroxyl, making the oxygen a stronger nucleophile. However, the 
mutagenesis experiments demonstrated that the potential proton-donating side chains 
present in the active site (R89, Y91, E109, and D122, and Y202) are not essential for 
Tsn15 activity (Figure 6.20). These data argue against the notion that T-22 is the substrate 
of Tsn15. However, if T-22 is not the substrate of Tsn15, then it suggests that dT-22 is. The 
dehydration of T-22 to dT-22 could occur spontaneously, rather than catalysed by Tsn15, 
through a sterically favourable six-membered transition state (Figure 6.24). Whether Tsn15 




Figure 6.25 Proposed mechanism of spontaneous dehydration of T-22 to form dT-22. The dehydration 
of the C3 hemiacetal hydroxyl could occur via a six-membered transition state.  
 
However, if dT-22 is the true substrate of Tsn15, there is still the question as to why it 
appears to be in an inert conformation (Figure 6.15). There are several possible 
explanations for this, one being that the packing of the crystal lattice imposed conformation 
restraints on Tsn15, preventing dT-22 from adopting its reactive conformation. 
Alternatively/in addition, the overabundance of T-22 compared to Tsn15 used in the 
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favoured the substrate, even if conversion to tetronasin was also occurring. As the 
substrate should have a higher binding affinity to Tsn15 than the product, this could have 
led to dT-22 co-crystallising in the active site.  
 
Assuming dT-22 is the true substrate of Tsn15, there is still the question as to which of the 
proposed mechanisms is the most likely. The Tsn15 mutagenesis experiments indicated 
that a general acid/base-catalysed mechanism, as presented in mechanisms 5, 6, 7, and 8 
is unlikely (Figure 5.31, Figure 6.23c). In the remaining mechanisms, 9 and 10, Tsn15 
catalyses a pericyclic rearrangement to form the tetrahydropyran ring and fragment the 
decalin ring, forming tetronasin. The pericyclic rearrangement could either occur after 
hemiacetal dehydration (mechanism 10), or before (mechanism 9). As established, 
Mechanism 10 is unlikely, as it would result in an oxygen atom derived from water being 
incorporated into C3 keto of tetronasin. Previous isotopic feeding experiments have shown 
that this does not happen175. From the data collected in this thesis, mechanism 9 (redrawn 
in figure 6.25) therefore appears the most likely. Mechanism 9 has an additional advantage 
as homologues of Tsn15 are known to catalyse pericyclic reactions in other pathways 
(such AbyU158, PyrI4159, and AOC2160,296). A pericyclic mechanism would also not 
necessarily depend on acidic/basic side chains, only that the substrate be oriented in a 
correct conformation for the reaction to occur. The inability to identity essential acidic/basic 
amino acids in the active site of Tsn15 therefore provides additional support (Figure 6.20). 
Essential amino acid residues were also not identified in active sites of the Tsn15 
homologues AbyU158 and PyrI4159, and the unrelated [4+2] cyclases PyrE3163 and SpnF155. 
While the mechanism appears the most likely (Figure 6.25), the alternatives cannot be 
ruled out without additional experiments. A valuable experiment would be obtaining 
evidence for the formation of dT-22 during the Tsn15 reaction with T-22, or capturing dT-22 
directly and testing its competence as a Tsn15 substrate. Either of these experiments could 











Figure 6.26 Proposed mechanism for formation of the cyclohexane and tetrahydropyran rings of 
tetronasin. Tsn11 catalyses an INVHDA reaction to form an oxadecalin intermediate. The oxadecalin is then 
hydrated to form the cyclic hemiacetal T-22. T-22 then undergoes a dehydration reaction to form dT-22 (it is 
unknown whether this occurs spontaneously or is catalysed by Tsn15), which is converted into tetronasin 1 







































































Chapter 7: Key findings and future directions 
 
7.1 Research motivation 
 
The primary goal of this research was to understand how the cyclohexane and 
tetrahydropyran rings are formed in the polyether tetronate ionophores tetronasin, 
tetronomycin, and tetromadurin. Although research on polyether tetronate biosynthesis, 
tetronasin in particular, began over 20 years ago, how these two rings form remained a 
mystery. Different theories were proposed, the most prominent being that the cyclohexane 
and tetrahydropyran rings are formed in a single step via metal catalysis175,177. In 2015, a 
study on the biosynthesis of the spirotetronate versipelostatin provided the first hint that an 
enzyme is instead responsible157. A single enzyme, VstJ, was found to catalyse formation 
of the spirotetronate moiety of versipelostatin via an apparent [4+2] cycloaddition (Diels-
Alder reaction)157. Unexpectedly, a homologue of vstJ was also identified in the 
biosynthetic gene cluster of tetronomycin, one of the polyether tetronates111,157. The 
function of tmn8 was unknown, as none of the polyether tetronates possess a 
spirotetronate moiety. An exciting possibility was that Tmn8, although resembling a [4+2] 
cyclase, was actually responsible for catalysing cyclohexane and/or tetrahydropyran 
formation. Polyether natural products, in addition to often being antibiotics, have recently 
demonstrated potential as anticancer drugs173. Discovering the enzyme(s) responsible for 
the cyclohexane and tetrahydropyran formation in the polyether tetronates could enable 
them to be used as synthetic biology tools for synthesising novel analogues. As such, there 
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7.2 Key findings 
 
The first goal of this thesis was to determine if vstJ homologues are also present in the 
BGCs of tetronasin and tetromadurin. To achieve this, the tetromadurin BGC (the mad 
cluster) in the genome of A. verrucosispora was first identified (Chapter 3). The mad 
cluster was immediately identifiable, containing the necessary type I PKS genes to produce 
the tetromadurin carbon backbone and accessory genes for the biosynthesis of its key 
features. Like tetronomycin, tetronate ring biosynthesis for tetromadurin uses a glyceryl-
ACP unit. Tetronasin therefore remains the only known polyether tetronate (and tetronate 
natural product in general) to use glycolyl-ACP for tetronate biosynthesis. The carbon 
backbone of tetromadurin is produced by seven type I PKS (MadAI-MadAVII), together 
contributing a loading module and 14 extension modules that correspond well to the 
theoretical linear intermediate of tetromadurin. The one exception was module 12, which 
contains an apparent inactive KR domain despite this module apparently reducing the C7 
β-keto group of the polyketide intermediate. How reduction of the C7 keto group occurs is 
still unclear, but could involve a domain from an adjacent module.  
 
Next, BLAST was used to successfully identify vstJ homologues in the mad and tsn 
clusters. In addition, genes homologous to a second class [4+2] were also identified in the 
BGC of all three polyether tetronates. These genes were homologues of pyrE3, a recently 
characterised [4+2] cyclase responsible for dialkyldecalin formation in pyrroindomycin 
biosynthesis161. Intriguingly, the gene encoding the PyrE3 homologue in the tmn cluster, 
tmn9, had previously been shown to be essential for tetronomycin biosynthesis, albeit for 
unknown reasons111.  
 
Coding-frame gene deletions of each [4+2] cyclase homologue were performed to 
investigate their role in the polyether tetronate biosynthesis (Chapter 4). Deletion of the 
vstJ homologues tmn8, tsn15, and mad31 abolished biosynthesis of their respective 
polyether tetronate almost entirely. Likewise deletion of the pyrE3 homologues mad10 and 
tsn11 also abolished tetromadurin and tetronasin production, respectively. Both classes of 
[4+2] cyclase homologue are therefore required for polyether tetronate biosynthesis. The S. 
longisporoflavus ∆tsn11 mutant produced a new metabolite (T-16) with the same molecular 
weight as tetronasin, consistent with it being a precyclisation form of tetronasin lacking the 
cyclohexane and tetrahydropyran rings. T-16 was also produced by the S. longisporoflavus 
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∆tsn11 ∆tsn15 double mutant, indicating that Tsn15 can only act after Tsn11. The next step 
was to enough isolate T-16 for structural characterisation by NMR.  
 
Approximately 12.5 mg of T-16 was isolated from an upscaled fermentation of S. 
longisporoflavus ∆tsn11 (Chapter 5). A purification protocol was developed using C18 solid 
phase extraction cartridges followed by semipreparative HPLC. Detailed NMR 
characterisation of T-16 confirmed it as a tetronasin analogue in which the tetronate and 
tetrahydrofuran rings had formed, but the cyclohexane and tetrahydropyran rings had not. 
When T-16 was incubated with Tsn11 it was converted into a new metabolite, labelled T-
22. T-22 could be subsequently converted into tetronasin by incubating it with Tsn15. 
Tsn11 and Tsn15 therefore act in an enzymatic cascade to form the cyclohexane and 
tetrahydropyran rings of tetronasin. The Tsn11 in vitro assay was scaled up to isolate ca. 3 
mg of T-22 for NMR structural characterisation. T-22 still lacked the tetrahydropyran ring of 
tetronasin, but the cyclohexane ring had closed within a larger oxadecalin moiety. The 
oxadecalin moiety was unexpected but is consistent with Tsn11 catalysing an apparent 
INVHDA reaction, reminiscent of the reaction catalysed by PyrE3161. Notably, the product of 
this apparent [4+2] cycloaddition, the oxadecalin moiety, is not present in the final 
tetronasin structure, meaning Tsn11 catalyses a latent reaction. Tsn15 then catalyses 
tetrahydropyran ring formation and fragments the oxadecalin moiety to form tetronasin. 
Tsn11 and Tsn15 therefore catalyse different reactions from their homologues in 
spirotetronate/spirotetramate pathways. The same enzymatic cascade mechanism is likely 
responsible for forming the cyclohexane and tetrahydropyran rings of tetronomycin and 
tetromadurin. Collaborators from the University of Warwick used chemical probes to offload 
tetronasin intermediates prematurely, indicating that the tetrahydrofuran ring likely forms 
prior to chain release. The final proposed order of ring formation is therefore 1) 
tetrahydrofuran, 2) tetronate, 3) cyclohexane, 4) tetrahydropyran.   
 
Despite the structure similarities between tetronasin, tetronomycin, and tetromadurin, 
Tmn8 and Mad31 could not substitute for Tsn15 in vivo or in vitro. Likewise Tmn9 was 
unable to substitute for Tsn11 (Mad10 could not be purified, unfortunately). Like PyrE3, 
Tsn11 resembles an FAD-dependent monooxygenase and binds an FAD cofactor. 
Chemically reducing this FAD cofactor using sodium dithionite did not affect Tsn11 activity, 
indicated that it does not have a catalytic role.  
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Finally, Tsn15 was crystallised and its structure was solved at 1.8 Å resolution (Chapter 6). 
Tsn15 is a homodimer with each monomer comprised of an eight-strand β-barrel and a α-
helix based dimerisation domain. Despite a low sequence identity (ca. 20%) Tsn15 shares 
the same fold as the [4+2] cyclases PyrI4159 and AbyU158, the allene oxide cyclases160,296, 
and, noted for this first time in this work, the pyocyanin demethylase PodA293. In attempt to 
gain insight into the mechanism of Tsn15, collaborator Fernanda Paiva (University of São 
Paulo, Brazil) cocrystallised T-22 with Tsn15. Within the β-barrel cavity of Tsn15 a 
dehydrated form of T-22 (dT-22) had cocrystallised, enabling key substrate binding 
residues (S142, Q164, and W190) to be identified. S142 and Q164 both formed hydrogen 
bonds to the tetronate ring, while W190 made π-stacking interaction with the oxadecalin 
portion of dT-22. Despite the insight gained into substrate binding, the mechanism of 
Tsn15 remains uncertain. dT-22 appears bound to Tsn15 in an inert conformation, so it is 
possible that T-22 is the real substrate and dT-22 is a spontaneous dehydration shunt 
product. Regardless, there are two main possible mechanisms for Tsn15: acid/base 
catalysis or pericyclic ring closure. The acid/base catalytic mechanism appears unlikely as 
acidic/basic amino acids in the active site were shown by mutagenesis to not be essential 
for Tsn15 activity. The alternative is that Tsn15 closes the tetrahydropyran ring/opens the 
oxadecalin ring via a pericyclic rearrangement. The lack of essential acid/base side chains 
in the active site therefore favours the pericyclic mechanism, though additional experiments 
are necessary to confirm.   
 
7.3 Future Directions 
 
An area of this thesis that clearly requires expansion upon is the proposed mechanisms of 
Tsn11 and Tsn15. Continued efforts to crystallise Tsn11 to solve its structure would be 
valuable, as a crystal structure would be the best starting point for mechanistic analysis. 
Even better would be if Tsn11 were cocrystallised with its substrate, T-16. If the 
cocrystallisation was unsuccessful an alternative could be to try docking T-16 
computationally. Site-directed mutagenesis could then be performed to probe the putative 
binding pocket of Tsn11 for catalytic residues. A docking approach was used for the Tsn11 
homologue, PyrE3 after cocrystallisation with its substrate failed163.  
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Additional experiments are also required to elucidate the mechanism of Tsn15. An 
important milestone in future work will be to determine whether T-22 or dT-22 is its true 
substrate. To study the mechanism in more detail Fernanda Paiva is planning to conduct 
comprehensive molecular dynamic (MD) simulations of the Tsn15-ligand complex. These 
simulations will predict the conformational flexibility of dT-22 in the active site of Tsn15, and 
whether the active site could accommodate the pericyclic mechanism proposed. Analogous 
MD simulation calculations have been performed on the [4+2] cyclase AbyU that supported 
its [4+2] cycloaddition mechanism158.  
 
Another outstanding question is how the stereochemistry of the cyclohexane and 
tetrahydropyran rings is established. The cyclohexane and tetrahydropyran rings of 
tetronasin and tetronomycin have the opposite stereochemistry. Once the mechanisms of 
Tsn11 and Tsn15 are known it would therefore be very interesting to compare their 
structures to the structures of Tmn9 and Tmn8, respectively. Such analysis has the 
potential to identify any key amino acid residues involved in controlling the stereochemistry 
at C4, C5, C10, and C13.  
 
Following on from the last point, the substrate tolerance of Tsn11 and Tsn15 could also be 
explored. Analogues of T-16 and T-22 could be created synthetically or semi-synthetically 
and tested as substrates for Tsn11 or Tsn15, respectively. Such substrate tolerance would 
be a valuable feature for using Tsn11 and Tsn15 as synthetic biology tools to produce 
novel polyether tetronates. Now that the key of substrate-binding side chains in Tsn15 
have been identified (Chapter 6), amino acids adjacent to the binding site could be 
mutated in attempt to better accommodate T-22 analogues.  
 
Related to substrate tolerance, but unrelated to polyether tetronates, it would be interesting 
to determine if the tetrodecamycin biosynthetic pathway could be engineered to produce a 
novel “abyssomicin” compound. The biosynthesis pathway of tetrodecamycin contains 
TedJ, a homologue of PyrE3, that catalyses the intramolecular [4+2] cycloaddition to form 
the dialkyldecalin core of tetrodecamycin165. However, the theoretical linear tetrodecamycin 
precursor strongly resembles a linear abyssomicin compound. It would therefore be 
interesting to knock-out tedJ and knock-in an abyU-like [4+2] cyclase to determine if a 
different cyclisation product would be generated (Figure 7.1). 
  






Figure 7.1 Proposed method of engineering the tetrodecamycin pathway to produce a novel 
abyssomicin. The pyrE3 homologue, tedJ, could be deleted from the tetrodecamycin BGC and replaced with 
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A mystery that still remains in tetronasin biosynthesis is why the tsn cluster contains two 
FabH-like enzymes (Tsn9 and Tsn13). These two FabH enzymes share 45% sequence 
identity and previous work in the Leadlay lab demonstrated that each is essential for 
tetronasin biosynthesis (Sun et al., unpublished). The relative contributions of Tsn9 and 
Tsn13 in catalysing tetronate ring formation (assuming that is their role) are therefore 
unknown. One possibility is that the two FabH-like enzymes are required for incorporating 
the usual glycolyl-ACP unit (rather than glyceryl-ACP), perhaps one catalysing C-C bond 
formation and the other catalysing C-O bond formation. FabH enzymes are 
homodimeric306,307, so another possibility is that Tsn9 and Tsn13 form a heterocomplex to 
form the tetronate ring in a single step. The best way to test this would be if tetronate ring 
biosynthesis could be reconstituted in vitro using glycolyl-ACP, Tsn9, Tsn13, and a suitable 
ACP-bound β-keto thioester substrate (Figure 7.2) (as was done for the tetronate RK-
682)122. Sourcing a suitable substrate would be by far the most difficult aspect of this 
experiment, as Tsn9 and Tsn13 would likely be substrate specific. Chemically synthesising 
the theoretical linear β-keto thioester intermediate of tetronasin would likely be very difficult 
and impede progress. Simpler β-keto thioester substrates could be tested, such as the RK-
682 precursor122, but their likelihood of being accepted by Tsn9/Tsn13 is unknown and 
likely to be low. An alternative strategy could be to feed the S. longisporoflavus ∆tsn9 and 
S. longisporoflavus ∆tsn13 mutants the same chemical probes used in this thesis to 
prematurely offload polyketide intermediates. The identity of these intermediates could 




Figure 7.2 Biosynthesis of the tetronasin tetronate ring. The role of the FabH-like enzymes Tsn9 and 

















Chapter 7: Key findings and future directions 
	 240 
7.4 Concluding remarks 
 
In this work the [4+2] cyclase homologues Tsn11 and Tsn15 were shown to be responsible 
for forming the cyclohexane and tetrahydropyran rings of tetronasin, solving a long-
standing mystery in the field of polyether tetronates. Tsn11 appears to catalyse a latent 
[4+2] cycloaddition reaction, forming an oxadecalin intermediate that is subsequently 
fragmented by Tsn15 to form tetronasin. The prevalence of such latent cyclisation 
reactions in other natural product biosynthesis pathways will be an interesting topic to 
explore further. The activity of Tsn15 also suggests that there are additional novel 
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Appendix Notes  
 
Appendix note 1 
The sequence of Tsn15. Prior to this thesis, a different gene in the tetronasin gene cluster, 
an ABC transporter, was named Tsn15. The Tsn15 described in this paper was not 
annotated. As such, the ABC transporter has been renamed Tsn15b and Tsn15 now refers 



















Appendix note 2 
Revised sequence of Tsn11. Closer examination of the tsn11 gene compared to the 
deposited sequence revealed the start codon to be an additional 12 bp 5’ of the previously 
annotated start codon. The new start codon was a methionine (ATG) rather than a leucine 
(TTG) and was six bp downstream from a likely Shine-Delgarno sequence (GGAAGAA). 













Appendix note 3 
Revised sequence of Tmn9. During cloning of tmn9 it was noted that the sequence differed 
slightly from that previously published15 (confirmed by sequencing independent PCR 










































































Appendix Figure 1  
BSA standard curve using Bradford reagent. A BSA standard curve was prepared using the Bradford reagent. 














y = 0.4356x + 0.0242 

























Appendix Figure 2 
MS3 fragmentation of tetronasin produced by S. longisporoflavus. The MS3 fragmentation patterns of the 
[M+Na]+ and the [M+H]+ ions of the tetronasin produced by S. longisporoflavus were compared to the same 
MS3 fragments from a tetronasin standard. a, The MS3 spectra from the [M+Na]+ ion (625 -> 607 (−H2O) -> 
fragments) for tetronasin produced in vivo by S. longisporoflavus (top) and a standard (bottom). b, The MS3 
spectra from the [M+H]+ ion (603 -> 585 (−H2O) -> fragments) for tetronasin produced in vivo by S. 
longisporoflavus (top) and a standard (bottom). The detected fragments were in good accordance with those 
previously observed for tetronasin268. 
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247.43 379.61 407.61 499.73 425.61 361.66 269.50 327.54 297.54 
407.71 












Appendix Figure 3 
MS3 mass spectra of intermediate T-16. a, Top: MS3 spectra of the T-16 m/z = 603 [M+H−H2O]+ ion: m/z = 
603 -> 585 (−H2O) -> fragments. Bottom: MS3 spectra of the tetronasin 1 m/z = 603 [M+H]+ ion: m/z = 603 -> 
585 (−H2O) -> fragments. b, Top: MS3 spectra of the T-16 m/z = 625 [M+Na−H2O]+ ion: m/z = 625 -> 607 
(−H2O) -> fragments. Bottom: MS3 spectra of the tetronasin 1 m/z = 603 [M+Na]+ ion: m/z = 625 -> 607 











































































Figure x  MS3 mass spectra of intermediate T-16. a, Top: MS3 spectra of the T-16 
m/z = 603 [M+H-H2O]+ ion: m/z = 603 -> 585 (-H2O) -> fragments. Bottom: MS3 spectra 
of the tetronasin 1 m/z = 603 [M+H]+ ion: m/z = 603 -> 585 (-H2O) -> fragments. b, Top: 
MS3 spectra of the T-16 m/z = 625 [M+Na-H2O]+ ion: m/z = 625 -> 607 (-H2O) -> 
fragments. Bottom: MS3 spectra of the tetronasin 1 m/z = 603 [M+Na]+ ion: m/z = 625 -> 























Appendix Figure 4 
In vitro conversion of T-16 into tetronasin using purified Tsn11 and Tsn15. The in vitro conversion of T-16 into 
tetronasin 1 by Tsn11 and Tsn15 was monitored by HPLC analysis. (I) T-16 incubated in the absence of 
enzymes. (II) Conversion of T-16 into T-22 using Tsn11 (III) No reaction occurred when T-16 was incubated 
with Tsn15 alone. (IV) Conversion of T-16 into tetronasin 1 using Tsn11 and Tsn15. (V) Conversion of T-22 













min 6 8 10 12 14 
λ = 266 nm 
T-16 standard 
T-16 + Tsn11   
T-16 + Tsn15   
T-16 + Tsn11 + Tsn15   



















Appendix Figure 5 
MS3 spectra of the T-22. a, Top: MS3 spectra of the T-22 m/z = 603 [M+H−H2O]+ ion: m/z = 603 -> 585 
(−H2O) -> fragments. Bottom: MS3 spectra of the tetronasin 1 m/z = 603 [M+H]+ ion: m/z = 603 -> 585 (−H2O) 
-> fragments. b, Top: MS3 spectra of the T-22 m/z = 625 [M+Na−H2O]+ ion: m/z = 625 -> 607 (−H2O) -> 













































































Figure x  MS3 mass spectra of T-22. a, Top: MS3 spectra of the T-22 m/z = 603 
[M+H-H2O]+ ion: m/z = 603 -> 585 (-H2O) -> fragments. Bottom: MS3 spectra of the 
tetronasin 1 m/z = 603 [M+H]+ ion: m/z = 603 -> 585 (-H2O) -> fragments. b, Top: MS3 
spectra of the T-22 m/z = 625 [M+Na-H2O]+ ion: m/z = 625 -> 607 (-H2O) -> fragments. 
Bot om: MS3 spectra of the tetronasin 1 m/z = 603 [M+Na]+ ion: m/z = 625 -> 607 (-





















Appendix Figure 6  
Purification and activity of Fre. a, Fre cloned into pET28a(+) and purified from E.coli using Ni-affinity. b, Fre 
co-purified with a flavin cofactor bound to it. Adding NADPH resulted in a detectable drop in UV/Vis 
















































Fre Fre  + NADPH 





Appendix Figure 7  
Dimerisation interface of Tsn15 (Figure made by Fernanda Paiva). The online structural biology tool 
PDBsum299 (EMBL-EBI) was used to generate a diagram showing the various interactions between the two 
chains of Tsn15. Orange dashes = non-polar interactions. The thickness of the dashes is proportional to the 
number of atomic interactions. Blue line = hydrogen bonds. Red lines = salt bridges. Colour of ellipses: red = 
negatively charged amino acid; blue = positively charged amino acid; magenta = aromatic amino acid; green 








































































Appendix Figure 8 
Comparison of the Cα chains between Tsn15 and Tsn15-ligand complex. (Figure made by Fernanda Paiva). 
Aligning the two structures revealed no significant changes to the Cα positions upon substrate binding. Green 





































Appendix Figure 9  
Chain B of the Tsn15-ligand complex. a, Resolvable portion of dT-22 present in chain B of Tsn15 (Fo-Fc 
contoured to 2.0 σ). The electron density of the tetrahydrofuran portion of the molecule (from C17 onwards) 












































Appendix Figure 10 























Appendix Figure 11 






















Appendix Figure 12 





















Appendix Figure 13 























Appendix Figure 14 




















Appendix Figure 15 

























Appendix Figure 16 
1H NMR spectrum of T-22 in CD3OD. *The peak at d 4.60 is due to a minor contaminant PhCH2OH (aromatic 






















Appendix Figure 17 




























Appendix Figure 18 






















Appendix Figure 19 






















Appendix Figure 20 





























Appendix Figure 21 
1H-1H NOESY spectrum of T-22 in CD3OD. Green off-diagonal peaks show positive NOEs. Blue off-diagonal 

































Appendix Figure 22 

















Appendix Table 1 






13C ppma 1H (HSQC) ppmb 1H (HMBC) ppmb Assignment COSY
c and/or 
NOESYd 
157.07 7.12 (1H, br d, J  8.3 Hz) 1.91, 1.063 C-5 2.64, 1.91, 1.46
d, 
1.063d 
140.1 5.23 (1H, d, J 10.0 Hz) 5.91, 4.29 & 4.25, 0.96 C-13 5.91c, 2.56, 0.96d 
136.12 5.71 (1H, dd, J 15.0 & 7.1 Hz) 4.03, 3.51, 2.22, 0.917 C-19 5.49, 4.03
d, 3.51d, 
2.22c, 0.917d 
135.88 - 5.77, 4.29 & 4.25 C-12 
 132.37 5.91 (1H, d, J 15.8 Hz) 5.23, 4.29 & 4.25, 2.09 C-11 5.77, 5.23
c, 4.29d & 
4.25d, 2.09c 
131.96 5.49 (1H, dd, J 15.0 & 7.2 Hz) 4.03, 2.22, 1.52-1.42 C-18 5.71, 4.03
c, 2.22c, 
0.917d 
128.73 5.77 (1H, dt, J 15.8 & 7.0 Hz) 5.91, 2.09 C-10 5.91, 4.29
d & 4.25d, 
2.09c 
- 4.59 (2H, br s) - 34-CH2  - 
86.16 3.51 (1H, dd, J 9.6 & 5.0 Hz) 5.71, 3.97, 2.22, 1.64, 0.917 C-21 
5.71d, 5.49d, 2.22c, 
1.96d, 0.917d 
80.32 3.97 (1H, ddd, J 8.8, 6.7, 4.6 Hz) 3.32, 1.96, 1.056 C-24 
3.32c, 1.96 & 1.64c, 
1.056d, 0.902d 
79.68 3.32 (1H, qd, J 6.1 & 4.6 Hz) 3.35, 1.96, 1.056 C-25 3.97c, 1.056c 
73.52 4.03 (1H, q, J 6.5 Hz) 5.71, 5.49, 1.50 & 1.44 C-17 5.71
d, 5.49c, 1.50c & 
1.44c  
57.82 4.29 & 4.25 (2 x 1H, d, J 11.7 Hz) 5.91, 5.23 C-30 5.91
d, 5.77d, 2.56d 
57.57 3.35 (3H, s) 3.32 OMe 1.056d 
37.08 2.22 (1H, m) 5.71, 5.49, 3.51, 0.917 C-20 5.71
c, 5.49c, 3.51c, 
0.917 
36.23 1.46 (2H, m) 2.09, 1.42, 1.063 C-7 7.12
d, 2.64c, 1.91d, 
1063d 




& 1.64 (1H, dd, J 12.4, 6.9 Hz) 
  
3.97c, 1.96c, 0.902d 
35.33 2.24 (1H, m)  1.96 & 1.64, 0.902 C-22 3.51d, 1.96, 0.902c 
35.01 1.50 & 1.44 (each 1H, m) 5.49, 4.03 C-16 4.03c 
34.51 2.64 (1H, m) 1.46, 1.063 C-6 7.12, 1.91
d, 1.46c, 
1.063c 
33.35 1.36 & 1.30 (each 1H, m) 5.23, 4.03, 1.50, 0.96 C-15 2.56 
33.24 2.09 (2H, m) 5.91, 5.77, 1.47 C-9 5.91c, 5.77c, 1.42c 
32.62 2.56 (1H, m) 1.50-1.35, 0.96 C-14 5.23
c, 4.29d & 4.25d, 
1.36 & 1.30, 0.96c 
27.5 1.42 (2H, m) 5.77, 2.09, 1.46 C-8 2.09c 
21.78 0.96 (3H, d, J 6.6 Hz) 5.23, 2.56, 1.36 & 1.30 C-29 5.23d, 2.56c 
19.82 1.063 (3H, d, J 6.6 Hz) 2.64, 1.91, 1.46  C-31 7.12d, 2.64c 
17.1 0.917 (3H, d, J 6.8 Hz) 5.71, 3.51, 2.22 C-28 5.71
d, 5.49d, 3.51d, 
2.22 
15.88 1.056 (3H, d, J 6.3 Hz) 3.97, 3.32 C-26 3.97d, 3.32c, 1.96d 
13.79 0.902 (3H, d, J 7.0 Hz) 3.51, 1.96 & 1.64 C-27 3.97d, 2.24c, 1.64d 
12.32 1.91 (3H, s) 7.12 (w) C-32 7.12, 2.64d 
     
arelative to 13C in CDCl3 at 77.23. brelative to residual protons in CDCl3 at 7.24. cCOSY and NOESY, dNOESY 




Appendix Table 2 
NMR spectroscopic data for intermediate T-22 (Table prepared by Dr. Finian Leeper) 
 
 
13C ppma 1H (HSQC) ppmb 1H (HMBC) ppmb Assignment COSY
c and/or 
NOESYd 
179.99 v.br    - 4.62 } C-33 - 
174.72 br    - 4.62 } C-1 - 
142.76 br 5.34 (1H, d, J 9.7 Hz) 4.33 & 4.06, 3.81, 0.952 C-13 
2.60c, 3.81d, 1.40d, 
0.952d 
136.17 5.69 (1H, dd, J 15.6 & 7.5 Hz) 4.01, 3.57, 2.225, 0.954 C-19 
5.46, 2.225c, 4.01d, 
3.57d, 0.954d 
135.18 br    - 4.06, 3.81 C-12 - 
133.47 5.46 (1H, dd, J 15.6 & 7.5 Hz) 4.01, 2.225, 1.52 C-18 5.69, 4.01
c, 2.225d, 
1.52d, 0.954d 
104.50 br    - 0.873 C-3 - 
99.38 v.br    - 4.62 C-2 - 
87.8 3.57 (1H, dd, J 9.2 & 4.2 Hz) 5.69, 3.96, 2.225, 1.68, 0.940 C-21 
2.285c, 2.225c, 
5.69d, 3.36d, 2.01d, 
0.954d 
83.57 3.81 (1H, br d, J 9.7 Hz) 5.34, 4.33 & 4.06 C-11 1.59c, 5.34d 
81.54 3.98 (1H, m) (ddd?) 3.36, 201, 1.076 C-24 3.36
c,2.01c, 1.68c, 
1.076d, 0.940d 
80.85 3.36 (1H, m) 3.36, 201, 1.076 C-25 3.98
c, 1.076c, 
3.57d, 2.01d 
73.9 4.01 (1H, m) (d?) 5.69, 5.46, 1.52 C-17 5.46
c, 1.52c, 5.69d, 
1.40d 
68.32 4.62 (2H, br s) - C-34 - 
57.76 3.36 (3H, s) 3.36 OMe - 
57.17 4.33 & 4.06 (each 1H, br d, J 11.0 Hz) 5.34, 3.81 C-30 
e 2.60d, 1.59d 
44.98 1.59 (1H, m) 3.81, 2.34, 1.70, 1.59, 0.862 C-5 2.355
c, 1.35 
38.59 2.225 (1H, dt, J 9.0 & 7.0 Hz) 5.69, 5.46, 0.954 C-20 5.69
c, 3.57c, 
0.954c, 5.46d 
37.01 1.70 & 1.06 (each 1H, m) 0.862 C-7 e 1.27d 
36.52 2.285 (1H, br q, J 6.0 Hz) 2.01 & 1.68, 0.940 C-22 3.57
c, 2.01c & 
1.68c, 0.940c 
36.43 1.59 (1H, m) 3.81, 2.355, 1.59 C-10 3.81c, 0.80, 4.06d 
36.20* } 2.01 (1H, ddd, J 12.5, 8.6 & 6.6    } Hz) & 1.68 (1H, m) 
} 3.57, 3.36, 2.285,    
} 0.940 } C-23 
e 3.98c, 2.285c, 
3.57d, 3.36d, 1.076d 
36.18* } 1.52 (2H, m) } 5.46, 2.60 } C-16 4.01c, 1.40, 5.46d 
35.51 2.355 (1H, qd, J 7.2 & 2.2 Hz) 0.873 C-4 1.59c, 0.873c 
34.53 1.35 (1H, m) 1.69, 1.59, 0.862 C-6 1.59, 0.862c 
34.11 1.40 (2H, m) 5.34, 4.01, 1.52, 0.952 C-15 
2.60c, 1.52, 5.34d, 
4.01d, 0.952d 
33.19 2.60 (1H, m) 5.34, 1.52, 0.952 C-14 5.34, 1.40
c, 0.952c, 
4.33d 
30.15 1.46 (br d, J 12 Hz) & 0.80 (br q, J 12 Hz) 3.81 C-9 
e 1.58 
26.56 1.69 & 1.27 (each 1H, m) - C-8 e 1.06, 1.70d 
22.01 0.952* (3H, d, J 6.6 Hz)* 5.34, 2.60, 1.40 C-29 2.60, 5.34d 
19.06 0.862 (3H, d, J 6.2 Hz) 1.06 C-31 1.35c, 2.355d 
17.59 0.954* (3H, d, J 6.6 Hz)* 5.69, 3.57, 2.225 C-28 2.225c, 5.69d, 5.46d 
15.87 1.076 (3H, d, J 6.3 Hz) 3.98, 3.36 C-26 3.36c, 3.98d, 2.01d 
14.04 0.940 (3H, d, J 6.8 Hz) 3.57, 2.28, 2.01, 1.68 C-27 2.285
c, 3.98d, 
2.225d, 1.68d 
10.08 0.873 (3H, d, J 6.6 Hz) 2.355, 1.59 C-32 2.355c, 1.59d 
 
arelative to 13C in CD3OD at 49.15. brelative to residual protons in CD3OD at 3.31. cCOSY and NOESY, dNOESY 
only, otherwise COSY only. ethese diastereotopic protons showed COSY & NOESY correlations with each 





Appendix table 3 
Crystallographic data (Table prepared by Fernanda Paiva). Values in parentheses are for 
the high resolution outer shell.  
 
 
PDB entry Tsn15 (6NOI) Tsn15-ligand (6NNW) 
   
Beamline 
Diamond Light Source 
(DLS) 
I04 beamline, Oxford, UK 
PETRAIII, beamline 13, 
Hamburg, Germany 
Resolution range (Å) 29.7  - 1.80 (1.84  - 1.80) 43.81  - 1.7 (1.76  - 1.70) 
Space group C 1 2 1 C 1 2 1 
Unit cell (Å) 128.8 36.9 91.8 90 107.5 90 
129.7 36.9 92.0 90 
107.8 90 
Total reflections 239480 (14251) 90988 (8254) 
Unique reflections 38365 (2014) 45893 (4205) 
Multiplicity 6.2 (3.9) 2.0 (2.0) 
Completeness (%) 99.0 (88.7) 98.8 (91.1) 
Mean I/sigma(I) 23.90 (6.56) 13.3 (2.0) 
Wilson B-factor 15.47 21.87 
R-merge 0.063 (0.218) 0.030 (0.338) 
R-meas 0.068 (0.253) 0.042 (0.479) 
R-pim 0.027 (0.125) 0.0298 (0.339) 
CC1/2 0.998 (0.949) 0.998 (0.788) 
CC* 1 (0.888) 1 (0.939) 
Reflections used 
in refinement 38363 (3503) 45883 (4202) 
Reflections used 1837 (173) 2318 (195) for R-free 
R-work 0.156 (0.191) 0.170 (0.299) 
R-free 0.186 (0.233) 0.204 (0.355) 
CC(work) 0.969 (0.932) 0.968 (0.867) 
CC(free) 0.967 (0.896) 0.961 (0.812) 
Number of non-hydrogen 
atoms 3669 3562 
macromolecules 3228 3211 
ligands 34 82 
solvent 407 269 
Protein residues 412 413 
RMS(bonds) (Å) 0.006 0.007 
RMS(angles) (Å) 0.89 0.9 
Ramachandran favored (%) 99 99.51 
Ramachandran allowed (%) 0.7 0.49 
Ramachandran outliers (%) 0 0 
Rotamer outliers (%) 0.56 0 
Clashscore 5.98 4.16 
Average B-factor (Å2) 22.8 28.97 
macromolecules 21.04 27.84 
ligands 37.10 39.71 
solvent 35.04 39.2 
Number of TLS groups 1 1 
	
	
 
	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
